



JUN 29 2004

TECH CENTER 1600/2900

APPENDIX A

(CLEAN VERSION OF SUBSTITUTE SPECIFICATION)

(Serial No. 09/767,041)



PATENT
Attorney Docket 4726US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EL740532647US

Date of Deposit with USPS: January 22, 2001

Person making Deposit: Daniel Thatcher

JUN 29 2004

TECH CENTER 1600/2900

APPLICATION FOR LETTERS PATENT

for

STREPTOCOCCUS SUI VACCINES AND DIAGNOSTIC TESTS

Inventors:

Hilda E. Smith

Attorney:
Allen C. Turner
Registration No. 33,041
Krista Weber Powell
Registration No. 48, 867
TRASK BRITT, P.C.
P.O. Box 2550
Salt Lake City, Utah 84110
(801) 532-1922



STREPTOCOCCUS SUIIS VACCINES AND DIAGNOSTIC TESTS

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to, and is a continuation of, International Application No. PCT/NL99/00460, filed on July 19, 1999, designating the United States of America, the contents of which are incorporated herein by this reference, the PCT International Patent Application itself claiming priority from European Patent Office Application Serial No. 98202465.5 filed July 22, 1998 and European Patent Office Application Serial No. 98202467.1 filed July 22, 1998.

JUN 29 2004

TECHNICAL FIELD

[0002] The invention relates to *Streptococcus* infections in pigs, vaccines directed against those infections, tests for diagnosing *Streptococcus* infections and bacterial vaccines. More particularly, the invention relates to vaccines directed against *Streptococcus* infections. TECH CENTER 1600/2900

BACKGROUND OF THE INVENTION

[0003] *Streptococcus* species, of which a large variety cause infections in domestic animals and man, are often grouped according to Lancefield's groups. Typing according to Lancefield occurs on the basis of serological determinants or antigens that are, among others, present in the capsule of the bacterium, and allows for only an approximate determination. Often, bacteria from different groups show cross-reactivity with each other, while other Streptococci cannot be assigned a group-determinant at all. Within groups, further differentiation is often possible on the basis of serotyping. These serotypes further contribute to the large antigenic variability of Streptococci, a fact that creates an array of difficulties within diagnosis of and vaccination against Streptococcal infections.

[0004] Lancefield group A *Streptococcus species* (Group A *Streptococci* "GAS," *Streptococcus pyogenes*) are common in children, causing nasopharyngeal infections and complications thereof. Among animals, cattle are especially susceptible to GAS infection which can cause mastitis.

[0005] Group A streptococci are the etiologic agents of streptococcal pharyngitis and impetigo, two of the most common bacterial infections in children, as well as a variety of less common, but potentially life-threatening, infections including soft tissue infections, bacteremia, and pneumonia. In addition, GAS are uniquely associated with the post-infectious autoimmune syndromes of acute rheumatic fever and post streptococcal glomerulonephritis.

[0006] Several recent reports suggest that the incidence of both serious infections due to GAS and acute rheumatic fever has increased during the past decade, focusing renewed interest on defining the attributes or virulence factors of the organism that may play a role in the pathogenesis of these diseases.

[0007] GAS produce several surface components and extracellular products that may be important in virulence. The major surface protein, M protein, has been studied in the most detail and has been convincingly shown to play a role in both virulence and immunity. Isolates rich in M protein are able to grow in human blood, a property thought to reflect the capacity of N protein to interfere with phagocytosis, and these isolates tend to be virulent in experimental animals.

[0008] Lancefield group B *Streptococcus* (“GBS”) are most often seen in cattle, causing mastitis; however, human infants are susceptible as well, often with fatal consequences. Group B streptococci (GBS) constitute a major cause of bacterial sepsis and meningitis among human neonates born in the United States and Western Europe and are emerging as significant neonatal pathogens in developing countries as well.

[0009] It is estimated that GBS strains are responsible for 10,000 to 15,000 cases of invasive infection in neonates in the United States alone. Despite advances in early diagnosis and treatment, neonatal sepsis due to GBS continues to carry a mortality rate of 15 to 20%. In addition, survivors of GBS meningitis have 30 to 50% incidence of long-term neurologic sequelae. Over the past two decades, increasing recognition of GBS as an important pathogen for human infants has generated renewed interest in defining the bacterial and host factors important in virulence of GBS and in the immune response to GBS infection.

[0010] Particular attention has focused on the capsular polysaccharide as the predominant surface antigen of the organisms. In a modification of the system originally developed by Rebecca Lancefield, GBS strains are serotyped on the basis of antigenic differences in their capsular

polysaccharides and the presence or absence of serologically defined C proteins. While GBS isolated from non-human sources often lack a serologically detectable capsular, a large majority of strains associated with neonatal infection belong to one of four major capsular serotypes, Ia, Ib, II or III. The capsular polysaccharide forms the outermost layer around the exterior of the bacterial cell, superficial to the cell wall. The capsule is distinct from the cell wall-associated group B carbohydrate. It has been suggested that the presence of sialic acid, in the capsule of bacteria that causes meningitis, is important for allowing these bacteria to breach the blood-brain barrier. Indeed, in *S. agalactiae*, sialic acid has been shown to be critical for the virulence function of the type III capsule. The capsule of *S. suis* serotype is composed of glucose, galactose, N-acetylglucosamine, rhamnose and sialic acid.

[0011] The group B polysaccharide, in contrast to the type-specific capsule, is present on all GBS strains and is the basis for serogrouping the organisms into Lancefield's group B. Early studies by Lancefield and co-workers showed that antibodies raised in rabbits against whole GBS organisms protected mice against challenge with strains of homologous capsular type, demonstrating the central role of the capsular polysaccharide as a protective antigen. Studies in the 1970s by Baker and Kasper demonstrated that cord blood of human infants with type III GBS sepsis uniformly had low or undetectable levels of antibodies directed against the type III capsule, suggesting that a deficiency of anticapsular antibody was a key factor in susceptibility of human neonates to GBS disease.

[0012] Lancefield group C infections, such as those with *S. equi*, *S. zooepidemicus*, *S. dysgalactiae*, and others, are mainly seen in horses, cattle and pigs, but can also cross the species barrier to humans. Lancefield group D (*S. bovis*) infections are found in all mammals and some birds, sometimes resulting in endocarditis or septicemia.

[0013] Lancefield groups E, G, L, P, U and V (*S. porcinus*, *s. canis*, *s. dysgalactiae*) are found in various hosts, causing neonatal infections, nasopharyngeal infections or mastitis.

[0014] Within Lancefield groups R, S and T (and with ungrouped types), *Streptococcus suis* is an important cause of meningitis, septicemia, arthritis and sudden death in young pigs (4, 46). Incidentally, it can also cause meningitis in man (1). *S. suis* strains are usually identified and classified by their morphological, biochemical and serological characteristics (58, 59, 46).

Serological classification is based on the presence of specific antigenic polysaccharides. So far, 35 different serotypes have been described (9, 56, 14). In several European countries, *S. suis* serotype 2 is the most prevalent type isolated from diseased pigs, followed by serotypes 9 and 1. Serological typing of *S. suis* is performed using different types of agglutination tests. In these tests, isolated and biochemically characterized *S. suis* cells are agglutinated with a panel of 35 specific sera. These methods are very laborious and time-consuming.

[0015] Little is known about the pathogenesis of the disease caused by *S. suis*, let alone about its various serotypes such as type 2. Various bacterial components, such as extracellular and cell-membrane associated proteins, fimbriae, hemagglutinins, and hemolysis, have been suggested as virulence factors (9, 10, 11, 15, 16, 47, 49). However, the precise role of these protein components in the pathogenesis of the disease remains unclear (37). It is well known that the polysaccharide capsule of various Streptococci and other gram-positive bacteria plays an important role in pathogenesis (3, 6, 35, 51, 52). The capsule enables these microorganisms to resist phagocytosis and is therefore regarded as an important virulence factor. Recently, a role of the capsule of *S. suis* in the pathogenesis was suggested as well (5). However, the structure, organization and function of the genes responsible for capsule polysaccharide synthesis (“*cps*”) in *S. suis* is unknown. Within *S. suis*, serotype 1 and 2 strains can differ in virulence for pigs (41, 45, 49). Some type 1 and 2 strains are virulent, other strains are not. Because both virulent and non-virulent strains of serotype 1 and 2 strains are fully encapsulated, it may even be that the capsule is not a relevant factor required for virulence.

[0016] Attempts to control *S. suis* infections or disease are still hampered by the lack of knowledge about the epidemiology of the disease and the lack of effective vaccines and sensitive diagnostics. It is well known and generally accepted that the polysaccharide capsule of various Streptococci and other gram-positive bacteria plays an important role in pathogenesis. The capsule enables these microorganisms to resist phagocytosis and is therefore regarded as an important virulence factor.

[0017] Compared to encapsulated *S. suis* strains, non-encapsulated *S. suis* strains are phagocytosed by murine polymorphonuclear leucocytes to a greater degree. Moreover, an increase in thickness of capsule was noted for *in vivo* grown virulent strains while no increase was observed for

avirulent strains. Therefore, these data again demonstrate the role of the capsule in the pathogenesis for *S. suis* as well.

[0018] Ungrouped *Streptococcus species*, such as *S. mutans*, causing caries in humans, *S. uberis*, causing mastitis in cattle, and *S. pneumoniae*, causing major infections in humans, and *Enterococcus faecilalis* and *E. faecium*, further contribute to the large group of Streptococci.

[0019] *Streptococcus pneumoniae* (the pneumococcus) is a human pathogen causing invasive diseases, such as pneumonia, bacteremia, and meningitis. Despite the availability of antibiotics, pneumococcal infections remain common and can still be fatal, especially in high-risk groups, such as young children and elderly people. Particularly in developing countries, many children under the age of five years die each year from pneumococcal pneumonia. *S. pneumoniae* is also the leading cause of otitis media and sinusitis. These infections are less serious, but nevertheless incur substantial medical costs, especially when leading to complications, such as permanent deafness. The normal ecological niche of the pneumococcus is the nasopharynx of man. The entire human population is colonized by the pneumococcus at one time or another, and at a given time, up to 60% of individuals may be carriers. Nasopharyngeal carriage of pneumococci by man is often accompanied by the development of protection against infection by the same serotype. Most infections do not occur after prolonged carriage but follow exposure to recently acquired strains. Many bacteria contain surface polysaccharides that act as a protective layer against the environment. Surface polysaccharides of pathogenic bacteria usually make the bacteria resistant to the defense mechanisms of the host, for example, the lytic action of serum or phagocytosis. In this respect, the serotype-specific capsular polysaccharide (“CP”) of *Streptococcus pneumoniae*, is an important virulence factor. Unencapsulated strains are avirulent, and antibodies directed against the CP are protective. Protection is serotype specific; each serotype has its own, specific CP structure. Ninety different capsular serotypes have been identified. Currently, CPs of 23 serotypes are included in a vaccine.

[0020] Vaccines directed against *Streptococcus* infections typically aim to utilize an immune response directed against the polysaccharide capsule of the various *Streptococcus species*, especially since the capsule is considered a primary virulence factor for these bacteria. During

infection, the capsule provides resistance against phagocytosis and thus protects the bacteria from the immune system of the host, and from elimination by macrophages and neutrophils.

[0021] The capsule particularly confers the bacterium resistance to complement-mediated opsonophagocytosis. In addition, some bacteria express capsular polysaccharides (CPs) that mimic host molecules, thereby avoiding the immune system of the host. Also, even when the bacteria have been phagocytosed, intracellular killing is hampered by the presence of a capsule.

[0022] It is generally thought that the bacterium will get recognized by the immune system through the anticapsular-antibodies or serum-factors bound to its capsule and will, through opsonization, get phagocytosed and killed only when the host has antibodies or other serum factors directed against capsule antigens.

[0023] However, these antibodies are serotype-specific, and will often only confer protection against only one of the many serotypes known within a group of *Streptococci*.

[0024] For example, current commercially available *S. suis* vaccines, which are generally based on whole-cell-bacterial preparations, or on capsule-enriched fractions of *S. suis*, confer only limited protection against heterologous strains. Also, the current pneumococcal vaccine that was licensed in the United States in 1983, consists of purified CPs of 23 pneumococcal serotypes whereas at least 90 CP types exist.

[0025] The composition of this pneumococcal vaccine was based, on the frequency of the occurrence of disease isolates in the US and cross-reactivity between various serotypes. Although this vaccine protects healthy adults against infections caused by serotypes included in the vaccine, it fails to raise a protective immune response in infants younger than 18 months and it is less effective in elderly people. In addition, the vaccine confers only limited protection in patients with immunodeficiencies and hematology malignancies.

[0026] Thus, improved vaccines are needed against *Streptococcus* infections. Much attention is directed toward producing CP vaccines by producing the relevant polysaccharides via chemical or recombinant means. However, chemical synthesis of polysaccharides is costly, and capsular polysaccharide synthesis by recombinant means necessitates knowledge about the relevant genes, which is not always available, and needs to be determined for every relevant serotype.

DISCLOSURE OF THE INVENTION

[0027] The invention provides an isolated or recombinant nucleic acid encoding a capsular (*cps*) gene cluster of *Streptococcus suis*. Biosynthesis of capsule polysaccharides has generally been studied in a number of Gram-positive and Gram-negative bacteria (32). In Gram-negative bacteria, but also in a number of Gram-positive bacteria, genes which are involved in the biosynthesis of polysaccharides are clustered at a single locus.

[0028] *Streptococcus suis* capsular genes, as provided by the invention, show a common genetic organization involving three distinct regions. The central region is serotype specific and encodes enzymes responsible for the synthesis and polymerization of the polysaccharides. The central region is flanked by two regions conserved in *Streptococcus suis* which encode proteins for common functions, such as transport of the polysaccharide across the cellular membrane. However, between species, only low homologies exist, hampering easy comparison and detection of seemingly similar genes. Knowing the nucleic acid encoding the flanking regions allows type-specific determination of nucleic acid of the central region of *Streptococcus suis* serotypes as, for example, described herein.

[0029] The invention provides an isolated or recombinant nucleic acid encoding a capsular gene cluster of *Streptococcus suis* or a gene or gene fragment derived thereof. Such a nucleic acid is, for example, provided by hybridizing chromosomal DNA derived from any one of the *Streptococcus suis* serotypes to a nucleic acid encoding a gene derived from a *Streptococcus suis* serotype 1, 2 or 9 capsular gene cluster, as provided by the invention (*see*, for example, Tables 4 and 5) and cloning of (type-specific) genes as, for example, described herein. At least 14 open reading frames are identified. Most of the genes belong to a single transcriptional unit, identifying a coordinate control of these genes. The genes, and the enzymes and proteins they encode, act in concert to provide the capsule with the relevant polysaccharides.

[0030] The invention provides *cps* genes and proteins encoded thereof involved in regulation (CpsA), chain length determination (CpsB, C), export (CpsC) and biosynthesis (CpsE, F, G, H, J, K). Although, at first glance, the overall organization seemed to be similar to that of the *cps* and *eps* gene clusters of a number of Gram-positive bacteria (19, 32, 42), overall homologies are low

(see, table 3). The region involved in biosynthesis is located at the center of the gene cluster and is flanked by two regions containing genes with more common functions.

[0031] The invention provides an isolated or recombinant nucleic acid encoding a capsular gene cluster of *Streptococcus suis* serotype 2, or a gene or gene fragment derived thereof, preferably as identified in FIG. 3. Genes in this gene cluster are involved in polysaccharide biosynthesis of capsular components and antigens. For a further description of such genes see, for example, Table 2. For example, a *cpsA* gene is provided functionally encoding regulation of capsular polysaccharide synthesis, whereas *cpsB* and *cpsC* are functionally involved in chain-in-chain length determination. Other genes, such as *cpsD*, *E*, *F*, *G*, *H*, *I*, *J*, *K* and related genes, are involved in polysaccharide synthesis, functioning, for example, as glucosyl- or glycosyltransferase. The *cpsF*, *G*, *H*, *I*, *J* genes encode more type-specific proteins than the flanking genes which are found more-or-less conserved throughout the species and can serve as a base for selection of primers or probes in PCR-amplification or cross-hybridization experiments for subsequent cloning.

[0032] The invention further provides an isolated or recombinant nucleic acid encoding a capsular gene cluster of *Streptococcus suis* serotype 1 or a gene or gene fragment derived thereof, preferably as identified in FIG. 4.

[0033] In addition, the invention provides an isolated or recombinant nucleic acid encoding a capsular gene cluster of *Streptococcus suis* serotype 9 or a gene or gene fragment derived thereof, preferably as identified in FIG. 5.

[0034] Furthermore, the invention provides, for example, a fragment of the *cps* locus, or parts thereof, involved in the capsular polysaccharide biosynthesis of *S. suis* exemplified herein for serotypes 1, 2 or 9, and allows easy identification or detection of related fragments derived of other serotypes of *S. suis*.

[0035] The invention provides a nucleic acid probe or primer derived from a nucleic acid according to the invention allowing species or serotype-specific detection of *Streptococcus suis*. Such a probe or primer (used interchangeably herein) is, for example, a DNA, RNA or PNA (peptide nucleic acid) probe hybridizing with capsular nucleic acid as provided by the invention. Species-specific detection is provided preferably by selecting a probe or primer sequence from a species-specific region (e.g. flanking region) whereas serotype-specific detection is provided

preferably by selecting a probe or primer sequence from a type-specific region (*e.g.* central region) of a capsular gene cluster as provided by the invention. Such a probe or primer can be used in a further unmodified form, for example, in cross-hybridization or polymerase-chain reaction (PCR) experiments as, for example described in the experimental part herein. The invention provides the isolation and molecular characterization of additional type-specific *cps* genes of *S. suis* types 1 and 9.

In addition, we describe the genetic diversity of the *cps* loci of serotypes 1, 2 and 9 among the 35 *S. suis* serotypes known. Type-specific probes are identified. Also, a type-specific PCR, for example, for serotype 9, is provided, being a rapid, reliable and sensitive assay used directly on nasal or tonsillar swabs or other samples of infected or carrier animals.

[0036] The invention also provides a probe or primer according to the invention with at least one reporter molecule. Examples of reporter molecules are manifold and known in the art; for example, a reporter molecule can include additional nucleic acid provided with a specific sequence (*e.g.* oligo-dT) hybridizing to a corresponding sequence in which hybridization can easily be detected, for example, because it has been immobilized to a solid support.

[0037] Yet other reporter molecules include chromophores, *e.g.* fluorochromes for visual detection, for example, by light microscopy or fluorescent *in situ* hybridization (“FISH”) techniques, or include an enzyme such as horseradish peroxidase for enzymatic detection, *e.g.* in enzyme-linked assays (“EIA”). Yet other reporter molecules include radioactive compounds for detection in radiation-based assays.

[0038] In a preferred embodiment of the invention, at least one probe or primer according to the invention is provided (labeled) with a reporter molecule and a quencher molecule, together with an unlabeled probe or primer in a PCR-based test allowing rapid detection of specific hybridization.

[0039] The invention further provides a diagnostic test or test kit including a probe or primer as provided by the invention. Such a test or test kit is, for example, a cross-hybridization test or PCR-based test advantageously used in rapid detection and/or serotyping of *Streptococcus suis*.

[0040] The invention further provides a protein or fragment thereof encoded by a nucleic acid according to the invention. Examples of such a protein or fragment are proteins described in Table 2. For example, a *cpsA* protein is provided that functionally encodes regulation of capsular

polysaccharide synthesis, whereas *cpsB* and *cpsC* are functionally involved in chain-in-chain length determination. Other proteins or functional fragments thereof, as provided by the invention, such as *cpsD*, *E*, *F*, *G*, *H*, *I*, *J*, *K* and related proteins, are involved in polysaccharide biosynthesis, functioning, for example, as glucosyl- or glycosyltransferase in polysaccharide biosynthesis of *Streptococcus suis* capsular antigen.

[0041] The invention also provides a method of producing a *Streptococcus suis* capsular antigen including using a protein or functional fragment thereof as provided by the invention, and provides therewith a *Streptococcus suis* capsular antigen obtainable by such a method.

[0042] A comparison of the predicted amino acid sequences of the *cps2* genes with sequences found in the databases allowed the assignment of functions to the open reading frames. The central region contains the type-specific glycosyltransferases and the putative polysaccharide polymerase. This region is flanked by two regions encoding for proteins with common functions, such as regulation and transport of polysaccharide across the membrane. Biosynthesis of *Streptococcus* capsular polysaccharide antigen using a protein or functional fragment thereof is advantageously used in chemo-enzymatic synthesis and the development of vaccines which offer protection against serotype-specific Streptococcal disease, and is also advantageously used in the synthesis and development of multivalent vaccines against Streptococcal infections. Such vaccines elicit anticapsular antibodies which confer protection.

[0043] Furthermore, the invention provides an acapsular *Streptococcus* mutant for use in a vaccine, a vaccine strain derived thereof and a vaccine derived thereof. Surprisingly, and against the grain of common doctrine, the invention provides use of a *Streptococcus* mutant deficient in capsular expression in a vaccine.

[0044] Acapsular *Streptococcus* mutants have long been known in the art and can be found in nature. Griffith (*J. Hyg.* 27:113-159, 1928) demonstrated that pneumococci could be transformed from one type to another. If he injected live rough (acapsular or unencapsulated) type 2 pneumococci into mice, the mice would survive. If, however, he injected the same dose of live rough type 2 mixed with heat-killed smooth (encapsulated) type 1 into a mouse, the mouse would die, and, from the blood, he could isolate live smooth type 1 pneumococci. At that time, the significance of this transforming principle was not understood. However, understanding came when

it was shown that DNA constituted the genetic material responsible for phenotypic changes during transformation.

[0045] *Streptococcus* mutants deficient in capsular expression are found in several forms. Some are fully deficient and have no capsule at all, others form a deficient capsule, characterized by a mutation in a capsular gene cluster. Deficiency can, for instance, include capsular formation wherein the organization of the capsular material has been rearranged as, for example, demonstrable by electron microscopy. Yet others have a nearly fully developed capsule which is only deficient in a particular sugar component.

[0046] Now, after much advance of biotechnology and despite the fact that little is still known about the exact localization and sequence of genes involved in capsular synthesis in *Streptococci*, it is possible to create mutants of *Streptococci*, for example, by homologous recombination or transposon mutagenesis, which has, for example, been done for GAS (Wessels et al., *PNAS* 88:8317-8321, 1991), for GBS (Wessels et al., *PNAS* 86: 8983-8987, 1989), for *S. suis* (Smith, ID-DLO Annual report 1996, page 18-19; Charland et al., *Microbiol.* 144:325-332, 1998) and *S. pneumoniae* (Kolkman et al., *J. Bact.* 178:3736-3741, 1996). Such recombinant derived mutants, or isogenic mutants, can easily be compared with the wild-type strains from which they have been derived.

[0047] In a preferred embodiment, the invention provides use of a recombinant-derived *Streptococcus* mutant deficient in capsular expression in a vaccine. Recombinant techniques useful in producing such mutants are, for example, homologous recombination, transposon mutagenesis, and others, wherein deletions, insertions or (point) mutations are introduced in the genome. Advantages of using recombinant techniques include the stability of the obtained mutants (especially with homologous recombination and double cross-over techniques), and the knowledge about the exact site of the deletion, mutation or insertion.

[0048] In another embodiment, the invention provides a stable mutant deficient in capsular expression obtained, for example, through homologous recombination or cross-over integration events. Examples of such a mutant can be found herein, such as mutants 10cpsB or 10cpsEF are stable mutants as provided by the invention.

[0049] The invention also provides a *Streptococcus* vaccine strain and vaccine that has been derived from a *Streptococcus* mutant deficient in capsular expression. In general, the strain or vaccine is applicable within the whole range of Streptococcal infections, including animals or man or with zoonotic infections. It is, of course, now possible to first select a common vaccine strain and derive a *Streptococcus* mutant deficient in capsular expression thereof for the selection of a vaccine strain and use in a vaccine according to the invention.

[0050] In a preferred embodiment, the invention provides use of a *Streptococcus* mutant deficient in capsular expression in a vaccine wherein the *Streptococcus* mutant is selected from the group composed of *Streptococcus* group A, *Streptococcus* group B, *Streptococcus suis* and *Streptococcus pneumoniae*. Herewith the invention provides vaccine strains and vaccines for use with these notoriously heterologous Streptococci, of which a multitude of serotypes exist. With a vaccine, as provided by the invention, that is derived from a specific *Streptococcus* mutant that is deficient in capsular expression, the difficulties relating to lack of heterologous protection can be circumvented since these mutants do not rely on capsular antigens, per se, to induce protection.

[0051] In a preferred embodiment, the vaccine strain is selected for its ability to survive, or even replicate, in an immune-competent host or host cells and thus can persist for a certain period, varying from 1-2 days to more than one or two weeks, in a host, despite its deficient character.

[0052] Although an immunodeficient host will support replication of a wide range of bacteria that are deficient in one or more virulence factors, in general, it is considered a characteristic of pathogenicity of Streptococci that they can survive for certain periods or replicate in a normal host or host cells such as macrophages. For example, Williams and Blakemore (*Neuropath. Appl. Neurobiol.* 16, 345-356, 1990; *Neuropath. Appl. Neurobiol.* 16, 377-392, 1990; *J. Infect. Dis.* 162, 474-481, 1990) show that both polymorphonuclear cells and macrophage cells are capable of phagocytosing pathogenic *S. suis* in pigs lacking anti-*S. suis* antibodies; only pathogenic bacteria could survive and multiply inside macrophages and the pig.

[0053] In a preferred embodiment, the invention, however, provides a deficient or avirulent mutant or vaccine strain which is capable of surviving at least 4-5 days, preferably at least 8-10 days in the host, thereby allowing the development of a solid immune response to subsequent *Streptococcus* infection,

[0054] Due to its persistent but avirulent character, a *Streptococcus* mutant or vaccine strain, as provided by the invention, is well suited to generate specific and/or long-lasting immune responses against Streptococcal antigens. Moreover, possible specific immune responses of the host directed against a capsule are relatively irrelevant because a vaccine strain, as provided by the invention, is typically not recognized by such antibodies.

[0055] In addition, the invention provides a *Streptococcus* vaccine strain, according to the invention, which strain includes a mutant capable of expressing a *Streptococcus* virulence factor or antigenic determinant.

[0056] In a preferred embodiment, the invention provides a *Streptococcus* vaccine strain, according to the invention, which includes a mutant capable of expressing a *Streptococcus* virulence factor wherein the virulence factor or antigenic determinant is selected from a group of cellular components, such as muramidase-released protein ("MRP"), extracellular factor ("EF"), and cell-membrane associated proteins, 60kDA heat shock protein, pneumococcal surface protein A (Psp A), pneumolysin, C protein, protein M, fimbriae, hemagglutinins and hemolysis or components functionally related thereto.

[0057] In a preferred embodiment, the invention provides a *Streptococcus* vaccine strain including a mutant capable of over-expressing the virulence factor. In this way, the invention provides a vaccine strain for incorporation in a vaccine which specifically causes a host immune response directed against antigenically important determinants of virulence (listed above), thereby providing specific protection against the determinants. Over-expression can, for example, be achieved by cloning the gene involved behind a strong promoter, which is, for example, constitutionally expressed in a multicopy system, either in a plasmid or via integration in a genome.

[0058] In yet another embodiment, the invention provides a *Streptococcus* vaccine strain, according to the invention, including a mutant capable of expressing a non-*Streptococcus* protein. Such a vector-*Streptococcus* vaccine strain allows, when used in a vaccine, protection against pathogens other than *Streptococcus*.

[0059] Due to its persistent but avirulent character, a *Streptococcus* vaccine strain or mutant as provided by the invention is well suited to generate specific and long-lasting immune responses, not only against Streptococcal antigens, but also against other antigens expressed by the

strain. Specifically, antigens derived from another pathogen are now expressed without the detrimental effects of the antigen or pathogen which would otherwise have harmed the host.

[0060] An example of such a vector is a *Streptococcus* vaccine strain or mutant wherein the antigen is derived from a pathogen, such as *Actinobacillus pleuropneumonia*, *Mycoplasma*, *Bordetella*, *pasteurella*, *E. coli*, *Salmonella*, *campylobacter*, *Serpulina* and others.

[0061] The invention also provides a vaccine including a *Streptococcus* vaccine strain or mutant according to the invention and a pharmaceutically acceptable carrier or adjuvant. Carriers or adjuvants are well known in the art; examples are phosphate buffered saline, physiological salt solutions, (double-) oil-in-water emulsions, aluminumhydroxide, Specol, block- or co-polymers, and others.

[0062] A vaccine according to the invention can include a vaccine strain either in a killed or live form. For example, a killed vaccine including a strain having (over)expressed a Streptococcal or heterologous antigen or virulence factor is very well suited for eliciting an immune response. In a preferred embodiment, the invention provides a vaccine wherein the strain is live, due to its persistent but avirulent character; a *Streptococcus* vaccine strain, as provided by the invention, is well suited to generate specific and long-lasting immune responses.

[0063] The invention also provides a method for controlling or eradicating a Streptococcal disease in a population comprising vaccinating subjects in the population with a vaccine according to the invention.

[0064] In a preferred embodiment, a method for controlling or eradicating a Streptococcal disease is provided including testing a sample, such as a blood sample, or nasal or throat swab, feces, urine, or other samples such as can be sampled at or after slaughter, collected from at least-one subject, such as an infant or a pig, in a population partly or wholly vaccinated with a vaccine according to the invention for the presence of encapsulated Streptococcal strains or mutants. Since a vaccine strain or mutant according to the invention is not pathogenic, and can be distinguished from wild-type strains by capsular expression, the detection of (fully) encapsulated Streptococcal strains indicates that wild-type infections are still present. Such wild-type infected subjects can then be isolated from the remainder of the population until the infection has passed. With domestic animals, such as pigs, it is even possible to remove the infected subject from the population as a whole by

culling. Detection of wild-type strains can be achieved via traditional culturing techniques, or by rapid detection techniques such as PCR detection.

[0065] In yet another embodiment, the invention provides a method for controlling or eradicating a Streptococcal disease including testing a sample collected from at least one subject in a population partly or wholly vaccinated with a vaccine according to the invention for the presence of capsule-specific antibodies directed against Streptococcal strains. Capsule-specific antibodies can be detected with classical techniques known in the art, such as used for Lancefield's group typing or serotyping.

[0066] A preferred embodiment for controlling or eradicating a Streptococcal disease in a population includes vaccinating subjects in the population with a vaccine according to the invention and testing a sample collected from at least one subject in the population for the presence of encapsulated Streptococcal strains and/or for the presence of capsule-specific antibodies directed against Streptococcal strains.

[0067] For example, a method is provided wherein the Streptococcal disease is caused by *Streptococcus suis*.

[0068] The invention also provides a diagnostic assay for testing a sample for use in a method according to the invention including at least one means for the detection of encapsulated Streptococcal strains and/or for the detection of capsule-specific antibodies directed against Streptococcal strains.

[0069] The invention further provides a vaccine including an antigen according to the invention and a suitable carrier or adjuvant. The immunogenicity of a capsular antigen provided by the invention is, for example, increased by linking to a carrier (such as a carrier protein), allowing the recruitment of T-cell help in developing an immune response.

[0070] The invention further provides a recombinant microorganism provided with at least a part of a capsular gene cluster derived from *Streptococcus suis*. The invention provides for example a lactic acid bacterium provided with at least a part of a capsular gene cluster derived from *Streptococcus suis*. Various food-grade lactic acid bacteria (*Lactococcus lactis*, *Lactobacillus casei*, *Lactobacillus plantarium* and *Streptococcus gordonii*) have been used as delivery systems for mucosal immunization. It has now been shown that oral (or mucosal) administration of recombinant

L. lactis, *Lactobacillus*, and *Streptococcus gordonii* can elicit local IgA and/or IgG antibody responses to an expressed antigen. The use of oral routes for immunization against infective diseases is desirable because oral vaccines are easier to administer and have higher compliance rates, and because mucosal surfaces are the portals of entry for many pathogenic microbial agents. It is within the skill of the artisan to provide such microorganisms with (additional) genes.

[0071] The invention further provides a recombinant *Streptococcus suis* mutant provided with a modified capsular gene cluster. It is within the skill of the artisan to swap genes within a species. In a preferred embodiment, an avirulent *Streptococcus suis* mutant is selected to be provided with at least a part of a modified capsular gene cluster according to the invention.

[0072] The invention further provides a vaccine including a microorganism or a mutant provided by the invention. An advantage of such a vaccine over currently used vaccines is that they include accurately defined microorganisms and well-characterized antigens, allowing accurate determination of immune responses against various antigens of choice.

[0073] The invention is further explained in the experimental part of this description without limiting the invention thereto.

DESCRIPTION OF THE DRAWINGS

[0074] **FIG. 1** illustrates the organization of the *cps2* gene cluster of *S. suis* type 2.

[0075] (A) Genetic map of the *cps2* gene cluster. The shadowed arrows represent potential ORFs. Interrupted ORFs indicate the presence of stop codons or frame-shift mutations. Gene designations are indicated below the ORFs. The closed arrows indicate the position of the potential promoter sequences. | indicates the position of the potential transcription regulator sequence. ||| indicates the position of the 100-bp repeated sequence.

[0076] (B) Physical map of the *cps2* locus. Restriction sites are as follows: A: *AluI*; C: *ClaI*; E: *EcoRI*; H: *HindIII*; K: *KpnI*; M: *MluI*; N: *NsiI*; P: *PstI*; S: *SnaBI*; Sa: *SacI*; X: *XbaI*.

[0077] (C) The DNA fragments cloned in the various plasmids.

[0078] **FIG. 2** illustrates ethidium bromide stained agarose gel showing PCR products obtained with chromosomal DNA of *S. suis* strains belonging to the serotypes 1,2, 1/2, 9 and 14 and *cps2J*, *cps1I*, and *cps9H* primer sets as described herein.

[0079] (A) *cpsII* primers; (B) *cps2J* primers and (C) *cps9H* primers.

[0080] Lanes 1-3: serotype 1 strains; lanes 4-6: serotype 2 strains; lanes 7-9: serotype 1/2 strains; lanes 10-12: serotype 9 strains and lanes 13-15: serotype 14 strains.

[0081] (B) Ethidium bromide stained agarose gel showing PCR products obtained with tonsillar swabs collected from pigs carrying *S. suis* type 2, type 1 or type 9 strains and *cps2J*, *cpsII* and *cpsH* primer sets as described in Materials and Methods. Bacterial DNA suitable for PCR was prepared by using the multiscreen methods as described previously (20).

[0082] (C) *cpsII* primers. (B) *cps2J* primers and (C) *cps9H* primers.

[0083] Lanes 1-3: PCR products obtained with tonsillar swabs collected from pigs carrying *S. suis* type 1 strains; lanes 4-6: PCR products obtained with tonsillar swabs collected from pigs carrying *S. suis* type 2 strains; lanes 7-9: PCR products obtained with tonsillar swabs collected from pigs carrying *S. suis* type 9 strains; lanes 10-12: PCR products obtained with chromosomal DNA from serotype 9, 2 and 1 strains respectively; lane 13: negative control, no DNA present.

[0084] FIG. 3 illustrates the CPS2 nucleotide sequences and corresponding amino acid sequences from the open reading frames.

[0085] FIG. 4 illustrates the CPS1 nucleotide sequences and corresponding amino acid sequences from the open reading frames.

[0086] FIG. 5 illustrates the CPS9 nucleotide sequences and corresponding amino acid sequences from the open reading frames.

[0087] FIG. 6 illustrates the CPS7 nucleotide sequences and corresponding amino acid sequences from the open reading frames.

[0088] FIG. 7 illustrates alignment of the N-terminal parts of Cps2J and Cps2K.

[0089] Identical amino acids are marked by bars. The amino acids shown in bold are also conserved in Cps14I, Cps24J of *S. pneumoniae* and several other glycosyltransferases (19). The aspartate residues marked by asterisks are strongly conserved.

[0090] FIG. 8 illustrates transmission electron micrographs of thin sections of various *S. suis* strains.

[0091] (A) wild-type strain 10;

[0092] (B) mutant strain 10cpsB;

[0093] (C) mutant strain 10cpsEF.

[0094] Bar = 100 nm

[0095] **FIG. 9** illustrates the kinetics of phagocytosis of wild-type and mutant *S. suis* strains.

[0096] (A) Kinetics of phagocytosis of wild-type and mutant *S. suis* strains by porcine alveolar macrophages. Phagocytosis was determined as described herein. The Y-axis represents the number of CFU per milliliter in the supernatant fluids as determined by plate counting, the X-axis represents time in minutes.

[0097] □ wild-type strain 10;

[0098] ○ mutant strain 10cpsB;

[0099] Δ mutant strain 10cpsEF.

[00100] (B) Kinetics of intracellular killing of wild-type and mutant *S. suis* strains by porcine AM. The intracellular killing was determined as described herein. The Y-axis represents the number of CFU per ml in the supernatant fluids after lysis of the macrophages as determined by plate counting, the X-axis represents time in minutes.

[00101] □ wild-type strain 10;

[00102] ○ mutant strain 10cpsB;

[00103] Δ mutant strain 10cpsEF.

[00104] **FIG. 10** illustrates the nucleotide sequence alignment of the highly conserved 100-bp repeated element.

[00105] 1) 100-bp repeat between cps2G and cps2H

[00106] 2) 100-bp repeat within “cps2M”

[00107] 3) 100-bp repeat between cps20 and cps2P

[00108] **FIG. 11** illustrates the cps2, cps9 and cps7 gene clusters of *S. suis* serotypes 2, 9 and 7.

[00109] (A) Genetic organization of the cps2 gene cluster [84]. The large arrows represent potential ORFs. Gene designations are indicated below the ORFs. Identically filled arrows represent ORFs which showed homology. The small closed arrows indicate the position of the potential promoter sequences. | indicates the position of the potential transcription regulator sequence.

[00110] (B) Physical map and genetic organization of the *cps9* gene cluster [15]. Restriction sites are as follows: B: *Bam*HI; P: *Pst*I; H: *Hind*III; X: *Xba*I. The DNA fragments cloned in the various plasmids are indicated. The open arrows represent potential ORFs.

[00111] (C) Physical map and genetic organization of the *cps7* gene cluster. Restriction sites are as follows: C: *Clal*; P: *Pst*I; Sc: *Sca*I. The DNA fragments cloned in the various plasmids are indicated. The open arrows represent potential ORFs.

[00112] **FIG. 12** illustrates ethidium bromide stained agarose gel showing PCR products.

[00113] (A) Ethidium bromide stained agarose gel showing PCR products obtained with chromosomal DNA of *S. suis* strains belonging to the serotypes 1, 2, 9 and 7 and the *cps7H* primer set. Strain designations are indicated above the lanes. C: negative control, no DNA present. M: molecular size marker (lambda digested with *Eco*RI and *Hind*III).

[00114] (B) Ethidium bromide stained agarose gel showing PCR products obtained with serotype 7 strains collected in different countries and from different organs. Bacterial DNA suitable for PCR was prepared by using the multiscreen method as described herein [89]. Strain designations are indicated above the lanes. M: molecular size marker (lambda digested with *Eco*RI and *Hind*III).

DETAILED DESCRIPTION OF THE INVENTION

Experimental part

MATERIAL AND METHODS

Bacterial strains and growth conditions.

[00115] The bacterial strains and plasmids used in this study are listed in Table 1. *S. suis* strains were grown in Todd-Hewitt broth (code CM189, Oxoid), and plated on Columbia agar blood base (code CM331, Oxoid) containing 6% (v/v) horse blood. *E. coli* strains were grown in Luria broth (28) and plated on Luria broth containing 1.5% (w/v) agar. If required, antibiotics were added to the plates at the following concentrations: spectinomycin: 100 µg/ml for *S. suis* and 50 µg/ml for *E. coli* and ampicillin, 50 µg/ml.

[00116] **Serotyping.** The *S. suis* strains were serotyped by the slide agglutination test with serotype-specific antibodies (44).

[00117] DNA techniques. Routine DNA manipulations were performed as described by Sambrook et al. (36).

[00118] Alkaline phosphatase activity. To screen for PhoA fusions in *E. coli*, plasmid libraries were constructed. Therefore, chromosomal DNA of *S. suis* type 2 was digested with *AluI*. The 300-500-bp fragments were ligated to *SmaI*-digested pPHOS2. Ligation mixtures were transformed to the PhoA⁻ *E. coli* strain CC118. Transformants were plated on LB media supplemented with 5- Bromo-4-chloro-3-indolylfosfaat (BCIP, 50 µg/ml, Boehringer, Mannheim, Germany). Blue colonies were purified on fresh LB/BCIP plates to verify the blue phenotype.

[00119] DNA sequence analysis. DNA sequences were determined on a 373A DNA Sequencing System (Applied Biosystems, Warrington, GB). Samples were prepared by using an ABI/PRISM dye terminator cycle sequencing ready reaction kit (Applied Biosystems). Sequencing data were assembled and analyzed using the MacMollyTetra program. Custom-made sequencing primers were purchased from Life Technologies. Hydrophobic stretches within proteins were predicted by the method of Klein et al. (17). The BLAST program available on Netscape Navigator™ was used to search for protein sequences related to the deduced amino acid sequences.

[00120] Construction of gene-specific knock-out mutants of *S. suis*. To construct the mutant strains 10cpsB and 10cpsEF, we electrotransformed the pathogenic serotype 2 strain 10 (45, 49) of *S. suis* with pCPS11 and pCPS28 respectively. In these plasmids, the *cpsB* and *cpsEF* genes were disturbed by the insertion of a spectinomycin-resistance gene. To create pCPS11, the internal 400 bp *PstI*-*BamHI* fragment of the *cpsB* gene in pCPS7 was replaced by the Spc^R gene. For this purpose, pCPS7 was digested with *PstI* and *BamHI* and ligated to the 1,200-bp *PstI*-*BamHI* fragment, containing the Spc^R gene, from pIC-spc. To construct pCPS28, we have used pIC20R. In this plasmid we inserted the *KpnI*-*SalI* fragment from pCPS17 (resulting in pCPS25) and the *XbaI*-*ClaI* fragment from pCPS20 (resulting in pCPS27). pCPS27 was digested with *PstI* and *XhoI* and ligated to the 1,200-bp *PstI*-*XhoI* fragment, containing the Spc^R gene of pIC-spc. The electrotransformation to *S. suis* was carried out as described before (38).

[00121] Southern blotting and hybridization. Chromosomal DNA was isolated as described by Sambrook et al. (36). DNA fragments were separated on 0.8% agarose gels and transferred to Zeta-Probe GT membranes (Bio-Rad) as described by Sambrook et al. (36). DNA

probes were labeled with [(³²P)dCTP (3000 Ci mmol⁻¹ Amersham) by use of a random primed labeling kit (Boehringer). The DNA on the blots was hybridized at 65°C with appropriate DNA probes as recommended by the supplier of the Zeta-Probe membranes. After hybridization, the membranes were washed twice with a solution of 40 mM sodium phosphate, pH 7.2, 1 mM EDTA, 5% SDS for 30 min at 65°C and twice with a solution of 40 mM sodium phosphate, pH 7.2, 1 mM EDTA, 1% SDS for 30 min at 65°C.

[00122] PCR. The primers used in the *cps2J* PCR correspond to the positions 13791-13813 and 14465-14443 in the *S. suis cps2* locus. The sequences were: 5'-CAAACGCAAGGAATTACGGTATC-3' (SEQ ID NO:1) and 5'-GAGTATCTAAAGAATGCCTATTG-3' (SEQ ID NO:2). The primers used for the *cps1I* PCR correspond to the positions 4398-4417 and 4839-4821 in the *S. suis cps1* sequence. The sequences were: 5'-GGCGGTCTAGCAGATGCTCG-3' (SEQ ID NO:3) and 5'-GCGAACTGTTAGCAATGAC-3' (SEQ ID NO:4). The primers used in the *cps9H* PCR correspond to the positions 4406-4126 and 4494-4475 in the *S. suis cps9* sequence. The sequences were: 5'-GGCTACATATAATGGAAGCCC3' (SEQ ID NO:5) and 5'-CGGAAGTATCTGGGCTACTG-3' (SEQ ID NO:6).

[00123] Construction of gene-specific knock-out mutants of *S. suis*. To construct the mutant strains 10cpsB and 10cpsEF, we electrotransformed the pathogenic serotype 2 strain 10 of *S. suis* with pCPS11 and pCPS28 respectively. In these plasmids, the *cpsB* and *cpsEF* genes were disturbed by the insertion of a spectinomycin-resistance gene. To create pCPS11, the internal 400 bp *PstI*-*BamHI* fragment of the *cpsB* gene in pCPS7 was replaced by the Spc^R gene. For this purpose, pCPS7 was digested with *PstI* and *BamHI* and ligated to the 1,200-bp *PstI*-*BamHI* fragment, containing the Spc^R gene, from pIC-spc. To construct pCPS28, we have used pIC20R. In this plasmid, we inserted the *KpnI*-*SalI* fragment from pCPS17 (resulting in pCPS25) and the *XbaI*-*ClaI* fragment from pCPS20 (resulting in pCPS27). pCPS27 was digested with *PstI* and *XhoI* and ligated to the 1,200-bp *PstI*-*XhoI* fragment, containing the spc^R gene of pIC-Spc. The electrotransformation to *S. suis* was carried out as described before (38).

[00124] Phagocytosis assay. Phagocytosis assays were performed as described by Leij et al. (23). Briefly, to opsonize the cells, 10⁷ *S. suis* cells were incubated with 6% SPF-pig serum for 30

min at 37°C in a head-over-head rotor at 6 rpm. 10^7 AM and 10^7 opsonized *S. suis* cells were combined and incubated at 37°C under continuous rotation at 6 rpm. At 0, 30, 60 and 90 min, 1-ml samples were collected and mixed with 4 ml of ice-cold EMEM to stop phagocytosis. Phagocytes were removed by centrifugation for 4 min at 110 x g and 4°C. The number of colony-forming units, (“CFU”) in the supernatants was determined. Control experiments were carried out simultaneously by combining 10^7 opsonized *S. suis* cells with EMEM (without AM).

[00125] Killing assays. AM (10^7 /ml) and opsonized *S. suis* cells (10^7 /ml) were mixed 1 : 1 and incubated for 10 min at 37°C under continuous rotation at 6 rpm. Ice-cold EMEM was added to stop further phagocytosis and killing. To remove extracellular *S. suis* cells, phagocytes were washed twice (4 min, 110 x g, 4°C) and resuspended in 5 ml EMEM containing 6% SPF serum. The tubes were incubated at 37°C under rotation at 6 rpm. After 0, 15, 30, 60 and 90 min, samples were collected and mixed with ice-cold EMEM to stop further killing. The samples were centrifuged for 4 min at 110 x g at 4°C and the phagocytic cells were lysed in EMEM containing 1% saponine for 20 min at room temperature. The number of CFU in the suspensions was determined.

[00126] Pigs. Germfree pigs, crossbreeds of Great Yorkshire and Dutch Landrace, were obtained from sows by caesarian sections. The surgery was performed in sterile flexible film isolators. Pigs were allotted to groups, each consisting of 4 pigs, and were housed in sterile stainless steel incubators.

[00127] Experimental infections. Pigs were inoculated intranasally with *S. suis* type 2 as described before. To predispose the pigs for infection with *S. suis*, five-day old pigs were inoculated intranasally with about 10^7 CFU of *Bordetella bronchiseptica* strain 92932. Two days later, the pigs were inoculated intranasally with *S. suis* type 2 (10^6 CFU). Pigs were monitored twice daily for clinical signs of disease, such as fever, nervous signs and lameness. Blood samples were collected three times a week from each pig. White blood cells were counted with a cell counter. To monitor infection with *S. suis* and *B. bronchiseptica* and to check for absence of contaminants, we collected swabs of nasopharynx and feces daily. The swabs were plated directly onto Columbia agar containing 6% horse blood. After three weeks, the pigs were killed and examined for pathological changes. Tissue specimens from the central nervous system, serosae, and joints were examined bacteriologically and histologically as described herein (45, 49). Colonization of the serosae was

scored positively when *S. suis* was isolated from the pericardium, thoracic pleura or the peritoneum. Colonization of the joints was scored positively when *S. suis* was isolated from one or more joints (12 joints per animal were scored).

[00128] Vaccination and challenge. One week old pigs were vaccinated intravenously with a dosage of 10⁶ cfu of the *S. suis* strains 10cpsEF or 10cpsB. Three weeks later, the pigs were challenged intravenously with the pathogenic serotype 2 strain 10 (10⁷ cfu). Disease monitoring, hematological, serological and bacteriological examinations as well as post-mortum examinations were as described before under experimental infections.

[00129] Electron Microscopy. Bacteria were prepared for electron microscopy as described by Wagenaar et al. (50). Shortly, bacteria were mixed with agarose MP (Boehringer) of 37°C to a concentration of 0.7%. The mixture was immediately cooled on ice. Upon gelifying, samples were cut into 1 to 1.5 mm slices and incubated in a fixative containing 0.8% glutaraldehyde and 0.8% osmiumtetroxide. Subsequently, the samples were fixed and stained with uranyl acetate by microwave stimulation, dehydrated and imbedded in eponaraldite resin. Ultra-thin sections were counterstained with lead citrate and examined with a Philips CM 10 electron microscope at 80 kV. (FIG. 8.)

[00130] Isolation of porcine alveolar macrophages (AM). Porcine AM were obtained from the lungs of specific pathogen-free (“SPF”) pigs. Lung lavage samples were collected as described by van Leengoed et al. (43). Cells were suspended in EMEM containing 6% (v/v) SPF-pig serum and adjusted to 10 cells per ml.

RESULTS

Identification of the *cps* locus.

[00131] The *cps* locus of *S. suis* type 2 was identified through a strategy developed for the genetic identification of exported proteins (13, 31). In this system, a plasmid (pPHOS2) containing a truncated alkaline phosphatase gene (13) was used. The gene lacked the promoter sequence, the translational start site and the signal sequence. The truncated gene is preceded by a unique *Sma*I restriction site. Chromosomal DNA of *S. suis* type 2, digested with *Alu*I, was randomly cloned in this restriction site. Because translocation of PhoA across the cytoplasmic membrane of *E. coli* is

required for enzymatic activity, the system can be used to select for *S. suis* fragments containing a promoter sequence, a translational start site and a functional signal sequence. Among 560 individual *E. coli* clones tested, 16 displayed a dark blue phenotype when plated on media containing BCIP. DNA sequence analysis of the inserts from several of these plasmids was performed (results not shown) and the deduced amino acid sequences were analyzed. The hydrophobicity profile of one of the clones (pPHOS7, results not shown) showed that the N-terminal part of the sequence resembled the characteristics of a typical signal peptide: a short hydrophilic N-terminal region is followed by a hydrophobic region of 38 amino acids. These data indicate that the *phoA* system was successfully used for the selection of *S. suis* genes encoding exported proteins. Moreover, the sequences were analyzed for similarities present in the databases. The sequence of pPHOS7 showed a high similarity (37% identity) with the protein encoded by the *cps14C* gene of *Streptococcus pneumoniae* (19). This strongly suggests that pPHOS7 contains a part of the *cps* operon of *S. suis* type 2.

[00132] Cloning of the flanking *cps* genes. In order to clone the flanking *cps* genes of *S. suis* type 2, the insert of pPHOS7 was used as a probe to identify chromosomal DNA fragments which contain flanking *cps* genes. A 6-kb *HindIII* fragment was identified and cloned in pKUN19. This yielded clone pCPS6 (FIG. 1, part C). Sequence analysis of the insert of pCPS6 revealed that pCPS6 most probably contained the 5'-end of the *cps* locus, but still lacked the 3'-end. Therefore, sequences of the 3'-end of pCPS6 were in turn used as a probe to identify chromosomal fragments containing *cps* sequences located further downstream. These fragments were also cloned in pKUN19, resulting in pCPS17. Using the same system of chromosomal walking, plasmids pCPS18, pCPS20, pCPS23 and pCPS26, containing downstream *cps* sequences were subsequently generated.

[00133] Analysis of the *cps* operon. The complete nucleotide sequence of the cloned fragments was determined (FIG. 4). Examination of the compiled sequence revealed the presence of at least 13 potential open reading frames (Orfs), which were designated as Orf 2Y, Orf2X and Cps2A-Cps2K (FIG. 1, part A; FIG. 11, part A). Moreover, a 14th, incomplete Orf (Orf 2Z) was located at the 5'-end of the sequence. Two potential promoter sequences were identified. One was located 313 bp (locations 1885-1865 and 1884-1889) upstream of Orf2X. The other potential promoter sequence was located 68 bp upstream of Orf2Y (locations 2241-2236 and 2216-2211). Orf2Y is expressed in opposite orientation. Between Orfs 2Y and 2Z, the sequence contained a

potential stem-loop structure, which could act as a transcription terminator. Each Orf is preceded by a ribosome-binding site and the majority of the Orfs are very closely linked. The only significant intergenic gap was found between Cps2G and Cps2H (389 nucleotides). However, no obvious promoter sequences or potential stem-loop structures were found in this region. These data suggest that Orf2X and Cps2A-Cps2K are arranged as an operon.

[00134] An overview of all Orfs with their properties is shown in Table 2. The majority of the predicted gene products is related to proteins involved in polysaccharide biosynthesis. Orf2Z showed some similarity with the YitS protein of *Bacillus subtilis*. YitS was identified during the sequence analysis of the complete genome of *B. subtilis*. The function of the protein is unknown.

[00135] Orf2Y showed similarity with the YcxD protein of *B. subtilis* (53). Based on the similarity between YcxD and MocR of *Rhizobium meliloti* (33), YcxD was suggested to be a regulatory protein.

[00136] Orf2X showed similarity with the hypothetical YAAA proteins of *Haemophilus influenzae* and *E. coli*. The function of these proteins is unknown.

[00137] The gene products encoded by the *cps2A*, *cps2B*, *cps2C* and *cps2D* genes showed approximate similarity to the CpsA, CpsC, CpsD and CpsB proteins of several serotypes of *Streptococcus pneumoniae* (19), respectively. This suggests similar functions for these proteins. Hence, Cps2A may have a role in the regulation of the capsular polysaccharide synthesis. Cps2B and Cps2C could be involved in the chain length determination of the type 2 capsule and Cps2C can play an additional role in the export of the polysaccharide. The Cps2D protein of *S. suis* is related to the CpsB protein of *S. pneumoniae* and to proteins encoded by genes of several other Gram-positive bacteria involved in polysaccharide or exopolysaccharide synthesis, but their function is unknown (19).

[00138] The protein encoded by the *cps2E* gene showed similarity to several bacterial proteins with glycosyltransferase activities: Cps14E and Cps19fE of *S. pneumoniae* serotypes 14 and 19F (18, 19, 29), CpsE of *Streptococcus salvarius* (X94980) and CpsD of *Streptococcus agalactiae* (34). Recently, Kolkman et al. (18) showed that Cps14E is a glucosyl-1-phosphate transferase that links glucose to a lipid carrier, the first step in the biosynthesis of the *S. pneumoniae* type 14 repeating unit. Based on these data, a similar function may be fulfilled by Cps2E of *S. suis*.

[00139] The protein encoded by the *cps2F* gene showed similarity to the protein encoded by the *rfbU* gene of *Salmonella enteritica* (25). This similarity is most pronounced in the C-terminal regions of these proteins. The *rfbU* gene was shown to encode mannosyltransferase activity (25).

[00140] The *cps2G* gene encoded a protein that showed moderate similarity with the *rfbF* gene product of *Campylobacter hyoilei* (22), the *epsF* gene product of *S. thermophilus* (40) and the *capM* gene product of *S. aureus* (24). On the basis of similarity, the *rfbF*, *epsF* and *capM* genes are suggested to encode galactosyltransferase activities. Hence, a similar glycosyltransferase activity could be fulfilled by the *cps2G* gene product.

[00141] The *cps2H* gene encodes a protein that is similar to the N-terminal region of the *lgtD* gene product of *Haemophilus influenzae* (U32768). Moreover, the hydrophobicity plots of Cps2H and LgtD looked very similar in these regions (data not shown). Based on sequence similarity, the *lgtD* gene product was suggested to have glycosyltransferase activity (U32768).

[00142] The gene product encoded by the *cps2I* gene showed some similarity with a protein of *Actinobacillus actinomycetemcomitans* (AB002668). This protein is part of the gene cluster responsible for the serotype-b-specific antigen of *A. actinomycetemcomitans*. The function of the protein is unknown.

[00143] The gene products encoded by the *cps2J* and *cps2K* genes showed significant similarities to the Cps14J protein of *S. pneumoniae*. The *cps14J* gene of *S. pneumoniae* was shown to encode a β -1,4-galactosyltransferase activity. In *S. pneumoniae*, CpsJ is responsible for the addition of the fourth (*i.e.* last) sugar in the synthesis of the *S. pneumoniae* serotype 14 polysaccharide (20). Even some similarity was found between Cps2J and Cps2K (FIG. 2, 25.5% similarity). This similarity was most pronounced in the N-terminal regions of the proteins (FIG. 7). Recently, two small conserved regions were identified in the N-terminus of Cps14J and Cps14I and their homologues (20). These regions were predicted to be important for catalytic activity. Both regions, DXS and DXDD (FIG. 2), were also found in Cps2J and Cps2K.

[00144] **Distribution of the *cps2* genes in other *S. suis* serotypes.** To examine the relationship between the *cps2* genes and *cps* genes in the other *S. suis* serotypes, we performed cross-hybridization experiments. DNA fragments of the individual *cps2* genes were amplified by PCR, labeled with ^{32}P , and used to probe Southern blots of chromosomal DNA of the reference

strains of the 35 different *S. suis* serotypes. Large variations in the hybridization patterns were observed (Table 4). As a positive control, we used a probe specific for 16S rRNA. The 16S rRNA probe hybridized with all serotypes tested. However, none of the other genes tested were common in all serotypes. Based on the genetic organization of the genes, it was previously suggested that *orfX* and *cpsA-cpsK* genes are part of one operon and that the proteins encoded by these genes are all involved in polysaccharide biosynthesis. OrfY and OrfZ are not a part of this operon, and their role in the polysaccharide biosynthesis is unclear. Based on sequence similarity data, OrfY may be involved in regulation of the *cps2* genes. OrfZ is proposed to be unrelated to polysaccharide biosynthesis. Probes specific for the *orfZ*, *orfY*, *orfX*, *cpsA*, *cpsB*, *cpsC* and *cpsD* genes hybridized with most other serotypes. This suggests that the proteins encoded by these genes are not type-specific, but may perform more common functions in biosynthesis of the capsular polysaccharide. This confirms previous data which showed that the *cps2A-cps2D* genes showed strong similarity to *cps* genes of several serotypes of *Streptococcus pneumoniae*. Based on this similarity, Cps2A is possibly a regulatory protein, whereas Cps2B and Cps2C may play a role in length determination and export of polysaccharide. The *cps2E* gene hybridized with DNA of serotypes 1, 2, 14 and 1/2. The *cps2E* gene showed a strong similarity to the *cps14E* gene of *S. pneumoniae* (18). This enzyme was shown to have a glucosyl-1-phosphate activity and catalyzed the transfer of glucose to a lipid carrier (18). These data indicate that a glycosyltransferase closely related to Cps14E may be responsible for the first step in the biosynthesis of polysaccharide in the *S. suis* serotypes 1, 2, 14 and 1/2. The *cps2F*, *cps2G*, *cps2H*, *cps2I* and *cps2J* genes hybridized with chromosomal DNA of serotypes 2 and 1/2 only. The *cps2G* gene showed an additional weak hybridization signal with DNA of serotype 34. In agglutination tests, serotype 1/2 showed agglutination with sera specific for serotype 2 as well as with sera specific for serotype 1. This suggests that serotype 1/2 shares antigenic determinants with both types 1 and 2. The hybridization data confirmed these data. All putative glycosyltransferases present in serotype 2 are also present in serotype 1/2. The *cps2K* gene showed a hybridization pattern similar to the *cps2E* gene. Hybridization was observed with DNA of serotypes 1, 2, 14 and 1/2. Taken together, these hybridization data show that the *cps2* gene cluster can be divided into three regions: a central region

containing the type-specific genes is flanked by two regions containing common genes for various serotypes.

[00145] Cloning of the type-specific *cps* genes of serotypes 1 and 9. To clone the type-specific *cps* genes of *S. suis* serotype 1, the *cps2E* gene was used as a probe to identify chromosomal DNA fragments of type 1 which contain flanking *cps* genes. A 5 kb *EcoRV* fragment was identified and cloned in pKUN19. This yielded pCPS1-1 (FIG. 1, part B). This fragment was in turn used as a probe to identify an overlapping 2.2 kb *HindIII* fragment. pKUN19 containing this *HindIII* fragment was designated pCPS1-2. The same strategy was followed to identify and clone the type-specific *cps* genes of serotype 9. In this case, we used the *cps2D* gene as a probe. A 0.8 kb *HindIII-XbaI* fragment was identified and cloned, yielding pCPS9-1 (FIG. 1, part C). This fragment was in turn used as a probe to identify a 4 kb *XbaI* fragment. pKUN19 containing this 4 kb *XbaI* fragment was designated pCPS9-2.

[00146] Analysis of the cloned *cpsI* genes. The complete nucleotide sequence of the inserts of pCPS1-1 and pCPS1-2 was determined (FIG. 5). Examination of the sequence revealed the presence of five complete and two incomplete Orfs (FIG. 1, part B). Each Orf is preceded by a ribosome-binding site. In accord with data obtained for the *cps2* genes of serotype 2, the majority of the Orfs is very closely linked. The only significant gap (718 bp) was found between Cps1G and Cps1H. No obvious promoter sequences or potential stem-loop structures could be found in this region. This suggests that, as in serotype 2, the *cps* genes in serotype 1 are arranged in an operon.

[00147] An overview of the Orfs and their properties is shown in Table 2. As expected on the basis of the hybridization data (Table 4), the protein encoded by the *cps1E* gene was related to Cps2E of *S. suis* type 2 (identity of 86%). The fragment cloned in pCPS1-1 lacked the coding region for the first 7 amino acids of the *cps1E* gene.

[00148] The protein encoded by the *cps1F* and *cps1G* genes showed strong similarity to the Cps14F and Cps14G proteins of *Streptococcus pneumoniae* serotype 14, respectively (20). The function of the Cps14F is not completely clear, but it has been suggested that Cps14F has a role in glycosyltransferase activity. The *cps14G* gene of *S. pneumoniae* was shown to encode β -1,4-galactosyltransferase activity. In *S. pneumoniae* type 14, this activity is required for the second step in the biosynthesis of the oligosaccharide subunit (20). Based on the similarity of the data,

similar glycosyltransferase and enhancing activities are suggested for the *cps1G* and *cps1F* genes of *S. suis* type 1.

[00149] The protein encoded by the *cps1H* gene showed similarity to the Cps14H protein of *S. pneumoniae* (20). Based on sequence similarity, Cps14H was proposed to be the polysaccharide polymerase (20).

[00150] The protein encoded by the *cps1I* gene showed some similarity with the Cps14J protein of *S. pneumoniae* (19). The *cps14J* gene was shown to encode a β -1,4-galactosyltransferase activity, responsible for the addition of the fourth (*i.e.* last) sugar in the synthesis of the *S. pneumoniae* serotype 14 polysaccharide.

[00151] Between Cps1G and Cps1H, a gap of 718 bp was found. This region revealed three small Orfs. The three Orfs were expressed in three different reading frames and were not preceded by potential ribosome binding sites, nor contained potential start sites. However, the three potential gene products encoded by this region showed some similarity with three successive regions of the C-terminal part of the EpsK protein of *Streptococcus thermophilus* (27% identity, 40). The region related to the first 82 amino acids is lacking.

[00152] Analysis of the cloned *cps9* genes. We also determined the complete nucleotide sequence of the inserts of pCPS9-1 and pCPS9-2 (FIG. 6). Examination of the sequence revealed the presence of three complete and two incomplete Orfs (FIG. 1, part C). As in serotypes 1 and 2, all Orfs are preceded by a ribosome-binding site and are very closely coupled. As suggested by the hybridization data (Table 4), the Cps2D and Cps9D proteins were highly related (Table 2). Based on sequence comparisons, pCPS9-1 lacked the first 27 amino acids of the Cps9D protein.

[00153] The protein encoded by the *cps9E* gene showed some similarity with the CapD protein of *Staphylococcus aureus* serotype 1 (24). Based on sequence similarity data, the Cap1D protein was suggested to be an epimerase or a dehydratase involved in the synthesis of N-acetylfructosamine or N- acetylgalactosamine (63).

[00154] Cps9F showed some similarity to the CapM proteins of *S. aureus* serotypes 5 and 8 (61, 64, 65). Based on sequence similarity data, Cap5M and Cap8M are proposed to be glycosyltransferases (63).

[00155] The protein encoded by the *cps9G* gene showed some similarity to a protein of *Actinobacillus actinomycetemcomitans* (AB002668_4). This protein is part of a gene cluster responsible for the serotype b-specific antigens of *Actinobacillus actinomycetemcomitans*. The function of the protein is unknown.

[00156] The protein encoded by the *cps9H* gene showed some similarity to the *rfbB* gene of *Yersinia enterocolitica* (68). The RfbB protein was shown to be essential for O-antigen synthesis, but the function of the protein in the synthesis of the O:3 lipopolysaccharide is unknown.

[00157] **Serotype 1 and serotype 9-specific *cps* genes.** To determine whether the cloned fragments in pCPS1-1, pCPS1-2, pCPS9-1 and pCPS9-2 contained the type-specific genes for serotype 1 and 9, respectively, cross-hybridization experiments were performed. DNA fragments of the individual *cps1* and *cps9* genes were amplified by PCR, labeled with ³²P, and used to probe Southern blots of chromosomal DNA of the reference strains of the 35 different *S. suis* serotypes. The results are shown in Table 5. Based on the data obtained with the *cps2E* probe (Table 4), the *cps1E* probe was expected to hybridize with chromosomal DNA of *S. suis* serotypes 1, 2, 14, 27 and 1/2. The *cps1H*, *cps9E* and *cps9F* probes hybridized with most other serotypes. However, the *cps1F* and *cps1G* and *cps1I* probes hybridized with chromosomal DNA of serotypes 1 and 14 only. The *cps9G* and *cps9H* probes hybridized with serotype 9 only. These data suggest that the *cps9G* and *cps9H* probes are specific for serotype 9 and, therefore, could be useful tools for the development of rapid and sensitive diagnostic tests for *S. suis* type 9 infections.

[00158] **Type-specific PCR.** So far, the probes were tested on the 35 different reference strains only. To test the diagnostic value of the type-specific *cps* probes further, several other *S. suis* serotype 1, 2, 1/2, 9 and 14 strains were used. Moreover, since a PCR-based method would be even more rapid and sensitive than a hybridization test, we tested whether we could use a PCR for the serotyping of the *S. suis* strains. The oligonucleotide primer sets were chosen within the *cps2J*, *cps1I* and *cps9H* genes. Amplified fragments of 675 bp, 380 bp and 390 bp were expected, respectively. The results show that 675 bp fragments were amplified on type 2 and 1/2 strains using *cps2J* primers; 380 bp fragments were amplified on type 1 and 14 strains using *cps1I* primers and 390 bp fragments were amplified on type 9 strains using *cps9H* primers.

[00159] Construction of mutants impaired in capsule production. To evaluate the role of the capsule of *S. suis* type 2 in pathogenesis, we constructed two isogenic mutants in which capsule production was disturbed. To construct mutant 10cpsB, pCPS11 was used. In this plasmid, a part of the *cps2B* gene was replaced by the spectinomycin-resistance gene. To construct mutant strain 10cpsEF, the plasmid pCPS28 was used. In pCPS28, the 3'-end of *cps2E* gene, as well as the 5'-end of *cps2F* gene, were replaced by the spectinomycin-resistance gene. pCPS11 and pCPS28 were used to electrotransform strain 10 of *S. suis* type 2 and spectinomycin-resistant colonies were selected. Southern blotting and hybridization experiments were used to select double cross-over integration events (results not shown). To test whether the capsular structure of the strains 10cpsB and 10cpsEF was disturbed, we used a slide agglutination test using a suspension of the mutant strains in hyperimmune anti-*S. suis* type 2 serum (44). The results showed that even in the absence of serotype-specific antisera, the bacteria agglutinated. This indicates that, in the mutant strains, the capsular structure was disturbed. To confirm this, thin sections of wild-type and mutant strains were compared by electron microscopy. The results showed that, compared to the wild-type (FIG. 3, part A), the amount of capsule produced by the mutant strains was greatly reduced (FIG. 3, parts B and C). Almost no capsular material could be detected on the surface of the mutant strains.

Capsular mutants are sensitive to phagocytosis and killing by porcine alveolar macrophages ("PAM").

[00160] The capsular mutants were tested for their ability to resist phagocytosis by PAM in the presence of porcine SPF serum. The wild-type strain 10 seemed to be resistant to phagocytosis under these conditions (FIGS. 9A and 9B). In contrast, the mutant strains were efficiently ingested by macrophages (FIGS. 9A and 9B). After 90 minutes, more than 99.7% (strain 10cpsB) and 99.8% (strain 10cpsEF) of the mutant cells were ingested by the macrophages. Moreover, as shown in FIGS. 9A and 9B, the ingested strains were efficiently killed by the macrophages. 90-98% of all ingested cells were killed within 90 min. No differences could be observed between wild-type and mutant strains. These data indicate that the capsule of *S. suis* type 2 efficiently protects the organism from uptake by macrophages *in vitro*.

[00161] Capsular mutants are less virulent for germfree piglets. The virulence properties of the wild-type and mutant strains were tested after experimental infection of newborn germfree pigs (45, 49). Table 1 shows that specific and nonspecific signs of disease could be observed in all pigs inoculated with the wild-type strain. Moreover, all pigs inoculated with the wild-type strain died during the course of the experiment or were killed because of serious illness or nervous disorders (Table 3). In contrast, the pigs inoculated with strains 10cpsB and 10cpsEF showed no specific signs of disease and all pigs survived until the end of the experiment (Table 6). The temperature of the pigs inoculated with the wild-type strain increased 2 days after inoculation and remained high until day 5 (Table 3). The temperature of the pigs inoculated with the mutant strains sometimes exceeded 40°C, however, we could observe significant differences in the fever index (*i.e.*, percent of observations in an experimental group during which pigs showed fever (>40°C)) between pigs inoculated with wild-type and mutant strains. All pigs showed increased numbers of polymorphonuclear leucocytes (PMLs) ($>10 \times 10^9$ PMLs per liter) (Table 3). However, in pigs inoculated with the mutant strains, the percentage of samples with increased numbers of PMLs was considerably lower. *S. suis* strains and *B. bronchiseptica* could be isolated from the nasopharynx and feces swab samples of all pigs from 1 day post-infection until the end of the experiment (Table 3). Postmortem, the wild-type strain could frequently be isolated from the central nervous system (“CNS”), kidney, heart, liver, spleen, serosae, joints and tonsils. Mutant strains could easily be recovered from the tonsils, but were never recovered from the kidney, liver or spleen. Interestingly, low numbers of the mutant strains were isolated from the CNS, the serosae, the joints, the lungs and the heart. Taken together, these data strongly indicated that mutant *S. suis* strains, impaired in capsule production, are not virulent for young germfree pigs.

[00162] We describe the identification and the molecular characterization of the *cps* locus, involved in the capsular polysaccharide biosynthesis, of *S. suis*. Most of the genes seemed to belong to a single transcriptional unit, suggesting a coordinate control of these genes. Functions to most of the gene products were assigned. Regions involved in regulation (Cps2A), chain length determination (Cps2B, C), export (Cps2C) and biosynthesis (Cps2E, F, G, H, J, K) were identified. The region involved in biosynthesis is located at the center of the gene cluster and is flanked by two regions containing genes with more common functions. The incomplete *orf22* gene was located at

the 5'-end of the cloned fragment. Orf2Z showed some similarity with the YitS protein of *B. subtilis*. However, because the function of the YitS protein is unknown, this did not give us any information about the possible function of Orf2Z. Because the *orf2Z* gene is not a part of the *cps* operon, a role of this gene in polysaccharide biosynthesis is not expected. The Orf2Y protein showed some similarity with the YcxD protein of *B. subtilis* (53). The YcxD protein was suggested to be a regulatory protein. Similarly, Orf2Y may be involved in the regulation of polysaccharide biosynthesis. The Orf2X protein showed similarity with the YAAA proteins of *H. influenzae* and *E. coli*. The function of these proteins is unknown. In *S. suis* type 2, the *orf2X* gene seemed to be the first gene in the *cps2* operon. This suggests a role of Orf2X in the polysaccharide biosynthesis. In *H. influenzae* and *E. coli*, however, these proteins are not associated with capsular gene clusters. The analysis of isogenic mutants impaired in the expression of Orf2X should give more insight in the presumed role of Orf2X in the polysaccharide biosynthesis of *S. suis* type 2.

[00163] The gene products encoded by the *cps2E*, *cps2F*, *cps2G*, *cps2H*, *cps2J* and *cps2K* genes showed little similarity with glycosyltransferases of several Gram-positive or Gram-negative bacteria (18, 19, 20, 22, 25). The *cps2E* gene product shows some similarity with the Cps14E protein of *S. pneumoniae* (18, 19). Cps14E is a glucosyl-1-phosphate transferase that links glucose to a lipid carrier (18). In *S. pneumoniae* this is the first step in the biosynthesis of the oligosaccharide repeating unit. The structure of the *S. suis* serotype 2 capsule contains glucose, galactose, rhamnose, N-acetyl glucosamine and sialic acid in a ratio of 3:1:1:1:1 (7). Based on these data, we conclude that Cps2E of *S. suis* has glucosyltransferase activity and is involved in the linkage of the first sugar to the lipid carrier.

[00164] The C-terminal region of the *cps2F* gene product showed some similarity with the RfbU of *Salmonella enteritica*. RfbU was shown to have mannosyltransferase activity (24). Because mannosyl is not a component of the *S. suis* type 2 polysaccharide, a mannosyltransferase activity is not expected in this organism. Nevertheless, *cps2F* encodes a glycosyltransferase with another sugar specificity.

[00165] Cps2G showed moderate similarity to a family of gene products suggested to encode galactosyltransferase activities (22, 24, 40). Hence, a similar activity is shown for Cps2G.

[00166] Cps2H showed some similarity with LgtD of *H. influenzae* (U32768). Because LgtD was proposed to have glycosyltransferase activity, a similar activity is fulfilled by Cps2H.

[00167] Cps2J and Cps2K showed similarity to Cps14J of *S. pneumoniae* (20). Cps2J showed similarity with Cps14I of *S. pneumoniae* as well. Cps14I was shown to have N-acetyl glucosaminyltransferase activity, whereas Cps14J has a β -1,4-galactosyltransferase activity (20). In *S. pneumoniae*, Cps14I is responsible for the addition of the third sugar and Cps14J for the addition of the last sugar in the synthesis of the type 14 repeating unit (20). Because the capsule of *S. suis* type 2 contains galactose as well as N-acetyl glucosamine components, galactosyltransferase as well as N-acetyl glucoaminyltransferase activities could be envisaged for the *cps2J* and *cps2K* gene products, respectively. As was observed for Cps14I and Cps14J, the N-termini of Cps2J and Cps2K showed a significant degree of sequence similarity. Within the N-terminal domains of Cps14I and Cps14J, two small regions were identified, which were also conserved in several other glycosyltransferases (22). Within these two regions, two Asp residues were proposed to be important for catalytic activity. The two conserved regions, DXS and DXDD, were also found in Cps2J and Cps2K.

[00168] The function of Cps2I remains unclear. Cps2I showed some similarity with a protein of *A. actinomycetemcomitans*. Although this protein part is of the gene cluster responsible for the serotype-B-specific antigens, the function of the protein is unknown.

[00169] We further describe the identification and characterization of the *cps* genes specific for *S. suis* serotypes 1, 2 and 9. After the entire *cps2* locus of *S. suis* serotype 2 was cloned and characterized, functions for most of the *cps2* gene products could be assigned by sequence homologies. Based on these data, the glycosyltransferase activities, required for type specificity, could be located in the center of the operon. Cross-hybridization experiments, using the individual *cps2* genes as probes on chromosomal DNAs of the 35 different serotypes, confirmed this idea. The regions containing the type-specific genes of serotypes 1 and 9 could be cloned and characterized, showing that an identical genetic organization of the *cps* operons of other *S. suis* serotypes exists. The *cps1E*, *cps1F*, *cps1G*, *cps1H*, and *cps1I* genes revealed a striking similarity with *cps14E*, *cps14F*, *cps14G*, *cps14H* and *cps14J* genes of *S. pneumoniae*. Interestingly, *S. pneumoniae* serotype 14 is the serotype most commonly associated with pneumococcal infections in young children (54),

whereas *S. suis* serotype 1 strains are most commonly isolated from piglets younger than 8 weeks (46). In *S. pneumoniae*, the *cps14E*, *cps14G*, *cps14I* and *cps14J* encode the glycosyltransferases required for the synthesis of the type 14 tetrameric repeating unit, showing that the *cps1E*, *cps1G* and *cps1I* genes encoded glycosyltransferases. The precise functions of these genes as well as the substrate specificities of the enzymes can be established. In *S. pneumoniae*, the *cps14E* gene was shown to encode a glucosyl-1-phosphate transferase catalyzing the transfer of glucose to a lipid carrier. Moreover, *cpsE-like* genes were found in *S. pneumoniae* serotypes 9N, 13, 14, 15B, 15C, 18F, 18A and 19F (60). *CpsE* mutants were constructed in the serotypes 9N, 13, 14 and 15B. All mutant strains lacked glycosyltransferase activity (60). Moreover, in all these *S. pneumoniae* serotypes, the *cpsE* gene seemed to be responsible for the addition of glucose to the lipid carrier. Based on these data, we suggest that in *S. suis* type 1, the *cps1E* gene may fulfill a similar function. The structure of the *S. suis* type 1 capsule is unknown, but it is composed of glucose, galactose, N-acetyl glucosamine, N-acetyl galactosamine and sialic acid in a ratio of 1: 2.4: 1: 1:1.4 (5). Therefore, a role of a *cpsE-like* glycosyltransferase activity can easily be envisaged. *CpsE-like* sequences were also found in serotypes 2, 1/2 and 14.

[00170] For polysaccharide biosynthesis in *S. pneumoniae* type 14, transfer of the second sugar of the repeating unit to the first lipid-linked sugar is performed by the gene products of *cps14F* and *cps14G* (20). Similar to Cps14F and Cps14G, the *S. suis* type 1 proteins Cps1F and Cps1G may act as one glycosyltransferase performing the same reaction. Cps14F and Cps14G of *S. pneumoniae* showed similarity to the N-terminal half and C-terminal half of the SpsK protein of *Sphingomonas* (20, 67), respectively. This suggests a combined function for both proteins. Moreover, *cps14F*- and *cps14G*-like sequences were found in several serotypes of *S. pneumoniae* and these genes always seemed to exist together (60). The same was observed for *S. suis* type 1. The *cps1F* and *cps1G* probes hybridized with type 1 and type 14 strains.

[00171] According to the similarity found between the *cps1H* gene and the *cps14H* gene of *S. pneumoniae* (20), *cps1H* is expected to encode a polysaccharide polymerase.

[00172] The protein encoded by the *cps1I* gene showed some similarity with the Cps14J protein of *S. pneumoniae* (19). The *cps14J* gene was shown to encode a β -1,4-galactosyltransferase activity, responsible for the addition of the fourth (*i.e.* last) sugar in the synthesis of the *S.*

pneumoniae serotype 14 polysaccharide. In *S. suis* type 2, the proteins encoded by the *cps2J* and *cps2K* genes showed similarity to the Cps14J protein. However, no significant homologies were found between Cps2J, Cps2K and Cps1I. In the N-terminal regions of Cps14J and Cps14I, two small conserved regions, DXS and DXDD, were identified (19). These regions seemed to be important for catalytic activity (13). At the same positions in the sequence, Cps2I contained the regions DXS and DXED.

[00173] In the region between Cps1G and Cps1H, three small Orfs were identified. Since the Orfs were expressed in three different reading frames, and did not contain potential start sites, expression is not expected. However, the three potential gene products encoded by this region showed some similarity with three successive regions of the C-terminal part of the EpsK (protein of *Streptococcus thermophilus* (27% identity, 40). The region related to the first 82 amino acids is lacking. The EpsK protein was suggested to play a role in the export of the exopolysaccharide by rendering the polymerized exopolysaccharide more hydrophobic through a lipid modification. These data could suggest that the sequences in the region between Cps1G and Cps1H originated from an *epsK*-like sequence. Hybridization experiments showed that this *epsK*-like region is also present in other serotype 1 strains as well as in serotype 14 strains (results not shown).

[00174] The function of most of the cloned serotype 9 genes can be established. Based on sequence similarity data, the *cps9E* and *cps9F* genes could be glycosyltransferases (61, 24, 63, 64, 65). Moreover, the *cps9G* and *cps9H* genes showed similarity to genes located in regions involved in polysaccharide biosynthesis, but the function of these genes is unknown (68).

[00175] Cross-hybridization experiments using the individual *cps2*, *cps1* and *cps9* genes as probes showed that the *cps9G* and *cps9H* probes specifically hybridized with serotype 9 strains. Therefore, these are useful as tools for the identification of *S. suis* type 9 strains both for diagnostic purposes as well as in epidemiological and transmission studies. We previously developed a PCR method which can be used to detect *S. suis* strains in nasal and tonsil swabs of pigs (62). The method was used to identify pathogenic (EF-positive) strains of *S. suis* serotype 2. Besides *S. suis* type 2 strains, serotype 9 strains are frequently isolated from organs of diseased pigs. However, until now, a rapid and sensitive diagnostic test was not available for type 9 strains. Therefore, the type 9-specific probes or the type 9-specific PCR is of great diagnostic value. The *cps1F*, *cps1G* and

cps1I probes hybridized with serotype 1 as well as with serotype 14 strains. In coagglutination tests, type 1 strains react with the anti-type 1 as well as with the anti-type 14 antisera (56). This suggests the presence of common epitopes between these serotypes. On the other hand, type 1 strains agglutinated only with anti-type 1 serum (56, 57), indicating that it is possible to detect differences between those serotypes.

[00176] The *cps2F*, *cps2G*, *cps2H*, *cps2I* and *cps2J* probes hybridized with serotypes 2 and 1/2 only. Serotype 34 showed a weak hybridizing signal with the *cps2G* probe. As shown in agglutination tests, type 1/2 strains react with sera directed against type 1 as well as with sera directed against type 2 strains (46). Therefore, type 1/2 shared antigens with both types 1 and 2. Based on the hybridization patterns of serotype 1/2 strains with the *cps1*- and *cps2*-specific genes, serotype 1/2 seemed to be more closely related to type 2 strains than to type 1 strains. In our current studies, we identify type-specific genes, primers or probes which are used for the discrimination of serotypes 1, 14 and 2 and 1/2 and others of the 35 serotypes yet known. Furthermore, type-specific genes, primers or probes can now easily be developed for yet unknown serotypes, once they become isolated.

Cloning and characterization of a further part of the *cps2* locus.

[00177] Based on the established sequence, 11 genes, designated *cps2L* to *cps2T*, *orf2U* and *orf2V*, were identified. A gene homologous to genes involved in the polymerization of the repeating oligosaccharide unit (*cps20*) as well as genes involved in the synthesis of sialic acid (*cps2P* to *cps2T*) were identified. Moreover, hybridization experiments showed that the genes involved in the sialic acid synthesis are present in *S. suis* serotypes 1, 2, 14, 27 and 1/2. The “*cps2M*” and “*cps2N*” regions showed similarity to proteins involved in the polysaccharide biosynthesis of other Gram-positive bacteria. However, these regions seemed to be truncated or were non-functional as the result of frame-shift or point mutations. At its 3'-end, the *cps2* locus contained two insertional elements (“*orf2U*” and “*orf2V*”), both of which seemed to be non-functional.

[00178] To clone the remaining part of the *cps2* locus, sequences of the 3'-end of pCPS26 (FIG. 1, part C) were used to identify a chromosomal fragment containing *cps2* sequences located further downstream. This fragment was cloned in pKUN19, resulting in pCPS29. Using a similar

approach, we subsequently isolated the plasmids pCPS30 and pCPS34 containing downstream cps2 sequences (FIG. 1, part C).

Analysis of the cps2 operon.

[00179] The complete nucleotide sequence of the cloned fragments was determined. Examination of the compiled sequence revealed the presence of: a sequence encoding the C-terminal part of Cps2K, six apparently functional genes (designated cps2O-cps2T) and the remnants of 5 different ancestral genes (designated “cps2L,” “cps2M,” “cps2N,” “orf2U” and “orf2V”). The latter genes seemed to be truncated or incomplete as the result of the presence of stop codons or frame-shift mutations (FIG. 1, part A). Neither potential promoter sequences nor potential stem-loop structures could be identified within the sequenced region. A ribosome-binding site precedes each ORF and the majority of the ORFs are very closely linked. Three intergenic gaps were found: one between “cps2M” and “cps2N” (176 nucleotides), one between cps2O and cps2P (525 nucleotides), and one between cps2T and “orf2U” (200 nucleotides). These and our above data show that Orf2X and Cps2A-Orf2T are part of a single operon.

[00180] A list of all loci and their properties is shown in Table 4. The “cps2L” region contained three potential ORFs of 103, 79 and 152 amino acids, respectively, which were only separated from each other by stop codons. Only the first ORF is preceded by a potential ribosomal binding site and contained a methionine start codon. This suggests that “cps2L” originates from an ancestral cps2L gene, which coded for a protein of 339 amino acids. The function of this hypothetical cps2L protein remains unclear so far: no significant homologies were found between Cps2L and proteins present in the data libraries. It is not clear whether the first ORF of the “cps2L” region is expressed into a protein of 103 amino acids. The “cps2M” region showed homology to the N-terminal 134 amino acids of the NeuA proteins of *Streptococcus agalactiae* and *Escherichia coli* (AB017355, 32). However, although the “cps2M” region contained a potential ribosome binding site, a methionine start codon was absent. Compared with the *S. agalactiae* sequence, the ATG start codon was replaced by a lysin encoding AAG codon. Moreover, the region homologous to the first 58 amino acids of the *S. agalactiae* NeuA (identity 77%) was separated from the region homologous to amino acids 59-134 of NeuA by a repeated DNA sequence of 100-bp (*see herein*). In addition, the

region homologous to amino acids 59 to 95 of NeuA (identity 32%) and the region homologous to the amino acids 96 to 134 of NeuA (identity 50%) were present in different reading frames. Therefore, the partial and truncated NeuA homologue is probably nonfunctional in *S. suis*. The “cps2N” region showed homology to CpsJ of *S. agalactiae* (accession no. AB017355). However, sequences homologous to the first 88 amino acids of CpsJ were lacking in *S. suis*. Moreover, the homologous region was present in two different reading frames. The protein encoded by the cps2O gene showed homology to proteins of several streptococci involved in the transport of the oligosaccharide repeating unit (accession no. AB017355), suggesting a similar function for Cps2O. The proteins encoded by the cps2P, cps2S and cps2T genes showed homology to the NeuB, NeuD and NeuA proteins of *S. agalactiae* and *E. coli* (accession no AB017355). Because the “cps2M” region also showed homology to NeuA of *E. coli*, the *S. suis* cps2 locus contains a functional neuA gene (cps2T) as well as a nonfunctional (“cps2M”) gene. The mutual homology between these two regions showed an identity of 77% at the amino acid level over amino acids 1-58 and 49% over the amino acids 59-134. Cps2Q and Cps2R showed homology to the N-terminal and C-terminal parts of the NeuC protein of *S. agalactiae* and *E. coli*, respectively. This suggests that the function of the *S. agalactiae* NeuC protein in *S. suis* is likely fulfilled by two different proteins. In *E. coli*, the neu genes are known to be involved in the synthesis of sialic acid. NeuNAc is synthesized from N-acetylmannosamine and phosphoenolpyruvate by NeuNAc synthetase. Subsequently, NeuNAc is converted to CMP-NeuNAc by the enzyme CMP-NeuNAc synthetase. CMP-NeuNAc is the substrate for the synthesis of polysaccharide. In *E. coli*, K1 NeuB is the NeuNAc synthetase, and NeuA is the CMP-NeuNAc synthetase. NeuC has been implicated in the NeuNAc synthesis, but its precise role is not known. The precise role of NeuD is not known. A role of the Cps2P-Cps2T proteins in the synthesis of sialic acid can easily be envisaged, since the capsule of *S. suis* serotype 2 is rich in sialic acid. In *S. agalactiae*, sialic acid has been shown to be critical to the virulence function of the type III capsule. Moreover, it has been suggested that the presence of sialic acid in the capsule of bacteria which can cause meningitis may be important for these bacteria to breach the blood-brain barrier. So far, however, the requirement of the sialic acid for virulence of *S. suis* remains unclear.

[00181] “Orf2U” and “Orf2V” showed homology to proteins located on two different insertional elements. “Orf2U” is homologous to IS1194 of *Streptococcus thermophilus*, whereas “Orf2V” showed homology to a putative transposase of *Streptococcus pneumoniae*. This putative transposase was recently found to be associated with the type 2 capsular locus of *S. pneumoniae*. Compared with the original insertional elements in *S. thermophilus* and *S. pneumoniae*, both “Orf2U” and “Orf2V” are likely to be non-functional due to frame shift mutations within their coding regions.

[00182] A striking observation was the presence of a sequence of 100 bp (FIG. 10) which was repeated three times within the cps2 operon. The sequence is highly conserved (between 94% and 98%) and was found in the intergenic regions between cps2G and cps2H, within “cps2M” and between cps2O and cps2P. No significant homologies were found between this 100-bp direct repeat sequence and sequences present in the data libraries, suggesting that the sequence is unique for *S. suis*.

Distribution of the cps2 sequences among the 35 *S. suis* serotypes.

[00183] To examine the presence of sialic acid encoding genes in other *S. suis* serotypes, we performed cross-hybridization experiments. DNA fragments of the individual cps2 genes were amplified by PCR, radiolabeled with ³²P and hybridized to chromosomal DNA of the reference strains of the 35 different *S. suis* serotypes. As a positive control, we used a probe specific for *S. suis* 16S rRNA. The 16S rRNA probe hybridized with almost equal intensities to all serotypes tested (Table 4). The “cps2L” sequence hybridized with DNA of serotypes 1, 2, 14 and 1/2. The “cps2M”, cps2O, cps2P, cps2Q, cps2R, cps2S and cps2T genes hybridized with DNA of serotypes 1, 2, 14, 27 and 1/2. Because the cps2P-cps2T genes are most likely involved in the synthesis of sialic acid, these results suggest that sialic acid is also a part of the capsule in the *S. suis* serotypes 1, 2, 14, 27 and 1/2. This is in agreement with the finding that the serotypes 1, 2 and 1/2 possess a capsule that is rich in sialic acid. Although the chemical compositions of the capsules of serotypes 14 and 27 are unknown, recent agglutination studies using sialic acid-binding lectins suggested the presence of sialic acid in *S. suis* serotype 14, but not in serotype 27. In these studies, sialic acid was also detected in serotypes 15 and 16. Since the latter observation is not in agreement with our

hybridization studies, it might be that other genes, not homologous to the *cps2P-cps2T* genes, are responsible for the sialic acid synthesis in serotypes 15 and 16.

[00184] A probe based on “*cps2N*” sequences hybridized with DNA from serotypes 1, 2, 14 and 1/2. A probe specific for “*orf2U*” hybridized with serotypes 1, 2, 7, 14, 24, 27, 32, 34, and 1/2, whereas a probe specific for “*orf2V*” hybridized with many different serotypes. In addition, we prepared a probe specific for the 100-bp direct repeat sequence. This probe hybridized with the serotypes 1, 2, 13, 14, 22, 24, 27, 29, 32, 34 and 1/2 (Table 4). To analyze the number of copies of the direct repeat sequence within the *S. suis* serotype 2 chromosome, a Southern blot hybridization and analysis was performed. Therefore, chromosomal DNA of *S. suis* serotype 2 was digested with *NcoI* and hybridized with a ³²P-labeled direct repeat sequence. Only one hybridizing fragment, containing the three direct repeats present on the *cps2* locus, was found (results not shown). This indicates that the 100-bp direct repeat sequence is only associated with the *cps2* locus. In *S. pneumoniae*, a 115-bp long repeated sequence was found to be associated with the capsular genes of serotypes 1, 3, 14 and 19F. In *S. pneumoniae*, this 115-bp sequence was also found in the vicinity of other genes involved in pneumococcal virulence (hyaluronidase and neuraminidase genes). A regulatory role of the 115-bp sequence in coordinate control of these virulence-related genes was suggested.

[00185] To study the role of the capsule in resistance to phagocytosis and in virulence, we constructed two isogenic mutants in which capsule synthesis was disturbed. In 10cpsB, the *cps2B* gene was disturbed by the insertion of an antibiotic-resistance gene, whereas in 10cpsEF, parts of the *cps2E* and *cps2F* genes were replaced. Both mutant strains seemed to be completely unencapsulated. Because the *cps2* genes seemed to be part of an operon, polar effects cannot be excluded. Therefore, these data did not give any information about the role of Cps2B, Cps2E or Cps2F in the polysaccharide biosynthesis. However, the results clearly show that the capsular polysaccharide of *S. suis* type 2 is a surface component with antiphagocytic activity. *In vitro* wild-type encapsulated bacteria are ingested by phagocytes at a very low frequency, whereas the mutant unencapsulated bacteria are efficiently ingested by porcine macrophages. Within 2 hours, over 99.6% of mutant bacteria were ingested and over 92% of the ingested bacteria were killed. Intracellularly, wild-type as well as mutant strains seemed to be killed with the same efficiency. This suggests that the loss of

capsular material is associated with loss of capacity to resist uptake by macrophages. This loss of resistance to *in vitro* phagocytosis was associated with a substantial attenuation of the virulence in germfree pigs. All pigs inoculated with the mutant strains survived the experiment and did not show any specific clinical signs of disease. Only some aspecific clinical signs of disease could be observed. Moreover, mutant bacteria could be reisolated from the pigs. This supports the idea that, as in other pathogenic Streptococci, the capsule of *S. suis* acts as an important virulence factor. Transposon mutants prepared by Charland impaired in the capsule production showed a reduced virulence in pigs and mice. To construct these mutants, the type 2 reference strain S735 was used. We previously showed that this strain is only weakly virulent for young pigs. Moreover, the insertion site of the transposon is unsolved so far.

As a further example herein a rapid PCT test for *Streptococcus suis* type 7 is described.

[00186] Recent epidemiological studies on *Streptococcus suis* infections in pigs indicated that, besides serotypes 1, 2 and 9, serotype 7 is also frequently associated with diseased animals. For the latter serotype, however, no rapid and sensitive diagnostic methods are available. This hampers prevention and control programs. Here we describe the development of a type-specific PCR test for the rapid and sensitive detection of *S. suis* serotype 7. The test is based on DNA sequences of capsular (*cps*) genes specific for serotype 7. These sequences could be identified by cross-hybridization of several individual *cps* genes with the chromosomal DNAs of 35 different *S. suis* serotypes.

[00187] *Streptococcus suis* is an important cause of meningitis, septicemia, arthritis and sudden death in young pigs [69, 70]. It can, however, also cause meningitis in man (71). Attempts to control the disease are still hampered by the lack of sufficient knowledge about the epidemiology of the disease and the lack of effective vaccines and sensitive diagnostics.

[00188] *S. suis* strains can be identified and classified by their morphological, biochemical and serological characteristics (70, 73, 74). Serological classification is based on the presence of specific antigenic determinants. Isolated and biochemically characterized *S. suis* cells are agglutinated with a panel of specific sera. These typing methods are very laborious and

time-consuming and can only be performed on isolated colonies. Moreover, it has been reported that nonspecific cross-reactions may occur among different types of *S. suis* (75, 76).

[00189] So far, 35 different serotypes have been described (7, 78, 79). *S. suis* serotype 2 is the most prevalent type isolated from diseased pigs, followed by serotypes 9 and 1. However, recently, serotype 7 strains were also frequently isolated from diseased pigs (80, 81, 82). This suggests that infections with *S. suis* serotype 7 strains seemed to be an increasing problem. Moreover, the virulence of *S. suis* serotype 7 strains was confirmed by experimental infection of young pigs (83).

[00190] Recently, rapid and sensitive PCR assays specific for serotypes 2 (and 1/2), 1 (and 14) and 9 were developed (84). These assays were based on the *cps* loci of *S. suis* serotypes 2, 1 and 9 (84, 85). However, until now, no rapid and sensitive diagnostic test was available for *S. suis* serotype 7. Herein we describe the development of a PCR test for the rapid and sensitive detection of *S. suis* serotype 7 strains. The test is based on DNA sequences which form a part of the *cps* locus of *S. suis* serotype 7. Compared with the serological serotyping methods, the PCR assay was a rapid, reliable and sensitive assay. Therefore, this test, in combination with the PCR tests which we previously developed for serotypes 1, 2 and 9, will undoubtedly contribute to a more rapid and reliable diagnosis of *S. suis* and may facilitate control and eradication programs.

Materials and Methods

Bacterial strains, growth conditions and serotyping.

[00191] The bacterial strains and plasmids used in this study are listed in Table 7. The *S. suis* reference strains were obtained from M. Gottschalk, Canada. *S. suis* strains were grown in Todd-Hewitt broth (code CM189, Oxoid), and plated on Columbia agar blood base (code CM331, Oxoid) containing 6% (v/v) horse blood. *E. coli* strains were grown in Luria broth (86) and plated on Luria broth containing 1.5% (w/v) agar. If required, ampicillin was added to the plates. The *S. suis* strains were serotyped by the slide agglutination test with serotype-specific antibodies (70).

DNA techniques.

[00192] Routine DNA manipulations and PCR reactions were performed as described by Sambrook et al. (88). Blotting and hybridization were performed as described previously (84, 86).

DNA sequence analysis.

[00193] DNA sequences were determined on a 373A DNA Sequencing system (Applied Biosystems, Warrington, GB). Samples were prepared by use of an ABI/PRISM dye terminator cycle sequencing ready reaction kit (Applied Biosystems). Custom-made sequencing primers were purchased from Life Technologies. Sequencing data were assembled and analyzed using the McMollyTetra program. The BLAST program was used to search for protein sequences homologous to the deduced amino acid sequences.

PCR.

[00194] The primers used for the *cps7H* PCR correspond to the positions 3334-3354 and 3585-3565 in the *S. suis* *cps7* locus. The sequences were: 5'-AGCTCTAACACGAAATAAGGC-3' (SEQ ID NO:7) and 5'-GTCAAACACCCTGGATAGCCG-3' (SEQ ID NO:8).

[00195] The reaction mixtures contained 10 mM Tris-HCl, pH 8.3; 1.5 mM MgCl₂; 50 mM KCl; 0.2 mM of each of the four deoxynucleotide triphosphates; 1 microM of each of the primers and 1U of AmpliTaq Gold DNA polymerase (Perkin Elmer Applied Biosystems, New Jersey). DNA amplification was carried out in a Perkin Elmer 9600 thermal cycler and the program consisted of an incubation for 10 min at 95°C and 30 cycles of 1 min at 95°C, 2 min at 56°C and 2 min at 72°C.

Results and discussion

Cloning of the serotype 7-specific *cps* genes.

[00196] To isolate the type-specific *cps* genes of *S. suis* serotype 7, we used the *cps9E* gene of serotype 9 as a probe to identify chromosomal DNA fragments of type 7 containing homologous DNA sequences (84). A 1.6-kb PstI fragment was identified and cloned in pKUN19. This yielded pCPS7-1 (FIG. 11, part C). In turn, this fragment was used as a probe to identify an overlapping 2.7

kb ScaI-ClaI fragment. pGEM7 containing the latter fragment was designated pCPS7-2 (FIG. 11, part C).

Analysis of the cloned cps 7 genes.

[00197] The complete nucleotide sequences of the inserts of pCPS7-1, pCPS7-2 were determined. Examination of the cps7 sequence revealed the presence of two complete and two incomplete open reading frames (ORFs) (FIG. 11, part C). All ORFs are preceded by a ribosome-binding site. In accord with the data obtained for the cps1, cps2 and cps9 genes of serotypes 1, 2 and 9, respectively, the type 7 ORFs are very closely linked to each other. The only significant intergenic gap was that found between cps7E and cps7F (443 nucleotides). No obvious promoter sequences or potential stem-loop structures were found in this region. This suggests that, as in serotypes 1, 2 and 9, the cps genes in serotype 7 form part of an operon.

[00198] An overview of the ORFs and their properties is shown in Table 8. As expected on the basis of the hybridization data (84), the Cps9E and Cps7E proteins showed a high similarity (identity 99%, Table 8). Based on sequence comparisons between Cps9E and Cps7E, the PstI fragment of pCPS7-1 lacks the region encoding the first 371 codons of Cps7E. The C-terminal part of the protein encoded by the cps7F gene showed some similarity with the BplG protein of *Bordetella pertussis* (88), as well as with the C-terminal part of *S. suis* Cps2E (85). Both BplG and Cps2E were suggested to have glycosyltransferase activity and are probably involved in the linkage of the first sugar to the lipid carrier (85, 88). The protein encoded by the cps7G gene showed similarity with the BlpF protein of *Bordetella pertussis* (88). BlpF is likely to be involved in the biosynthesis of an amino sugar, suggesting a similar function for Cps7G. The protein encoded by the cps7H gene showed similarity with the WbdN protein of *E. coli* (89) as well as with the N-terminal part of the Cps2K protein of *S. suis* (81). Both WbdN and Cps2K were suggested to have glycosyltransferase activity (85, 89).

Serotype 7-specific cps genes.

[00199] To determine whether the cloned fragments in pCPS7-1 and pCPS7-2 contained serotype 7-specific DNA sequences, cross-hybridization experiments were performed. DNA

fragments of the individual *cps7* genes were amplified by PCR, labeled with ³²P, and used to probe spot blots of chromosomal DNA of the reference strains of 35 different *S. suis* serotypes. The results are summarized in Table 9. As expected, based on the data obtained with the *cps9E* probe (84), the *cps7E* probe hybridized with chromosomal DNA of many different *S. suis* serotypes. The *cps7F* and *cps7G* probes showed hybridization with chromosomal DNA of *S. suis* serotypes 4, 5, 7, 17, and 23. However, the *cps7H* probe hybridized with chromosomal DNA of serotype 7 only, indicating that this gene is specific for serotype 7.

Type-specific PCR.

[00200] We tested whether we could use PCR instead of hybridization for the typing of the *S. suis* serotype 7 strains. For that purpose, we selected an oligonucleotide primer set within the *cps7H* gene with which an amplified fragment of 251-bp was expected. In addition, we included in our analysis several *S. suis* serotype 7 strains, other than the reference strain. These strains were obtained from different countries and were isolated from different organs (Table 7). The results show that indeed a fragment of about 250-bp was amplified with all type 7 strains used (FIG. 12, part B), whereas no PCR products were obtained with serotype 1, 2 and 9 strains (FIG. 12, part A). This suggests that the PCR test, as described here, is a rapid diagnostic tool for the identification of *S. suis* serotype 7 strains. Until now, such a diagnostic test was not available for serotype 7 strains. Together with the recently developed PCR assays for serotypes 1, 2, 1/2, 14 and 9, this assay may be an important diagnostic tool to detect pigs carrying serotype 2, 1/2, 1, 14, 9 and 7 strains and may facilitate control and eradication programs.

SEQUENCE LISTING

<110> Smith, Hilda
<120> STREPTOCOCCUS SUIS VACCINES AND DIAGNOSTIC TESTS
<130> 2183-4726
<150> PCT/NL99/00460
<151> 1999-07-19
<150> EP98202465.5
<151> 1998-07-22
<150> EP98202467.1
<151> 1998-07-22
<160> 53
<170> PatentIn version 3.0

<210> 1
<211> 23
<212> DNA
<213> Artificial
<220>
<223> Primer
<400> 1

caaacgcaag gaattacggt atc

23

<210> 2
<211> 23
<212> DNA
<213> Artificial
<220>

<223> primer

<400> 2

gagtatcctaa agaatgccta ttg

23

<210> 3

<211> 20

<212> DNA

<213> Artificial

<220>

<223> primer

<400> 3

ggcgggtctag cagatgctcg

20

<210> 4

<211> 19

<212> DNA

<213> Artificial

<220>

<223> primer

<400> 4

gcgaactggt agcaatgac

19

<210> 5

<211> 21

<212> DNA

<213> Artificial

<220>

<223> primer

| | |
|-------------------------|----|
| <400> 5 | |
| ggctacatat aatggaagcc c | 21 |
| <210> 6 | |
| <211> 20 | |
| <212> DNA | |
| <213> Artificial | |
| <220> | |
| <223> primer | |
| <400> 6 | |
| cggaagtatc tgggctactg | 20 |
| <210> 7 | |
| <211> 21 | |
| <212> DNA | |
| <213> Artificial | |
| <220> | |
| <223> primer | |
| <400> 7 | |
| agctctaaca cgaaataagg c | 21 |
| <210> 8 | |
| <211> 21 | |
| <212> DNA | |
| <213> Artificial | |
| <220> | |
| <223> primer | |

<400> 8

gtcaaacacc ctggatagcc g

21

<210> 9

<211> 6992

<212> DNA

<213> Streptococcus suis

<220>

<221> misc_feature

<222> (1)..(6992)

<223> CPS 2

<400> 9

```
atcgccaaac gaaattggca ttatttgata tgatagcagt tgcaatttct gcaatcttaa 60
caagtcatat accaaatgct gatttaaadc gttctggaat ttttatcata atgatgggttc 120
attattttgc attttttata tctcgtatgc cagttgaatt tgagtataga ggtaatctga 180
tagagtttga aaaaacattt aactatagta taatatttgc aatttttctt acggcagtat 240
catttttggt ggagaataat ttgcacttt caagacgtgg tgccgtgtat ttcacattaa 300
taaacttcgt tttggtatac ctatttaacg taattattaa gcagtttaag gatagctttc 360
tattttcgac aatctatcaa aaaaagacga ttctaattac aacggctgaa cgatgggaaa 420
atatgcaagt tttatttgaa tcacataaac aaattcaaaa aaatcttggt gcattggtag 480
ttttaggtac agaaatagat aaaattaatt tatcattacc gctctattat tctgtggaag 540
aagctataga gttttcaaca agggaagtgg tcgaccacgt ctttataaat ctaccaagtg 600
agttttttaga cgtaaagcaa ttcgtttcag attttgagtt gttaggtatt gatgtaagcg 660
ttgatattaa ttcattcggg ttactgcgt tgaaaaacaa aaaaatccaa ctgctaggtg 720
accatagcat tgtaactttt tccacaaatt tttataagcc tagtcatatc atgatgaaac 780
gacttttgga tatactcgga gcggtagtcg ggttaattat ttgtggtata gtttctatct 840
tgttagttcc aattattcgt agagatggtg gaccggctat ttttgctcag aaacgagttg 900
```


gacagaatgg acgcataattht acatttctaca agttttcgatc gatgtatgtht gatgctgagg 960
agcgcaaaaa agacttgctc agccaaaacc agatgcaagg gtgggtatgt tttaaaatgg 1020
gaaaaacgat cctagaatta ctccaattgg acatttcata cgcaaaaaaca agtttagacg 1080
agttaccaca gttttataat gttttaattg gcgatatgag tctagttggt acacgtccac 1140
ctacagttga tgaatttgaa aaatatactc ctggtcaaaa gagacgattg agttttaaac 1200
cagggattac aggtctctgg caggttagtg gtcgtagtaa tatcacagac ttcgacgacg 1260
tagttcggtht ggacttagca tacattgata attggactat ctggtcagat attaaaattht 1320
tattaaagac agtgaaagtht gtattgthtga gagagggaa g taagtaaaag tatatgaaag 1380
tttgthtggtht cggttcttca gggggacatt tgactcactt gtatttgtht aaaccgthttht 1440
ggaaggaaga agaacgthttht tgggtaacat ttgataaaga ggatgcaaga agtctthtthtga 1500
agaatgaaaa aatgtatcca tgthtacttht caacaaatcg caatctcatt aatttagthtga 1560
aaaatacttht cttagcttht aaaatthttac gtgatgagaa accagatgtht attatthtcat 1620
ctggtgcggc cgthtgcgtht cccttcttht acatcgga aa actatthtggaa gcaaagacga 1680
tttatattga agtattthgat cgagthtaata aatctacatt aactggaaaa ctagthttatc 1740
ccgtaacaga tathththtatt gthtcagthgg aagaaatgaa gaaggtatat cctaaatcta 1800
ttaactthgg gagtathththt taatgaththt tgtaacagtht ggaactcatg aacaacagtht 1860
taatcgattg ataaaagaga ttgaththtatt gaaaaaaaat ggaagtataa ccgacgaaat 1920
atthtattcaa acaggatatt ctgactatat tccagaatat tgcaagtata aaaaatthtct 1980
cagttacaaa gaaatggaac aatatattaa caaatcagaa gtagthtatht gccacggagg 2040
ccccgtact tttatgaatt cattatccaa aggaaaaaaa caattattgt ttcctagaca 2100
aaaaaagtht ggtgaacatg taaatgatca tcaagtagag tttgtaagaa gaaththtaca 2160
agataataat atththtattta tagaaaatat agatgaththt tttgaaaaaa ttattgaagt 2220
ttctaagcaa actaacttht catcaaataa taaththththt tgtgaaagat taaaacaaat 2280
agthtgaaaaa tthtaatgagg atcaagaaaa tgaataataa aaaagatgca taththtgataa 2340
tggtttatca taathththtct cagaththttac tggagagggaa tacagatatt atcatcttct 2400
ctcaggagaa tgcacaccat tagthtctctc agaataacctg tataattatt ttaaatactc 2460

tcaggattta tatgttgaat ttacaaaaga tgagcaaaaa tataaagaaa ataggatata 2520
 tgaacgagtt aaatgttaca gattatttcc taatatatca gaaaaaacta ttgataatgt 2580
 actgtttaga attttattaa gaatgtatcg agcttttgaa tactatttac aaagattggt 2640
 gtttattgat agaataaaaa acatgggtcta agaataagat ttgggttctaa ttgggtttcg 2700
 cttccacatg attttgtggc aattctttta tcaaatagaaa acgaaacagc ttattttattt 2760
 aagtaatcta aatgtccaga tgaactattt atacagacaa ttatagaaaa atatgaattt 2820
 tcaaatagat tatctaaata tggaaattta agatatataa agtggaaaaa atcaacatct 2880
 tctcctattg tctttacaga tgattctatt gatgaattgc taaatgcaag aaatttaggt 2940
 tttttatttg ctagaaagtt aaaaatagaa aataaatcta aatttaaaga aattattact 3000
 aaaaaataaa atagttgatt ttgtgagagt aatgtatgtt taaattattt aaatatgacc 3060
 cggaatattt tatttttaag tacttctggt tgattatttt tattccagag caaaagtatg 3120
 tatttttatt aatttttatg aatttaattt tatttcatat aaaatttttg aaaactaagc 3180
 taatattaaa aaatgaaatt ttattgtttt tattatggtc tatattatgt tttgtttcag 3240
 tagtcacaag tatgtttgtt gaaataaatt ttgaaagatt atttgcagat tttactgctc 3300
 ccataatttg gattattgca ataatgtatt ataatttgta ttcatttata aatattgatt 3360
 ataaaaaatt aaaaaatagt atctttttta gttttttagt tttattaggt atatctgcat 3420
 tgtatattat tcaaaatggg aaagatatgt tatttttaga cagacacctt ataggactag 3480
 actatcttat aacaggcgctc aaaacaaggt tggttggctt tatgaactat cctacgttaa 3540
 ataccactac aattatagtt tcaattccgt taatctttgc acttataaaa aataaaatgc 3600
 aacaattttt tttcttgtgt cttgctttta taccgatcta ttttaagtga tcgagaattg 3660
 gtagtttatc gctagcaata ttaattatat gcttggtatg gagatatata ggtggaaaat 3720
 ttgcttggat aaaaaagcta atagtaatat ttgtaatact acttattatt ttaaatactg 3780
 aattgcttta ccatgaaatt ttggctgttt ataattctag agaatcaagt aacgaagcta 3840
 gatttattat ttatcaagga agtattgata aagtattaga aaacaatatt ttatttggat 3900
 atggaatatc cgaatattca gttacgggaa cttggctcgg aagtcattca ggctatatat 3960
 cattttttta taaatcagga atagttgggt tgattttact gatgttttct tttttttatg 4020

ttataaaaaa aagttatgga gttaatgggg aaacagcact attttatttt acatcattag 4080
 ccatattttt catatatgaa acaatagatc cgattattat tatattagta ctattctttt 4140
 cttcaatagg tatttggaat aatataaatt ttaaaaagga tatggagaca aaaaatgaat 4200
 gatttaattt cagttattgt accaatttat aatgtccaag attatcttga taaatgtatt 4260
 aacagtatta ttaaccaaac atataactaat ttagagggtta ttctcgtaaa tgatggaagt 4320
 actgatgatt ctgagaaaat ttgcttaaac tatatgaaga acgatggaag aattaaatat 4380
 tacaagaaaa ttaatggcgg tctagcagat gctcgaaatt tcggactaga acatgcaaca 4440
 ggtaaatata ttgcttttgt cgattctgat gactatatag aagttgcaat gttcgagaga 4500
 atgcatgata atataactga gtataatgcc gatatagcag agatagattt ttgttttagta 4560
 gacgaaaacg ggtatacaaa gaaaaaaga aatagtaatt ttcattgtctt aacgagagaa 4620
 gagactgtaa aagaattttt gtcaggatct aatatagaaa ataatgtttg gtgcaagctt 4680
 tattcacgag atattataaa agatataaaa ttccaaatta ataatagaag tattggtgag 4740
 gatttgcttt ttaatttgga ggtcttgaac aatgtaacac gtgtagtagt tgatactaga 4800
 gaatattatt ataattatgt cattcgtaac agttcgctta ttaatcagaa attctctata 4860
 aataatattg atttagtcac aagattggag aattaccctt ttaagttaaa aagagagttt 4920
 agtcattatt ttgatgcaaa agttattaaa gagaagggtta aatgtttaaa caaaatgtat 4980
 tcaacagatt gtttggataa tgagttcttg ccaatattag agtcttatcg aaaagaaata 5040
 cgtagatatc catttattaa agcgaaaaga tatttatcaa gaaagcattt agttacgttg 5100
 tatttgatga aattttcgcc taaactatat gtaatgttat ataagaaatt tcaaaagcag 5160
 tagaggtaaa aatggataaa attagtgtta ttgttccagt ttataatgta gataaatatt 5220
 taagtagttg tatagaaagc attattaatc aaaattataa aaatatagaa atattattga 5280
 tagatgatgg ctctgtagat gattctgcta aaatatgcaa ggaatatgca gaaaaagata 5340
 aaagagtaaa aatttttttc actaatcata gtggagtatc aaatgctaga aatcatggaa 5400
 taaagcggag tacagctgaa tatattatgt ttgttgactc tgatgatgtt gttgatagta 5460
 gattagtaga aaaattatat tttaatatta taaaaagtag aagtgattta tctggttggt 5520
 tgtacgctac tttttcagaa aatataaata attttgaagt gaataatcca aatattgatt 5580

ttgaagcaat taataccgtg caggacatgg gagaaaaaaa ttttatgaat ttgtatataa 5640
 ataatatattt ttctactcct gtttgtaaac tatataagaa aagatacata acagatcttt 5700
 ttcaagagaa tcaatgggta ggagaagatt tactttttta tctgcattat ttaaagaata 5760
 tagatagagt tagttatttg actgaacatc tttattttta taggagaggt atactaagta 5820
 cagtaaattc ttttaaagaa ggtgtgtttt tgcaattgga aaatttgcaa aaacaagtga 5880
 tagtattggt taagcaaata tatggtgagg attttgacgt atcaattggt aaagatacta 5940
 tacgttggca agtattttat tatagcttac taatgtttta atacggaaaa cagtctattt 6000
 ttgacaaatt ttttaattttt agaaatcttt ataaaaaata ttatttttaac ttgttaaaag 6060
 tatctaacia aaattctttg tctaaaaatt tttgtataag aattgtttcg aacaaagttt 6120
 ttaaaaaaat attatgggta taataggaag atatcatgga tactattagt aaaatttcta 6180
 taattgtacc tatatataat gtagaaaaat atttatctaa atgtatagat agcattgtaa 6240
 atcagacctt caaacatata gagattcttc tgggtgaatga cggtagtacg gataattcgg 6300
 aagaaatttg tttagcatat gcgaagaaag atagtcgcat tcggtattttt aaaaaagaga 6360
 acggcgggct atcagatgcc cgtaattatg gcataagtcg cgccaagggt gactacttag 6420
 cttttataga ctcagatgat tttattcatt cggagttcat ccaacgttta cacgaagcaa 6480
 ttgagagaga gaatgccctt gtggcagttg ctgggtatga tagggtagat gcttcggggc 6540
 atttcttaac agcagagccg ctctctacaa atcaggctgt tctgagcggc aggaatgttt 6600
 gtaaaaagct gctagaggcg gatgggtcatc gctttgtggt ggctgtaat aaactctata 6660
 aaaaagaact atttgaagat tttcgatttg aaaagggtaa gattcatgaa gatgaatact 6720
 tcacttatcg cttgctctat gagttagaaa aagttgcaat agttaaggag tgcttgact 6780
 attatgttga ccgagaaaat agtatcacia ctcttagcat gactgaccat cgcttcatt 6840
 gcctactgga atttcaaaat gaacgaatgg acttctatga aagtagagga gataaagagc 6900
 tcttactaga gtgttatcgt tcatttttag cctttgctgt tttgttttta ggcaaatata 6960
 atcattgggt gagcaaagc caaaagaagc tt 6992

<210> 10

<211> 239

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> ORF2Z

<400> 10

Ser Leu Asp Ile Asp His Met Met Glu Val Met Glu Ala Ser Lys Ser
1 5 10 15

Ala Ala Gly Ser Ala Cys Pro Ser Pro Gln Ala Tyr Gln Ala Ala Phe
20 25 30

Glu Gly Ala Glu Asn Ile Ile Val Val Thr Ile Thr Gly Gly Leu Ser
35 40 45

Gly Ser Phe Asn Ala Ala Arg Val Ala Arg Asp Met Tyr Ile Glu Glu
50 55 60

His Pro Asn Val Asn Ile His Leu Ile Asp Ser Leu Ser Ala Ser Gly
65 70 75 80

Glu Met Asp Leu Leu Val His Gln Ile Asn Arg Leu Ile Ser Ala Gly
85 90 95

Leu Asp Phe Pro Gln Val Val Glu Ala Ile Thr His Tyr Arg Glu His
100 105 110

Ser Lys Leu Leu Phe Val Leu Ala Lys Val Asp Asn Leu Val Lys Asn
115 120 125

Gly Arg Leu Ser Lys Leu Val Gly Thr Val Val Gly Leu Leu Asn Ile
130 135 140

Arg Met Val Gly Glu Ala Ser Ala Glu Gly Lys Leu Glu Leu Leu Gln
145 150 155 160

Lys Ala Arg Gly His Lys Lys Ser Val Thr Ala Ala Phe Glu Glu Met
165 170 175

Lys Lys Ala Gly Tyr Asp Gly Gly Arg Ile Val Met Ala His Arg Asn
180 185 190

Asn Ala Lys Phe Phe Gln Gln Phe Ser Glu Leu Val Lys Ala Ser Phe
195 200 205

Pro Thr Ala Val Ile Asp Glu Val Ala Thr Ser Gly Leu Cys Ser Phe
210 215 220

Tyr Ala Glu Glu Gly Gly Leu Leu Met Gly Tyr Glu Val Lys Ala
225 230 235

<210> 11

<211> 244

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> ORF2X

<400> 11

Met Lys Ile Ile Ile Pro Asn Ala Lys Glu Val Asn Thr Asn Leu Glu
1 5 10 15

Asn Ala Ser Phe Tyr Leu Leu Ser Asp Arg Ser Lys Pro Val Leu Asp
20 25 30

Ala Ile Ser Gln Phe Asp Val Lys Lys Met Ala Ala Phe Tyr Lys Leu
35 40 45

Asn Glu Ala Lys Ala Glu Leu Glu Ala Asp Arg Trp Tyr Arg Ile Arg
50 55 60

Thr Gly Gln Ala Lys Thr Tyr Pro Ala Trp Gln Leu Tyr Asp Gly Leu
65 70 75 80

Met Tyr Arg Tyr Met Asp Arg Arg Gly Ile Asp Ser Lys Glu Glu Asn
85 90 95

Tyr Leu Arg Asp His Val Arg Val Ala Thr Ala Leu Tyr Gly Leu Ile
100 105 110

His Pro Phe Glu Phe Ile Ser Pro His Arg Leu Asp Phe Gln Gly Ser
115 120 125

Leu Lys Ile Gly Asn Gln Ser Leu Lys Gln Tyr Trp Arg Pro Tyr Tyr
130 135 140

Asp Gln Glu Val Gly Asp Asp Glu Leu Ile Leu Ser Leu Ala Ser Ser
 145 150 155 160
 Glu Phe Glu Gln Val Phe Ser Pro Gln Ile Gln Lys Arg Leu Val Lys
 165 170 175
 Ile Leu Phe Met Glu Glu Lys Ala Gly Gln Leu Lys Val His Ser Thr
 180 185 190
 Ile Ser Lys Lys Gly Arg Gly Arg Leu Leu Ser Trp Leu Ala Lys Asn
 195 200 205
 Asn Ile Gln Glu Leu Ser Asp Ile Gln Asp Phe Lys Val Asp Gly Phe
 210 215 220
 Glu Tyr Cys Thr Ser Glu Ser Thr Ala Asn Gln Leu Thr Phe Ile Arg
 225 230 235 240
 Ser Ile Lys Met

<210> 12

<211> 481

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS2A

<400> 12

Met Lys Lys Arg Ser Gly Arg Ser Lys Ser Ser Lys Phe Lys Leu Val
 1 5 10 15
 Asn Phe Ala Leu Leu Gly Leu Tyr Ser Ile Thr Leu Cys Leu Phe Leu
 20 25 30
 Val Thr Met Tyr Arg Tyr Asn Ile Leu Asp Phe Arg Tyr Leu Asn Tyr
 35 40 45
 Ile Val Thr Leu Leu Leu Val Gly Val Ala Val Leu Ala Gly Leu Leu
 50 55 60

| | | | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Trp | Arg | Lys | Lys | Ala | Arg | Ile | Phe | Thr | Ala | Leu | Leu | Leu | Val | Phe | 65 | 70 | 75 | 80 |
| Ser | Leu | Val | Ile | Thr | Ser | Val | Gly | Ile | Tyr | Gly | Met | Gln | Glu | Val | Val | 85 | 90 | 95 | |
| Lys | Phe | Ser | Thr | Arg | Leu | Asn | Ser | Asn | Ser | Thr | Phe | Ser | Glu | Tyr | Glu | 100 | 105 | 110 | |
| Met | Ser | Ile | Leu | Val | Pro | Ala | Asn | Ser | Asp | Ile | Thr | Asp | Val | Arg | Gln | 115 | 120 | 125 | |
| Leu | Thr | Ser | Ile | Leu | Ala | Pro | Ala | Glu | Tyr | Asp | Gln | Asp | Asn | Ile | Thr | 130 | 135 | 140 | |
| Ala | Leu | Leu | Asp | Asp | Ile | Ser | Lys | Met | Glu | Ser | Thr | Gln | Leu | Ala | Thr | 145 | 150 | 155 | 160 |
| Ser | Pro | Gly | Thr | Ser | Tyr | Leu | Thr | Ala | Tyr | Gln | Ser | Met | Leu | Asn | Gly | 165 | 170 | 175 | |
| Glu | Ser | Gln | Ala | Met | Val | Phe | Asn | Gly | Val | Phe | Thr | Asn | Ile | Leu | Glu | 180 | 185 | 190 | |
| Asn | Glu | Asp | Pro | Gly | Phe | Ser | Ser | Lys | Val | Lys | Lys | Ile | Tyr | Ser | Phe | 195 | 200 | 205 | |
| Lys | Val | Thr | Gln | Thr | Val | Glu | Thr | Ala | Thr | Lys | Gln | Val | Ser | Gly | Asp | 210 | 215 | 220 | |
| Ser | Phe | Asn | Ile | Tyr | Ile | Ser | Gly | Ile | Asp | Ala | Tyr | Gly | Pro | Ile | Ser | 225 | 230 | 235 | 240 |
| Thr | Val | Ser | Arg | Ser | Asp | Val | Asn | Ile | Ile | Met | Thr | Val | Asn | Arg | Ala | 245 | 250 | 255 | |
| Thr | His | Lys | Ile | Leu | Leu | Thr | Thr | Thr | Pro | Arg | Asp | Ser | Tyr | Val | Ala | 260 | 265 | 270 | |
| Phe | Ala | Asp | Gly | Gly | Gln | Asn | Gln | Tyr | Asp | Lys | Leu | Thr | His | Ala | Gly | 275 | 280 | 285 | |
| Ile | Tyr | Gly | Val | Asn | Ala | Ser | Val | His | Thr | Leu | Glu | Asn | Phe | Tyr | Gly | 290 | 295 | 300 | |
| Ile | Asp | Ile | Ser | Asn | Tyr | Val | Arg | Leu | Asn | Phe | Ile | Ser | Phe | Leu | Gln | 305 | 310 | 315 | 320 |
| Leu | Ile | Asp | Leu | Val | Gly | Gly | Ile | Asp | Val | Tyr | Asn | Asp | Gln | Glu | Phe | 325 | 330 | 335 | |

Thr Ser Leu His Gly Asn Tyr His Phe Pro Val Gly Gln Val His Leu
 340 345 350
 Asn Ser Asp Gln Ala Leu Gly Phe Val Arg Glu Arg Tyr Ser Leu Thr
 355 360 365
 Gly Gly Asp Asn Asp Arg Gly Lys Asn Gln Glu Lys Val Ile Ala Ala
 370 375 380
 Leu Ile Lys Lys Met Ser Thr Pro Glu Asn Leu Lys Asn Tyr Gln Ala
 385 390 395 400
 Ile Leu Ser Gly Leu Glu Gly Ser Ile Gln Thr Asp Leu Ser Leu Glu
 405 410 415
 Thr Ile Met Ser Leu Val Asn Thr Gln Leu Glu Ser Gly Thr Gln Phe
 420 425 430
 Thr Val Glu Ser Gln Ala Leu Thr Gly Thr Gly Arg Ser Asp Leu Ser
 435 440 445
 Ser Tyr Ala Met Pro Gly Ser Gln Leu Tyr Met Met Glu Ile Asn Gln
 450 455 460
 Asp Ser Leu Glu Gln Ser Lys Ala Ala Ile Gln Ser Val Leu Val Glu
 465 470 475 480

Lys

<210> 13

<211> 229

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS2B

<400> 13

Met Asn Asn Gln Glu Val Asn Ala Ile Glu Ile Asp Val Leu Phe Leu
 1 5 10 15
 Leu Lys Thr Ile Trp Arg Lys Lys Phe Leu Ile Leu Leu Thr Ala Val
 20 25 30

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Thr | Ala | Gly | Leu | Ala | Phe | Val | Tyr | Ser | Ser | Phe | Leu | Val | Thr | Pro |
| | | 35 | | | | | 40 | | | | | 45 | | | |
| Gln | Tyr | Asp | Ser | Thr | Thr | Arg | Ile | Tyr | Val | Val | Ser | Gln | Asn | Val | Glu |
| | 50 | | | | | 55 | | | | | 60 | | | | |
| Ala | Gly | Ala | Gly | Leu | Thr | Asn | Gln | Glu | Leu | Gln | Ala | Gly | Thr | Tyr | Leu |
| 65 | | | | | 70 | | | | | 75 | | | | | 80 |
| Ala | Lys | Asp | Tyr | Arg | Glu | Ile | Ile | Leu | Ser | Gln | Asp | Val | Leu | Thr | Gln |
| | | | | 85 | | | | | 90 | | | | | 95 | |
| Val | Ala | Thr | Glu | Leu | Asn | Leu | Lys | Glu | Ser | Leu | Lys | Glu | Lys | Ile | Ser |
| | | | 100 | | | | | 105 | | | | | 110 | | |
| Val | Ser | Ile | Pro | Val | Asp | Thr | Arg | Ile | Val | Ser | Ile | Ser | Val | Arg | Asp |
| | | 115 | | | | | 120 | | | | | 125 | | | |
| Ala | Asp | Pro | Asn | Glu | Ala | Ala | Arg | Ile | Ala | Asn | Ser | Leu | Arg | Thr | Phe |
| | 130 | | | | | 135 | | | | | 140 | | | | |
| Ala | Val | Gln | Lys | Val | Val | Glu | Val | Thr | Lys | Val | Ser | Asp | Val | Thr | Thr |
| 145 | | | | | 150 | | | | | 155 | | | | | 160 |
| Leu | Glu | Glu | Ala | Val | Pro | Ala | Glu | Glu | Pro | Thr | Thr | Pro | Asn | Thr | Lys |
| | | | | 165 | | | | | 170 | | | | | 175 | |
| Arg | Asn | Ile | Leu | Leu | Gly | Leu | Leu | Ala | Gly | Gly | Ile | Leu | Ala | Thr | Gly |
| | | | 180 | | | | | 185 | | | | | 190 | | |
| Leu | Val | Leu | Val | Met | Glu | Val | Leu | Asp | Asp | Arg | Val | Lys | Arg | Pro | Gln |
| | | 195 | | | | | 200 | | | | | 205 | | | |
| Asp | Ile | Glu | Glu | Val | Met | Gly | Leu | Thr | Leu | Leu | Gly | Ile | Val | Pro | Asp |
| | 210 | | | | | 215 | | | | | 220 | | | | |
| Ser | Lys | Lys | Leu | Lys | | | | | | | | | | | |
| 225 | | | | | | | | | | | | | | | |

<210> 14

<211> 225

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS2C

<400> 14

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
| Met | Ala | Met | Leu | Glu | Ile | Ala | Arg | Thr | Lys | Arg | Glu | Gly | Val | Asn | Lys | |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | | |
| Thr | Glu | Glu | Tyr | Phe | Asn | Ala | Ile | Arg | Thr | Asn | Ile | Gln | Leu | Ser | Gly | |
| | | | 20 | | | | | 25 | | | | | 30 | | | |
| Ala | Asp | Ile | Lys | Val | Val | Gly | Ile | Thr | Ser | Val | Lys | Ser | Asn | Glu | Gly | |
| | | 35 | | | | | 40 | | | | | 45 | | | | |
| Lys | Ser | Thr | Thr | Ala | Ala | Ser | Leu | Ala | Ile | Ala | Tyr | Ala | Arg | Ser | Gly | |
| | 50 | | | | | 55 | | | | | 60 | | | | | |
| Tyr | Lys | Thr | Val | Leu | Val | Asp | Ala | Asp | Ile | Arg | Asn | Ser | Val | Met | Pro | |
| 65 | | | | | 70 | | | | | 75 | | | | | 80 | |
| Gly | Phe | Phe | Lys | Pro | Ile | Thr | Lys | Ile | Thr | Gly | Leu | Thr | Asp | Tyr | Leu | |
| | | | | 85 | | | | | 90 | | | | | 95 | | |
| Ala | Gly | Thr | Thr | Asp | Leu | Ser | Gln | Gly | Leu | Cys | Asp | Thr | Asp | Ile | Pro | |
| | | | 100 | | | | | 105 | | | | | 110 | | | |
| Asn | Leu | Thr | Val | Ile | Glu | Ser | Gly | Lys | Val | Ser | Pro | Asn | Pro | Thr | Ala | |
| | | 115 | | | | | 120 | | | | | 125 | | | | |
| Leu | Leu | Gln | Ser | Lys | Asn | Phe | Glu | Asn | Leu | Leu | Ala | Thr | Leu | Arg | Arg | |
| | 130 | | | | | 135 | | | | | 140 | | | | | |
| Tyr | Tyr | Asp | Tyr | Val | Ile | Val | Asp | Cys | Pro | Pro | Leu | Gly | Leu | Val | Ile | |
| 145 | | | | | 150 | | | | | 155 | | | | | 160 | |
| Asp | Ala | Ala | Ile | Ile | Ala | Gln | Lys | Cys | Asp | Ala | Met | Val | Ala | Val | Val | |
| | | | | 165 | | | | | 170 | | | | | 175 | | |
| Glu | Ala | Gly | Asn | Val | Lys | Cys | Ser | Ser | Leu | Lys | Lys | Val | Lys | Glu | Gln | |
| | | | 180 | | | | | 185 | | | | | 190 | | | |
| Leu | Glu | Gln | Thr | Gly | Thr | Pro | Phe | Leu | Gly | Val | Ile | Leu | Asn | Lys | Tyr | |
| | | 195 | | | | | 200 | | | | | 205 | | | | |
| Asp | Ile | Ala | Thr | Glu | Lys | Tyr | Ser | Glu | Tyr | Gly | Asn | Tyr | Gly | Lys | Lys | |
| | 210 | | | | | 215 | | | | | 220 | | | | | |
| Ala | | | | | | | | | | | | | | | | |
| 225 | | | | | | | | | | | | | | | | |

<210> 15

<211> 243

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS2D

<400> 15

Met Ile Asp Ile His Ser His Ile Ile Phe Gly Val Asp Asp Gly Pro
1 5 10 15

Lys Thr Ile Glu Glu Ser Leu Ser Leu Ile Ser Glu Ala Tyr Arg Gln
20 25 30

Gly Val Arg Tyr Ile Val Ala Thr Ser His Arg Arg Lys Gly Met Phe
35 40 45

Glu Thr Pro Glu Lys Ile Ile Met Ile Asn Phe Leu Gln Leu Lys Glu
50 55 60

Ala Val Ala Glu Val Tyr Pro Glu Ile Arg Leu Cys Tyr Gly Ala Glu
65 70 75 80

Leu Tyr Tyr Ser Lys Asp Ile Leu Ser Lys Leu Glu Lys Lys Lys Val
85 90 95

Pro Thr Leu Asn Gly Ser Cys Tyr Ile Leu Leu Glu Phe Ser Thr Asp
100 105 110

Thr Pro Trp Lys Glu Ile Gln Glu Ala Val Asn Glu Met Thr Leu Leu
115 120 125

Gly Leu Thr Pro Val Leu Ala His Ile Glu Arg Tyr Asp Ala Leu Ala
130 135 140

Phe Gln Ser Glu Arg Val Glu Lys Leu Ile Asp Lys Gly Cys Tyr Thr
145 150 155 160

Gln Val Asn Ser Asn His Val Leu Lys Pro Ala Leu Ile Gly Glu Arg
165 170 175

Ala Lys Glu Phe Lys Lys Arg Thr Arg Tyr Phe Leu Glu Gln Asp Leu
180 185 190

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Val | His | Cys | Val | Ala | Ser | Asp | Met | His | Asn | Leu | Tyr | Ser | Arg | Pro | Pro |
| | | 195 | | | | | 200 | | | | | 205 | | | |
| Phe | Met | Arg | Glu | Ala | Tyr | Gln | Leu | Val | Lys | Lys | Glu | Tyr | Gly | Glu | Asp |
| | 210 | | | | | 215 | | | | | 220 | | | | |
| Arg | Ala | Lys | Ala | Leu | Phe | Lys | Lys | Asn | Pro | Leu | Leu | Ile | Leu | Lys | Asn |
| 225 | | | | | 230 | | | | | 235 | | | | | 240 |
| Gln | Val | Gln | | | | | | | | | | | | | |

<210> 16

<211> 459

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS2E

<400> 16

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Asn | Ile | Glu | Ile | Gly | Tyr | Arg | Gln | Thr | Lys | Leu | Ala | Leu | Phe | Asp |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |
| Met | Ile | Ala | Val | Thr | Ile | Ser | Ala | Ile | Leu | Thr | Ser | His | Ile | Pro | Asn |
| | | | 20 | | | | | 25 | | | | | 30 | | |
| Ala | Asp | Leu | Asn | Arg | Ser | Gly | Ile | Phe | Ile | Ile | Met | Met | Val | His | Tyr |
| | | 35 | | | | | 40 | | | | | 45 | | | |
| Phe | Ala | Phe | Phe | Ile | Ser | Arg | Met | Pro | Val | Glu | Phe | Glu | Tyr | Arg | Gly |
| | 50 | | | | | 55 | | | | | 60 | | | | |
| Asn | Leu | Ile | Glu | Phe | Glu | Lys | Thr | Phe | Asn | Tyr | Ser | Ile | Ile | Phe | Val |
| 65 | | | | | 70 | | | | | 75 | | | | | 80 |
| Ile | Phe | Leu | Met | Ala | Val | Ser | Phe | Met | Leu | Glu | Asn | Asn | Phe | Ala | Leu |
| | | | | 85 | | | | | 90 | | | | | 95 | |
| Ser | Arg | Arg | Gly | Ala | Val | Tyr | Phe | Thr | Leu | Ile | Asn | Phe | Val | Leu | Val |
| | | | 100 | | | | | 105 | | | | | 110 | | |
| Tyr | Leu | Phe | Asn | Val | Ile | Ile | Lys | Gln | Phe | Lys | Asp | Ser | Phe | Leu | Phe |
| | | 115 | | | | | 120 | | | | | 125 | | | |

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
| Ser | Thr | Thr | Tyr | Gln | Lys | Lys | Thr | Ile | Leu | Ile | Thr | Thr | Ala | Glu | Leu | |
| | 130 | | | | | 135 | | | | | 140 | | | | | |
| Trp | Glu | Asn | Met | Gln | Val | Leu | Phe | Glu | Ser | Asp | Ile | Leu | Phe | Gln | Lys | |
| 145 | | | | | 150 | | | | | 155 | | | | | 160 | |
| Asn | Leu | Val | Ala | Leu | Val | Ile | Leu | Gly | Thr | Glu | Ile | Asp | Lys | Ile | Asn | |
| | | | | 165 | | | | | 170 | | | | | 175 | | |
| Leu | Pro | Leu | Pro | Leu | Tyr | Tyr | Ser | Val | Glu | Glu | Ala | Ile | Gly | Phe | Ser | |
| | | | 180 | | | | | 185 | | | | | 190 | | | |
| Thr | Arg | Glu | Val | Val | Asp | Tyr | Val | Phe | Ile | Asn | Leu | Pro | Ser | Glu | Tyr | |
| | | 195 | | | | | 200 | | | | | 205 | | | | |
| Phe | Asp | Leu | Lys | Gln | Leu | Val | Ser | Asp | Phe | Glu | Leu | Leu | Gly | Ile | Asp | |
| | 210 | | | | | 215 | | | | | 220 | | | | | |
| Val | Gly | Val | Asp | Ile | Asn | Ser | Phe | Gly | Phe | Thr | Val | Leu | Lys | Asn | Lys | |
| 225 | | | | | 230 | | | | | 235 | | | | | 240 | |
| Lys | Ile | Gln | Met | Leu | Gly | Asp | His | Ser | Ile | Val | Thr | Phe | Ser | Thr | Asn | |
| | | | | 245 | | | | | 250 | | | | | 255 | | |
| Phe | Tyr | Lys | Pro | Ser | His | Ile | Trp | Met | Lys | Arg | Leu | Leu | Asp | Ile | Leu | |
| | | | 260 | | | | | 265 | | | | | 270 | | | |
| Gly | Ala | Val | Val | Gly | Leu | Ile | Ile | Ser | Gly | Ile | Val | Ser | Ile | Leu | Leu | |
| | | 275 | | | | | 280 | | | | | 285 | | | | |
| Ile | Pro | Ile | Ile | Arg | Arg | Asp | Gly | Gly | Pro | Ala | Ile | Phe | Ala | Gln | Lys | |
| | 290 | | | | | 295 | | | | | 300 | | | | | |
| Arg | Val | Gly | Gln | Asn | Gly | Arg | Ile | Phe | Thr | Phe | Tyr | Lys | Phe | Arg | Ser | |
| 305 | | | | | 310 | | | | | 315 | | | | | 320 | |
| Met | Phe | Val | Asp | Ala | Glu | Val | Arg | Lys | Lys | Glu | Leu | Met | Ala | Gln | Asn | |
| | | | | 325 | | | | | 330 | | | | | 335 | | |
| Gln | Met | Gln | Gly | Gly | Met | Phe | Lys | Met | Asp | Asn | Asp | Pro | Arg | Ile | Thr | |
| | | | 340 | | | | | 345 | | | | | 350 | | | |
| Pro | Ile | Gly | His | Phe | Ile | Arg | Lys | Thr | Ser | Leu | Asp | Glu | Leu | Pro | Gln | |
| | | 355 | | | | | 360 | | | | | 365 | | | | |
| Phe | Tyr | Asn | Val | Leu | Ile | Gly | Asp | Met | Ser | Leu | Val | Gly | Thr | Arg | Pro | |
| | 370 | | | | | 375 | | | | | 380 | | | | | |
| Pro | Thr | Val | Asp | Glu | Phe | Glu | Lys | Tyr | Thr | Pro | Ser | Gln | Lys | Arg | Arg | |
| 385 | | | | | 390 | | | | | 395 | | | | | 400 | |

Leu Ser Phe Lys Pro Gly Ile Thr Gly Leu Trp Gln Val Ser Gly Arg
 405 410 415
 Ser Asp Ile Thr Asp Phe Asn Glu Val Val Arg Leu Asp Leu Thr Tyr
 420 425 430
 Ile Asp Asn Trp Thr Ile Trp Ser Asp Ile Lys Ile Leu Leu Lys Thr
 435 440 445
 Val Lys Val Val Leu Leu Arg Glu Gly Gly Gln
 450 455

<210> 17

<211> 389

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS2F

<400> 17

Met Arg Thr Val Tyr Ile Ile Gly Ser Lys Gly Ile Pro Ala Lys Tyr
 1 5 10 15
 Gly Gly Phe Glu Thr Phe Val Glu Lys Leu Thr Glu Tyr Gln Lys Asp
 20 25 30
 Lys Ser Ile Asn Tyr Phe Val Ala Cys Thr Arg Glu Asn Ser Ala Lys
 35 40 45
 Ser Asp Ile Thr Gly Glu Val Phe Glu His Asn Gly Ala Thr Cys Phe
 50 55 60
 Asn Ile Asp Val Pro Asn Ile Gly Ser Ala Lys Ala Ile Leu Tyr Asp
 65 70 75 80
 Ile Met Ala Leu Lys Lys Ser Ile Glu Ile Ala Lys Asp Arg Asn Asp
 85 90 95
 Thr Ser Pro Ile Phe Tyr Ile Leu Ala Cys Arg Ile Gly Pro Phe Ile
 100 105 110
 Tyr Leu Phe Lys Lys Gln Ile Glu Ser Ile Gly Gly Gln Leu Phe Val
 115 120 125

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
| Asn | Pro | Asp | Gly | His | Glu | Trp | Leu | Arg | Glu | Lys | Trp | Ser | Tyr | Pro | Val | |
| | 130 | | | | | 135 | | | | | 140 | | | | | |
| Arg | Gln | Tyr | Trp | Lys | Phe | Ser | Glu | Ser | Leu | Met | Leu | Lys | Tyr | Ala | Asp | |
| 145 | | | | | 150 | | | | | 155 | | | | | 160 | |
| Leu | Leu | Ile | Cys | Asp | Ser | Lys | Asn | Ile | Glu | Lys | Tyr | Ile | His | Glu | Asp | |
| | | | | 165 | | | | | 170 | | | | | 175 | | |
| Tyr | Arg | Lys | Tyr | Ala | Pro | Glu | Thr | Ser | Tyr | Ile | Ala | Tyr | Gly | Thr | Asp | |
| | | | 180 | | | | | 185 | | | | | 190 | | | |
| Leu | Asp | Lys | Ser | Arg | Leu | Ser | Pro | Thr | Asp | Ser | Val | Val | Arg | Glu | Trp | |
| | 195 | | | | | | 200 | | | | 205 | | | | | |
| Tyr | Lys | Glu | Lys | Glu | Ile | Ser | Glu | Asn | Asp | Tyr | Tyr | Leu | Val | Val | Gly | |
| 210 | | | | | | 215 | | | | | 220 | | | | | |
| Arg | Phe | Val | Pro | Glu | Asn | Asn | Tyr | Glu | Val | Met | Ile | Arg | Glu | Phe | Met | |
| 225 | | | | | 230 | | | | | 235 | | | | | 240 | |
| Lys | Ser | Tyr | Ser | Arg | Lys | Asp | Phe | Val | Leu | Ile | Thr | Asn | Val | Glu | His | |
| | | | | 245 | | | | | 250 | | | | | 255 | | |
| Asn | Ser | Phe | Tyr | Glu | Lys | Leu | Lys | Lys | Glu | Thr | Gly | Phe | Asp | Lys | Asp | |
| | | | 260 | | | | | 265 | | | | | 270 | | | |
| Lys | Arg | Ile | Lys | Phe | Val | Gly | Thr | Val | Tyr | Asn | Gln | Glu | Leu | Leu | Lys | |
| | 275 | | | | | | 280 | | | | | 285 | | | | |
| Tyr | Ile | Arg | Glu | Asn | Ala | Phe | Ala | Tyr | Phe | His | Gly | His | Glu | Val | Gly | |
| 290 | | | | | 295 | | | | | | 300 | | | | | |
| Gly | Thr | Asn | Pro | Ser | Leu | Leu | Glu | Ala | Leu | Ser | Ser | Thr | Lys | Leu | Asn | |
| 305 | | | | | 310 | | | | | 315 | | | | | 320 | |
| Leu | Leu | Leu | Asp | Val | Gly | Phe | Asn | Arg | Glu | Val | Gly | Glu | Glu | Gly | Ala | |
| | | | | 325 | | | | | 330 | | | | | 335 | | |
| Lys | Tyr | Trp | Asn | Lys | Asp | Asn | Leu | His | Arg | Val | Ile | Asp | Ser | Cys | Glu | |
| | | | 340 | | | | 345 | | | | | | 350 | | | |
| Gln | Leu | Ser | Gln | Glu | Gln | Ile | Asn | Asp | Met | Asp | Ser | Leu | Ser | Thr | Lys | |
| | 355 | | | | | | 360 | | | | | 365 | | | | |
| Gln | Val | Lys | Glu | Arg | Phe | Ser | Trp | Asp | Phe | Ile | Val | Asp | Glu | Tyr | Glu | |
| 370 | | | | | | 375 | | | | | 380 | | | | | |
| Lys | Leu | Phe | Lys | Gly | | | | | | | | | | | | |
| 385 | | | | | | | | | | | | | | | | |

<210> 18

<211> 385

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS2G

<400> 18

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
| Met | Lys | Lys | Ile | Leu | Tyr | Leu | His | Ala | Gly | Ala | Glu | Leu | Tyr | Gly | Ala | |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | | |
| Asp | Lys | Val | Leu | Leu | Glu | Leu | Ile | Lys | Gly | Leu | Asp | Lys | Asn | Glu | Phe | |
| | | | 20 | | | | | 25 | | | | | 30 | | | |
| Glu | Ala | His | Val | Ile | Leu | Pro | Asn | Asp | Gly | Val | Leu | Val | Pro | Ala | Leu | |
| | | 35 | | | | | 40 | | | | | 45 | | | | |
| Arg | Glu | Val | Gly | Ala | Gln | Val | Glu | Val | Ile | Asn | Tyr | Pro | Ile | Leu | Arg | |
| | 50 | | | | | 55 | | | | | 60 | | | | | |
| Arg | Lys | Tyr | Phe | Asn | Pro | Lys | Gly | Ile | Phe | Asp | Tyr | Phe | Ile | Ser | Tyr | |
| 65 | | | | | 70 | | | | | 75 | | | | | 80 | |
| His | His | Tyr | Ser | Lys | Gln | Ile | Ala | Gln | Tyr | Ala | Ile | Glu | Asn | Lys | Val | |
| | | | | 85 | | | | | 90 | | | | | 95 | | |
| Asp | Ile | Ile | His | Asn | Asn | Thr | Thr | Ala | Val | Leu | Glu | Gly | Ile | Tyr | Leu | |
| | | | 100 | | | | | 105 | | | | | 110 | | | |
| Lys | Arg | Lys | Leu | Lys | Leu | Pro | Leu | Leu | Trp | His | Val | His | Glu | Ile | Ile | |
| | | 115 | | | | | 120 | | | | | 125 | | | | |
| Val | Lys | Pro | Lys | Phe | Ile | Ser | Asp | Ser | Ile | Asn | Phe | Leu | Met | Gly | Arg | |
| | 130 | | | | | 135 | | | | | 140 | | | | | |
| Phe | Ala | Asp | Lys | Ile | Val | Thr | Val | Ser | Gln | Ala | Val | Ala | Asn | His | Ile | |
| 145 | | | | | 150 | | | | | 155 | | | | | 160 | |
| Lys | Gln | Ser | Pro | His | Ile | Lys | Asp | Asp | Gln | Ile | Ser | Val | Ile | Tyr | Asn | |
| | | | | 165 | | | | | 170 | | | | | 175 | | |
| Gly | Val | Asp | Asn | Lys | Val | Phe | Tyr | Gln | Ser | Asp | Ala | Arg | Ser | Val | Arg | |
| | | | 180 | | | | | 185 | | | | | 190 | | | |

| | | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|--|--|
| Glu | Arg | Phe | Asp | Ile | Asp | Glu | Glu | Ala | Leu | Val | Ile | Gly | Met | Val | Gly | | | |
| | | 195 | | | | | 200 | | | | | 205 | | | | | | |
| Arg | Val | Asn | Ala | Trp | Lys | Gly | Gln | Gly | Asp | Phe | Leu | Glu | Ala | Val | Ala | | | |
| | 210 | | | | | 215 | | | | | 220 | | | | | | | |
| Pro | Ile | Leu | Glu | Gln | Asn | Pro | Lys | Ala | Ile | Ala | Phe | Ile | Ala | Gly | Ser | | | |
| 225 | | | | | 230 | | | | | 235 | | | | | 240 | | | |
| Ala | Phe | Glu | Gly | Glu | Glu | Trp | Arg | Val | Val | Glu | Leu | Glu | Lys | Lys | Ile | | | |
| | | | | 245 | | | | | 250 | | | | | 255 | | | | |
| Ser | Gln | Leu | Lys | Val | Ser | Ser | Gln | Val | Arg | Arg | Met | Asp | Tyr | Tyr | Ala | | | |
| | | | 260 | | | | | 265 | | | | | 270 | | | | | |
| Asn | Thr | Thr | Glu | Leu | Tyr | Asn | Met | Phe | Asp | Ile | Phe | Val | Leu | Pro | Ser | | | |
| | | 275 | | | | | 280 | | | | | 285 | | | | | | |
| Thr | Asn | Pro | Asp | Pro | Leu | Pro | Thr | Val | Val | Leu | Lys | Ala | Met | Ala | Cys | | | |
| | 290 | | | | | 295 | | | | | 300 | | | | | | | |
| Gly | Lys | Pro | Val | Val | Gly | Tyr | Arg | His | Gly | Gly | Val | Cys | Glu | Met | Val | | | |
| 305 | | | | | 310 | | | | | 315 | | | | | 320 | | | |
| Lys | Glu | Gly | Val | Asn | Gly | Phe | Leu | Val | Thr | Pro | Asn | Ser | Pro | Leu | Asn | | | |
| | | | | 325 | | | | | 330 | | | | | 335 | | | | |
| Leu | Ser | Lys | Val | Ile | Leu | Gln | Leu | Ser | Glu | Asn | Ile | Asn | Leu | Arg | Lys | | | |
| | | | 340 | | | | 345 | | | | | 350 | | | | | | |
| Lys | Ile | Gly | Asn | Asn | Ser | Ile | Glu | Arg | Gln | Lys | Glu | His | Phe | Ser | Leu | | | |
| | | 355 | | | | | 360 | | | | | 365 | | | | | | |
| Lys | Ser | Tyr | Val | Lys | Asn | Phe | Ser | Lys | Val | Tyr | Thr | Ser | Leu | Lys | Val | | | |
| | 370 | | | | | 375 | | | | | 380 | | | | | | | |

Tyr
385

<210> 19

<211> 456

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> cps2h

<400> 19

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
| Met | Lys | Ile | Ile | Ser | Phe | Thr | Met | Val | Asn | Asn | Glu | Ser | Glu | Ile | Ile | |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | | |
| Glu | Ser | Phe | Ile | Arg | Tyr | Asn | Tyr | Asn | Phe | Ile | Asp | Glu | Met | Val | Ile | |
| | | | 20 | | | | | 25 | | | | | 30 | | | |
| Ile | Asp | Asn | Gly | Cys | Thr | Asp | Asn | Thr | Met | Gln | Ile | Ile | Phe | Asn | Leu | |
| | | 35 | | | | | 40 | | | | | 45 | | | | |
| Ile | Lys | Glu | Gly | Tyr | Lys | Ile | Ser | Val | Tyr | Asp | Glu | Ser | Leu | Glu | Ala | |
| | 50 | | | | | 55 | | | | | 60 | | | | | |
| Tyr | Asn | Gln | Tyr | Arg | Leu | Asp | Asn | Lys | Tyr | Leu | Thr | Lys | Ile | Ile | Ala | |
| 65 | | | | | 70 | | | | | 75 | | | | | 80 | |
| Glu | Lys | Asn | Pro | Asp | Leu | Ile | Ile | Pro | Leu | Asp | Ala | Asp | Glu | Phe | Leu | |
| | | | | 85 | | | | | 90 | | | | | 95 | | |
| Thr | Ala | Asp | Ser | Asn | Pro | Arg | Lys | Leu | Leu | Glu | Gln | Leu | Asp | Leu | Glu | |
| | | | 100 | | | | | 105 | | | | | 110 | | | |
| Lys | Ile | His | Tyr | Val | Asn | Trp | Gln | Trp | Phe | Val | Met | Thr | Lys | Lys | Asp | |
| | | 115 | | | | | 120 | | | | | 125 | | | | |
| Asp | Ile | Asn | Asp | Ser | Phe | Ile | Pro | Arg | Arg | Met | Gln | Tyr | Cys | Phe | Glu | |
| | 130 | | | | | 135 | | | | | 140 | | | | | |
| Lys | Pro | Val | Trp | His | His | Ser | Asp | Gly | Lys | Pro | Val | Thr | Lys | Cys | Ile | |
| 145 | | | | | 150 | | | | | 155 | | | | | 160 | |
| Ile | Ser | Ala | Lys | Tyr | Tyr | Lys | Lys | Met | Asn | Leu | Lys | Leu | Ser | Met | Gly | |
| | | | | 165 | | | | | 170 | | | | | 175 | | |
| His | His | Thr | Val | Phe | Gly | Asn | Pro | Asn | Val | Arg | Ile | Glu | His | His | Asn | |
| | | | 180 | | | | | 185 | | | | | 190 | | | |
| Asp | Leu | Lys | Phe | Ala | His | Tyr | Arg | Ala | Ile | Ser | Gln | Glu | Gln | Leu | Ile | |
| | | 195 | | | | | 200 | | | | | 205 | | | | |
| Tyr | Lys | Thr | Ile | Cys | Tyr | Thr | Ile | Arg | Asp | Ile | Ala | Thr | Met | Glu | Asn | |
| | 210 | | | | | 215 | | | | | 220 | | | | | |
| Asn | Ile | Glu | Thr | Ala | Gln | Arg | Thr | Asn | Gln | Met | Ala | Leu | Ile | Glu | Ser | |
| 225 | | | | | 230 | | | | | 235 | | | | | 240 | |
| Gly | Val | Asp | Met | Trp | Glu | Thr | Ala | Arg | Glu | Ala | Ser | Tyr | Ser | Gly | Tyr | |
| | | | | 245 | | | | | 250 | | | | | 255 | | |

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
| Asp | Cys | Asn | Val | Ile | His | Ala | Pro | Ile | Asp | Leu | Ser | Phe | Cys | Lys | Glu | |
| | | | 260 | | | | | 265 | | | | | 270 | | | |
| Asn | Ile | Val | Ile | Lys | Tyr | Asn | Glu | Leu | Ser | Arg | Glu | Thr | Val | Ala | Glu | |
| | | 275 | | | | | 280 | | | | | 285 | | | | |
| Arg | Val | Met | Lys | Thr | Gly | Arg | Glu | Met | Ala | Val | Arg | Ala | Tyr | Asn | Val | |
| | 290 | | | | | 295 | | | | | 300 | | | | | |
| Glu | Arg | Lys | Gln | Lys | Glu | Lys | Lys | Phe | Leu | Lys | Pro | Ile | Ile | Phe | Val | |
| 305 | | | | | 310 | | | | | 315 | | | | | 320 | |
| Leu | Asp | Gly | Leu | Lys | Gly | Asp | Glu | Tyr | Ile | His | Pro | Asn | Pro | Ser | Asn | |
| | | | 325 | | | | | | 330 | | | | | 335 | | |
| His | Leu | Thr | Ile | Leu | Thr | Glu | Met | Tyr | Asn | Val | Arg | Gly | Leu | Leu | Thr | |
| | | | 340 | | | | | 345 | | | | | 350 | | | |
| Asp | Asn | His | Gln | Ile | Lys | Phe | Leu | Lys | Val | Asn | Tyr | Arg | Leu | Ile | Ile | |
| | | 355 | | | | | 360 | | | | | 365 | | | | |
| Thr | Pro | Asp | Phe | Ala | Lys | Phe | Leu | Pro | His | Glu | Phe | Ile | Val | Val | Pro | |
| | 370 | | | | | 375 | | | | | 380 | | | | | |
| Asp | Thr | Leu | Asp | Ile | Glu | Gln | Val | Lys | Ser | Gln | Tyr | Val | Gly | Thr | Gly | |
| 385 | | | | | 390 | | | | | 395 | | | | | 400 | |
| Val | Asp | Leu | Ser | Lys | Ile | Ile | Ser | Leu | Lys | Glu | Tyr | Arg | Lys | Glu | Ile | |
| | | | | 405 | | | | | 410 | | | | | 415 | | |
| Gly | Phe | Ile | Gly | Asn | Leu | Tyr | Ala | Leu | Leu | Gly | Phe | Val | Pro | Asn | Met | |
| | | | 420 | | | | | 425 | | | | | 430 | | | |
| Leu | Asn | Arg | Ile | Tyr | Leu | Tyr | Ile | Gln | Arg | Asn | Gly | Ile | Ala | Asn | Thr | |
| | | 435 | | | | | 440 | | | | | 445 | | | | |
| Ile | Ile | Lys | Ile | Lys | Ser | Arg | Leu | | | | | | | | | |
| | 450 | | | | | 455 | | | | | | | | | | |

<210> 20

<211> 410

<212> PRT

<213> Streptococcus suis.

<220>

<221> misc_feature

<223> CPS2I

<400> 20

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
| Met | Gln | Ala | Asp | Arg | Arg | Lys | Thr | Phe | Gly | Lys | Met | Arg | Ile | Arg | Ile | |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | | |
| Asn | Asn | Leu | Phe | Phe | Val | Ala | Ile | Ala | Phe | Met | Gly | Ile | Ile | Ile | Ser | |
| | | | 20 | | | | | 25 | | | | | 30 | | | |
| Asn | Ser | Gln | Val | Val | Leu | Ala | Ile | Gly | Lys | Ala | Ser | Val | Ile | Gln | Tyr | |
| | | 35 | | | | | 40 | | | | | 45 | | | | |
| Leu | Ser | Tyr | Leu | Val | Leu | Ile | Leu | Cys | Ile | Val | Asn | Asp | Leu | Leu | Lys | |
| | 50 | | | | | 55 | | | | | 60 | | | | | |
| Asn | Asn | Lys | His | Ile | Val | Val | Tyr | Lys | Leu | Gly | Tyr | Leu | Phe | Leu | Ile | |
| 65 | | | | | 70 | | | | | 75 | | | | | 80 | |
| Ile | Phe | Leu | Phe | Thr | Ile | Gly | Ile | Cys | Gln | Gln | Ile | Leu | Pro | Ile | Thr | |
| | | | | 85 | | | | | 90 | | | | | 95 | | |
| Thr | Lys | Ile | Tyr | Leu | Ser | Ile | Ser | Met | Met | Ile | Ile | Ser | Val | Leu | Ala | |
| | | | 100 | | | | | 105 | | | | | 110 | | | |
| Thr | Leu | Pro | Ile | Ser | Leu | Ile | Lys | Asp | Ile | Asp | Asp | Phe | Arg | Arg | Ile | |
| | | 115 | | | | | 120 | | | | | 125 | | | | |
| Ser | Asn | His | Leu | Leu | Phe | Ala | Leu | Phe | Ile | Thr | Ser | Ile | Leu | Gly | Ile | |
| | 130 | | | | | 135 | | | | | 140 | | | | | |
| Lys | Met | Gly | Ala | Thr | Met | Phe | Thr | Gly | Ala | Val | Glu | Gly | Ile | Gly | Phe | |
| 145 | | | | | 150 | | | | | 155 | | | | | 160 | |
| Ser | Gln | Gly | Phe | Asn | Gly | Gly | Leu | Thr | His | Lys | Asn | Phe | Phe | Gly | Ile | |
| | | | | 165 | | | | | 170 | | | | | 175 | | |
| Thr | Ile | Leu | Met | Gly | Phe | Val | Leu | Thr | Tyr | Leu | Ala | Tyr | Lys | Tyr | Gly | |
| | | 180 | | | | | | 185 | | | | | 190 | | | |
| Ser | Tyr | Lys | Arg | Thr | Asp | Arg | Phe | Ile | Leu | Gly | Leu | Glu | Leu | Phe | Leu | |
| | | 195 | | | | | 200 | | | | | 205 | | | | |
| Ile | Leu | Ile | Ser | Asn | Thr | Arg | Ser | Val | Tyr | Leu | Ile | Leu | Leu | Leu | Phe | |
| | 210 | | | | | 215 | | | | | 220 | | | | | |
| Leu | Phe | Leu | Val | Asn | Leu | Asp | Lys | Ile | Lys | Ile | Glu | Gln | Arg | Gln | Trp | |
| 225 | | | | 230 | | | | | | 235 | | | | | 240 | |
| Ser | Thr | Leu | Lys | Tyr | Ile | Ser | Met | Leu | Phe | Cys | Ala | Ile | Phe | Leu | Tyr | |
| | | | | 245 | | | | | 250 | | | | | 255 | | |

Tyr Phe Phe Gly Phe Leu Ile Thr His Ser Asp Ser Tyr Ala His Arg
 260 265 270
 Val Asn Gly Leu Ile Asn Phe Phe Glu Tyr Tyr Arg Asn Asp Trp Phe
 275 280 285
 His Leu Met Phe Gly Ala Ala Asp Leu Ala Tyr Gly Asp Leu Thr Leu
 290 295 300
 Asp Tyr Ala Ile Arg Val Arg Arg Val Leu Gly Trp Asn Gly Thr Leu
 305 310 315 320
 Glu Met Pro Leu Leu Ser Ile Met Leu Lys Asn Gly Phe Ile Gly Leu
 325 330 335
 Val Gly Tyr Gly Ile Val Leu Tyr Lys Leu Tyr Arg Asn Val Arg Ile
 340 345 350
 Leu Lys Thr Asp Asn Ile Lys Thr Ile Gly Lys Ser Val Phe Ile Ile
 355 360 365
 Val Val Leu Ser Ala Thr Val Glu Asn Tyr Ile Val Asn Leu Ser Phe
 370 375 380
 Val Phe Met Pro Ile Cys Phe Cys Leu Leu Asn Ser Ile Ser Thr Met
 385 390 395 400
 Glu Ser Thr Ile Asn Lys Gln Leu Gln Thr
 405 410

<210> 21

<211> 332

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS2J

<400> 21

Met Glu Lys Val Ser Ile Ile Val Pro Ile Phe Asn Thr Glu Lys Tyr
 1 5 10 15
 Leu Arg Glu Cys Leu Asp Ser Ile Ile Ser Gln Ser Tyr Thr Asn Leu
 20 25 30

| | | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Glu | Ile | Leu | Leu | Ile | Asp | Asp | Gly | Ser | Ser | Asp | Ser | Ser | Thr | Asp | Ile | 35 | 40 | 45 |
| Cys | Leu | Glu | Tyr | Ala | Glu | Gln | Asp | Gly | Arg | Ile | Lys | Leu | Phe | Arg | Leu | 50 | 55 | 60 |
| Pro | Asn | Gly | Gly | Val | Ser | Asn | Ala | Arg | Asn | Tyr | Gly | Ile | Lys | Asn | Ser | 65 | 70 | 75 |
| Thr | Ala | Asn | Tyr | Ile | Met | Phe | Val | Asp | Ser | Asp | Asp | Ile | Val | Asp | Gly | 85 | 90 | 95 |
| Asn | Ile | Val | Glu | Ser | Leu | Tyr | Thr | Cys | Leu | Lys | Glu | Asn | Asp | Ser | Asp | 100 | 105 | 110 |
| Leu | Ser | Gly | Gly | Leu | Leu | Ala | Thr | Phe | Asp | Gly | Asn | Tyr | Gln | Glu | Ser | 115 | 120 | 125 |
| Glu | Leu | Gln | Lys | Cys | Gln | Ile | Asp | Leu | Glu | Glu | Ile | Lys | Glu | Val | Arg | 130 | 135 | 140 |
| Asp | Leu | Gly | Asn | Glu | Asn | Phe | Pro | Asn | His | Tyr | Met | Ser | Gly | Ile | Phe | 145 | 150 | 155 |
| Asn | Ser | Pro | Cys | Cys | Lys | Leu | Tyr | Lys | Asn | Ile | Tyr | Ile | Asn | Gln | Gly | 165 | 170 | 175 |
| Phe | Asp | Thr | Glu | Gln | Trp | Leu | Gly | Glu | Asp | Leu | Leu | Phe | Asn | Leu | Asn | 180 | 185 | 190 |
| Tyr | Leu | Lys | Asn | Ile | Lys | Lys | Val | Arg | Tyr | Val | Asn | Arg | Asn | Leu | Tyr | 195 | 200 | 205 |
| Phe | Ala | Arg | Arg | Ser | Leu | Gln | Ser | Thr | Thr | Asn | Thr | Phe | Lys | Tyr | Asp | 210 | 215 | 220 |
| Val | Phe | Ile | Gln | Leu | Glu | Asn | Leu | Glu | Glu | Lys | Thr | Phe | Asp | Leu | Phe | 225 | 230 | 235 |
| Val | Lys | Ile | Phe | Gly | Gly | Gln | Tyr | Glu | Phe | Ser | Val | Phe | Lys | Glu | Thr | 245 | 250 | 255 |
| Leu | Gln | Trp | His | Ile | Ile | Tyr | Tyr | Ser | Leu | Leu | Met | Phe | Lys | Asn | Gly | 260 | 265 | 270 |
| Asp | Glu | Ser | Leu | Pro | Lys | Lys | Leu | His | Ile | Phe | Lys | Tyr | Leu | Tyr | Asn | 275 | 280 | 285 |
| Arg | His | Ser | Leu | Asp | Thr | Leu | Ser | Ile | Lys | Arg | Thr | Ser | Ser | Val | Phe | 290 | 295 | 300 |

Lys Arg Ile Cys Lys Leu Ile Val Ala Asn Asn Leu Phe Lys Ile Phe
 305 310 315 320

Leu Asn Thr Leu Ile Arg Glu Glu Lys Asn Asn Asp
 325 330

<210> 22

<211> 332

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS2K

<400> 22

Met Ile Asn Ile Ser Ile Ile Val Pro Ile Tyr Asn Val Glu Gln Tyr
 1 5 10 15

Leu Ser Lys Cys Ile Asn Ser Ile Val Asn Gln Thr Tyr Lys His Ile
 20 25 30

Glu Ile Leu Leu Val Asn Asp Gly Ser Thr Asp Asn Ser Glu Glu Ile
 35 40 45

Cys Leu Ala Tyr Ala Lys Lys Asp Ser Arg Ile Arg Tyr Phe Lys Lys
 50 55 60

Glu Asn Gly Gly Leu Ser Asp Ala Arg Asn Tyr Gly Ile Ser Arg Ala
 65 70 75 80

Lys Gly Asp Tyr Leu Ala Phe Ile Asp Ser Asp Asp Phe Ile His Ser
 85 90 95

Glu Phe Ile Gln Arg Leu His Glu Ala Ile Glu Arg Glu Asn Ala Leu
 100 105 110

Val Ala Val Ala Gly Tyr Asp Arg Val Asp Ala Ser Gly His Phe Leu
 115 120 125

Thr Ala Glu Pro Leu Pro Thr Asn Gln Ala Val Leu Ser Gly Arg Asn
 130 135 140

Val Cys Lys Lys Leu Leu Glu Ala Asp Gly His Arg Phe Val Val Ala
 145 150 155 160

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Trp | Asn | Lys | Leu | Tyr | Lys | Lys | Glu | Leu | Phe | Asp | Phe | Arg | Phe | Glu | Lys |
| | | | | 165 | | | | | 170 | | | | | 175 | |
| Gly | Lys | Ile | His | Glu | Asp | Glu | Tyr | Phe | Thr | Tyr | Arg | Leu | Leu | Tyr | Glu |
| | | | 180 | | | | | 185 | | | | | 190 | | |
| Leu | Glu | Lys | Val | Ala | Ile | Val | Lys | Glu | Cys | Leu | Tyr | Tyr | Tyr | Val | Asp |
| | | 195 | | | | | 200 | | | | | 205 | | | |
| Arg | Glu | Asn | Ser | Ile | Ile | Thr | Ser | Ser | Met | Thr | Asp | His | Arg | Phe | His |
| | 210 | | | | | 215 | | | | | 220 | | | | |
| Cys | Leu | Leu | Glu | Phe | Gln | Asn | Glu | Arg | Met | Asp | Phe | Tyr | Glu | Ser | Arg |
| 225 | | | | | 230 | | | | | 235 | | | | | 240 |
| Gly | Asp | Lys | Glu | Leu | Leu | Leu | Glu | Cys | Tyr | Arg | Ser | Phe | Leu | Ala | Phe |
| | | | | 245 | | | | | 250 | | | | | 255 | |
| Ala | Val | Leu | Phe | Leu | Gly | Lys | Tyr | Asn | His | Trp | Leu | Ser | Lys | Gln | Gln |
| | | | 260 | | | | | 265 | | | | | 270 | | |
| Lys | Lys | Leu | Gln | Thr | Leu | Phe | Arg | Ile | Val | Tyr | Lys | Gln | Leu | Lys | Gln |
| | | 275 | | | | | 280 | | | | | 285 | | | |
| Asn | Lys | Arg | Leu | Ala | Leu | Leu | Met | Asn | Ala | Tyr | Tyr | Leu | Val | Gly | Cys |
| | 290 | | | | | 295 | | | | | 300 | | | | |
| Leu | His | Leu | Asn | Phe | Ser | Val | Phe | Leu | Lys | Thr | Gly | Lys | Asp | Lys | Ile |
| 305 | | | | | 310 | | | | | 315 | | | | | 320 |
| Gln | Glu | Arg | Leu | Arg | Arg | Ser | Glu | Ser | Ser | Thr | Arg | | | | |
| | | | | 325 | | | | | 330 | | | | | | |

<210> 23

<211> 467

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS20

<220>

<221> misc_feature

<222> (1)..(467)

<223> Xaa may be any amino acid

<400> 23

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
| Met | Ser | Lys | Lys | Ser | Ile | Val | Val | Ser | Gly | Leu | Val | Tyr | Thr | Ile | Gly | |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | | |
| Thr | Ile | Leu | Val | Gln | Gly | Leu | Ala | Phe | Ile | Thr | Leu | Pro | Ile | Tyr | Thr | |
| | | | 20 | | | | | 25 | | | | | 30 | | | |
| Arg | Val | Ile | Ser | Gln | Glu | Val | Tyr | Gly | Gln | Phe | Ser | Leu | Tyr | Asn | Ser | |
| | | 35 | | | | | 40 | | | | | 45 | | | | |
| Trp | Val | Gly | Leu | Val | Gly | Leu | Phe | Ile | Gly | Leu | Gln | Leu | Gly | Gly | Ala | |
| | 50 | | | | | 55 | | | | | 60 | | | | | |
| Phe | Gly | Pro | Gly | Trp | Val | His | Phe | Arg | Glu | Lys | Phe | Asp | Asp | Phe | Val | |
| 65 | | | | | 70 | | | | | 75 | | | | | 80 | |
| Ser | Thr | Leu | Met | Val | Ser | Ser | Ile | Ala | Phe | Phe | Leu | Pro | Ile | Phe | Gly | |
| | | | | 85 | | | | | 90 | | | | | 95 | | |
| Leu | Ser | Phe | Leu | Leu | Ser | Gln | Pro | Leu | Ser | Leu | Leu | Phe | Gly | Leu | Pro | |
| | | | 100 | | | | | 105 | | | | | 110 | | | |
| Asp | Trp | Val | Val | Pro | Leu | Ile | Phe | Leu | Gln | Ser | Leu | Met | Ile | Val | Val | |
| | | 115 | | | | | 120 | | | | | 125 | | | | |
| Gln | Gly | Phe | Phe | Thr | Thr | Tyr | Leu | Val | Gln | Arg | Gln | Gln | Ser | Met | Trp | |
| | 130 | | | | | 135 | | | | | 140 | | | | | |
| Thr | Leu | Pro | Leu | Ser | Val | Leu | Ser | Ala | Val | Ile | Asn | Thr | Ala | Leu | Ser | |
| 145 | | | | | 150 | | | | | 155 | | | | | 160 | |
| Leu | Phe | Leu | Thr | Phe | Pro | Met | Glu | Asn | Asp | Phe | Ile | Ala | Arg | Val | Met | |
| | | | | 165 | | | | | 170 | | | | | 175 | | |
| Ala | Asn | Pro | Ala | Thr | Thr | Gly | Val | Leu | Ala | Cys | Val | Ser | Xaa | Trp | Phe | |
| | | | 180 | | | | | 185 | | | | | 190 | | | |
| Ser | Gln | Lys | Lys | Asn | Gly | Leu | His | Phe | Arg | Lys | Asp | Tyr | Leu | Arg | Tyr | |
| | | 195 | | | | | 200 | | | | | 205 | | | | |
| Gly | Leu | Ser | Ile | Ser | Ile | Pro | Leu | Ile | Phe | His | Gly | Leu | Gly | His | Asn | |
| | 210 | | | | | 215 | | | | | 220 | | | | | |
| Val | Leu | Asn | Gln | Phe | Asp | Arg | Ile | Met | Leu | Gly | Lys | Met | Leu | Thr | Leu | |
| 225 | | | | | 230 | | | | | 235 | | | | | 240 | |

Ser Asp Val Ala Leu Tyr Ser Phe Gly Tyr Thr Leu Ala Ser Ile Leu
 245 250 255
 Gln Ile Val Phe Ser Ser Leu Asn Thr Val Trp Cys Pro Trp Tyr Phe
 260 265 270
 Glu Lys Lys Arg Gly Ala Asp Lys Asp Leu Leu Ser Tyr Val Arg Tyr
 275 280 285
 Tyr Leu Ala Ile Gly Leu Phe Val Thr Phe Gly Phe Leu Thr Ile Tyr
 290 295 300
 Pro Arg Leu Ala Met Leu Leu Gly Gly Ser Glu Tyr Arg Phe Ser Met
 305 310 315 320
 Gly Phe Ile Pro Met Ile Ile Val Gly Val Phe Phe Val Phe Leu Tyr
 325 330 335
 Ser Phe Pro Ala Asn Ile Gln Phe Tyr Ser Gly Asn Thr Lys Phe Leu
 340 345 350
 Pro Ile Gly Thr Phe Ile Ala Gly Val Leu Asn Ile Ser Val His Phe
 355 360 365
 Val Leu Ile Pro Thr Lys Asn Leu Trp Cys Cys Phe Ala Thr Thr Ala
 370 375 380
 Ser Tyr Leu Leu Leu Leu Val Leu His Tyr Phe Val Ala Lys Lys Lys
 385 390 395 400
 Tyr Ala Tyr Asp Glu Val Ala Ile Ser Thr Phe Val Lys Val Ile Ala
 405 410 415
 Leu Val Val Val Tyr Thr Gly Leu Met Thr Val Phe Val Gly Ser Ile
 420 425 430
 Trp Ile Arg Trp Ser Leu Gly Ile Ala Val Leu Val Val Tyr Ala Ile
 435 440 445
 Tyr Phe Arg Lys Glu Leu Thr Val Ala Leu Asn Thr Phe Arg Glu Lys
 450 455 460
 Arg Ser Lys
 465

<210> 24

<211> 338

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS2P

<400> 24

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
| Met | Val | Tyr | Ile | Ile | Ala | Glu | Ile | Gly | Cys | Asn | His | Asn | Gly | Asp | Val | |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | | |
| His | Leu | Ala | Arg | Lys | Met | Val | Glu | Val | Ala | Val | Asp | Cys | Gly | Val | Asp | |
| | | | 20 | | | | | 25 | | | | | 30 | | | |
| Ala | Val | Lys | Phe | Gln | Thr | Glu | Lys | Ala | Asp | Leu | Leu | Ile | Ser | Lys | Tyr | |
| | | 35 | | | | | 40 | | | | | 45 | | | | |
| Ala | Pro | Lys | Ala | Glu | Tyr | Gln | Lys | Ile | Thr | Thr | Gly | Glu | Ser | Asp | Ser | |
| | 50 | | | | | 55 | | | | | 60 | | | | | |
| Gln | Leu | Glu | Met | Thr | Arg | Arg | Leu | Glu | Leu | Ser | Phe | Glu | Glu | Tyr | Leu | |
| 65 | | | | | 70 | | | | | 75 | | | | | 80 | |
| Asp | Leu | Arg | Asp | Tyr | Cys | Leu | Glu | Lys | Gly | Val | Asp | Val | Phe | Ser | Thr | |
| | | | | 85 | | | | | 90 | | | | | 95 | | |
| Pro | Glu | Asp | Glu | Glu | Ser | Leu | Asp | Phe | Leu | Ile | Ser | Thr | Asp | Met | Pro | |
| | | | 100 | | | | | 105 | | | | | 110 | | | |
| Val | Tyr | Lys | Ile | Pro | Ser | Gly | Glu | Ile | Thr | Asn | Leu | Pro | Tyr | Leu | Glu | |
| | | 115 | | | | | 120 | | | | | 125 | | | | |
| Lys | Ile | Gly | Arg | Gln | Ala | Lys | Lys | Val | Ile | Leu | Ser | Thr | Gly | Met | Ala | |
| | 130 | | | | | 135 | | | | | 140 | | | | | |
| Val | Met | Asp | Glu | Ile | His | Gln | Ala | Val | Lys | Ile | Leu | Gln | Glu | Asn | Gly | |
| 145 | | | | | 150 | | | | 155 | | | | | | 160 | |
| Thr | Thr | Asp | Ile | Ser | Ile | Leu | His | Cys | Thr | Thr | Glu | Tyr | Pro | Thr | Pro | |
| | | | | 165 | | | | | 170 | | | | | 175 | | |
| Tyr | Pro | Ala | Leu | Asn | Leu | Asn | Val | Leu | His | Thr | Leu | Lys | Lys | Glu | Phe | |
| | | | 180 | | | | | 185 | | | | | 190 | | | |
| Pro | Asn | Leu | Thr | Ile | Gly | Tyr | Ser | Asp | His | Ser | Val | Gly | Ser | Glu | Val | |
| | | 195 | | | | | 200 | | | | | 205 | | | | |
| Pro | Ile | Ala | Ala | Ala | Ala | Met | Gly | Ala | Glu | Leu | Ile | Glu | Lys | His | Phe | |
| | 210 | | | | | 215 | | | | | 220 | | | | | |

Thr Leu Asp Asn Glu Met Glu Gly Pro Asp His Lys Ala Ser Ala Thr
 225 230 235 240
 Pro Asp Ile Leu Ala Ala Leu Val Lys Gly Val Arg Ile Val Glu Gln
 245 250 255
 Ser Leu Gly Lys Phe Glu Lys Glu Pro Glu Glu Val Glu Val Arg Asn
 260 265 270
 Lys Ile Val Ala Glu Lys Ser Ile Val Ala Lys Lys Ala Ile Ala Lys
 275 280 285
 Gly Glu Val Phe Thr Glu Glu Asn Ile Thr Val Lys Arg Pro Gly Asn
 290 295 300
 Gly Ile Ser Pro Met Glu Trp Tyr Lys Val Leu Gly Gln Val Ser Glu
 305 310 315 320
 Gln Asp Phe Glu Glu Asp Gln Asn Ile Cys His Ser Ala Phe Glu Asn
 325 330 335

Gln Met

<210> 25

<211> 170

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS2Q

<400> 25

Met Lys Lys Ile Cys Phe Val Thr Gly Ser Arg Ala Glu Tyr Gly Ile
 1 5 10 15
 Met Arg Arg Leu Leu Ser Tyr Leu Gln Asp Asp Pro Glu Met Glu Leu
 20 25 30
 Asp Leu Val Val Ala Thr Met His Leu Glu Glu Lys Tyr Gly Met Thr
 35 40 45
 Val Lys Asp Ile Glu Ala Asp Lys Arg Arg Ile Val Lys Arg Ile Pro
 50 55 60

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | His | Leu | Thr | Asp | Thr | Ser | Lys | Gln | Thr | Ile | Val | Lys | Ser | Leu | Ala |
| 65 | | | | | 70 | | | | | 75 | | | | | 80 |
| Thr | Leu | Thr | Glu | Gln | Leu | Thr | Val | Leu | Phe | Glu | Glu | Val | Gln | Tyr | Asp |
| | | | 85 | | | | | | 90 | | | | | 95 | |
| Leu | Val | Leu | Ile | Leu | Gly | Asp | Arg | Tyr | Glu | Met | Leu | Pro | Val | Ala | Asn |
| | | | 100 | | | | | 105 | | | | | 110 | | |
| Ala | Ala | Leu | Leu | Tyr | Asn | Ile | Pro | Ile | Cys | His | Ile | His | Gly | Gly | Glu |
| | | 115 | | | | | 120 | | | | | 125 | | | |
| Lys | Thr | Met | Gly | Asn | Phe | Asp | Glu | Ser | Ile | Arg | His | Ala | Ile | Thr | Lys |
| | 130 | | | | | 135 | | | | | 140 | | | | |
| Met | Ser | His | Leu | His | Leu | Thr | Ser | Thr | Asp | Glu | Phe | Arg | Asn | Arg | Val |
| 145 | | | | | 150 | | | | | 155 | | | | | 160 |
| Ile | Gln | Leu | Gly | Glu | Asn | Pro | Thr | Met | Tyr | | | | | | |
| | | | | 165 | | | | | 170 | | | | | | |

<210> 26

<211> 184

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS2R

<400> 26

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Glu | Leu | Gly | Ile | Asp | Phe | Ala | Glu | Asp | Tyr | Tyr | Val | Val | Leu | Phe |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |
| His | Pro | Val | Thr | Leu | Glu | Asp | Asn | Thr | Ala | Glu | Glu | Gln | Thr | Gln | Ala |
| | | | 20 | | | | | 25 | | | | | 30 | | |
| Leu | Leu | Asp | Ala | Leu | Lys | Glu | Asp | Gly | Ser | Gln | Cys | Leu | Ile | Ile | Gly |
| | | 35 | | | | | 40 | | | | | 45 | | | |
| Ser | Asn | Ser | Asp | Thr | His | Ala | Asp | Lys | Ile | Met | Glu | Leu | Met | His | Glu |
| | 50 | | | | | 55 | | | | | 60 | | | | |

Phe Val Lys Gln Asp Ser Asp Ser Tyr Ile Phe Thr Ser Leu Pro Thr
 65 70 75 80
 Arg Tyr Tyr His Ser Leu Val Lys His Ser Gln Gly Leu Ile Gly Asn
 85 90 95
 Ser Ser Ser Gly Leu Ile Glu Val Pro Ser Leu Gln Val Pro Thr Leu
 100 105 110
 Asn Ile Gly Asn Arg Gln Phe Gly Arg Leu Ser Gly Pro Ser Val Val
 115 120 125
 His Val Gly Thr Ser Lys Glu Ala Ile Val Gly Gly Leu Gly Gln Leu
 130 135 140
 Arg Asp Val Ile Asp Phe Thr Asn Pro Phe Glu Gln Pro Asp Ser Ala
 145 150 155 160
 Leu Gln Gly Tyr Arg Ala Ile Lys Glu Phe Leu Ser Val Gln Ala Ser
 165 170 175
 Thr Met Lys Glu Phe Tyr Asp Arg
 180

<210> 27

<211> 208

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS2S

<400> 27

Met Lys Lys Val Ala Phe Leu Gly Ala Gly Thr Phe Ser Asp Gly Val
 1 5 10 15
 Leu Pro Trp Leu Asp Arg Thr Arg Tyr Glu Leu Ile Gly Tyr Phe Glu
 20 25 30
 Asp Lys Pro Ile Ser Asp Tyr Arg Gly Tyr Pro Val Phe Gly Pro Leu
 35 40 45
 Gln Asp Val Leu Thr Tyr Leu Asp Asp Gly Lys Val Asp Ala Val Phe
 50 55 60

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Val | Thr | Ile | Gly | Asp | Asn | Val | Lys | Arg | Lys | Glu | Ile | Phe | Asp | Leu | Leu |
| 65 | | | | | 70 | | | | | 75 | | | | | 80 |
| Ala | Lys | Asp | His | Tyr | Asp | Ala | Leu | Phe | Asn | Ile | Ile | Ser | Glu | Gln | Ala |
| | | | 85 | | | | | | 90 | | | | | 95 | |
| Asn | Ile | Phe | Ser | Pro | Asp | Ser | Ile | Lys | Gly | Arg | Gly | Val | Phe | Ile | Gly |
| | | | 100 | | | | | 105 | | | | | 110 | | |
| Phe | Ser | Ser | Phe | Val | Gly | Ala | Asp | Ser | Tyr | Val | Tyr | Asp | Asn | Cys | Ile |
| | | 115 | | | | | 120 | | | | | 125 | | | |
| Ile | Asn | Thr | Gly | Ala | Ile | Val | Glu | His | His | Thr | Thr | Val | Glu | Ala | His |
| | 130 | | | | | 135 | | | | | 140 | | | | |
| Cys | Asn | Ile | Thr | Pro | Gly | Val | Thr | Ile | Asn | Gly | Leu | Cys | Arg | Ile | Gly |
| 145 | | | | | 150 | | | | | 155 | | | | | 160 |
| Glu | Ser | Thr | Tyr | Ile | Gly | Ser | Gly | Ser | Thr | Val | Ile | Gln | Cys | Ile | Glu |
| | | | | 165 | | | | | 170 | | | | | 175 | |
| Ile | Ala | Pro | Tyr | Thr | Thr | Leu | Gly | Ala | Gly | Thr | Val | Val | Leu | Lys | Ser |
| | | | 180 | | | | | 185 | | | | | 190 | | |
| Leu | Thr | Glu | Ser | Gly | Thr | Tyr | Val | Gly | Val | Pro | Ala | Arg | Lys | Ile | Lys |
| | | 195 | | | | | 200 | | | | | 205 | | | |

<210> 28

<211> 410

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS2T

<400> 28

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Glu | Pro | Ile | Cys | Leu | Ile | Pro | Ala | Arg | Ser | Gly | Ser | Lys | Gly | Leu |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |
| Pro | Asn | Lys | Asn | Met | Leu | Phe | Leu | Asp | Gly | Val | Pro | Met | Ile | Phe | His |
| | | | 20 | | | | | 25 | | | | | 30 | | |

| | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|--|
| Thr | Ile | Arg | Ala | Ala | Ile | Glu | Ser | Gly | Cys | Phe | Lys | Lys | Glu | Asn | Ile | | |
| | | 35 | | | | | 40 | | | | | 45 | | | | | |
| Tyr | Val | Ser | Thr | Asp | Ser | Glu | Val | Tyr | Lys | Glu | Ile | Cys | Glu | Thr | Thr | | |
| | 50 | | | | | 55 | | | | | 60 | | | | | | |
| Gly | Val | Gln | Val | Leu | Met | Arg | Pro | Ala | Asp | Leu | Ala | Thr | Asp | Phe | Thr | | |
| 65 | | | | | 70 | | | | | 75 | | | | | 80 | | |
| Thr | Ser | Phe | Gln | Leu | Asn | Glu | His | Phe | Leu | Gln | Asp | Phe | Ser | Asp | Asp | | |
| | | | | 85 | | | | | 90 | | | | | 95 | | | |
| Gln | Val | Phe | Val | Leu | Leu | Gln | Val | Thr | Ser | Pro | Leu | Arg | Ser | Gly | Lys | | |
| | | | 100 | | | | | 105 | | | | | 110 | | | | |
| His | Val | Lys | Glu | Ala | Met | Glu | Leu | Tyr | Gly | Lys | Gly | Gln | Ala | Asp | His | | |
| | | 115 | | | | | 120 | | | | | 125 | | | | | |
| Val | Val | Ser | Phe | Thr | Lys | Val | Asp | Lys | Ser | Pro | Thr | Leu | Phe | Ser | Thr | | |
| | 130 | | | | | 135 | | | | | 140 | | | | | | |
| Leu | Asp | Glu | Asn | Gly | Phe | Ala | Lys | Asp | Ile | Ala | Gly | Leu | Gly | Gly | Ser | | |
| 145 | | | | | 150 | | | | | 155 | | | | | 160 | | |
| Tyr | Arg | Arg | Gln | Asp | Glu | Lys | Thr | Leu | Tyr | Tyr | Pro | Asn | Gly | Ala | Ile | | |
| | | | | 165 | | | | | 170 | | | | | 175 | | | |
| Tyr | Ile | Ser | Ser | Lys | Gln | Ala | Tyr | Leu | Ala | Asp | Lys | Thr | Tyr | Phe | Ser | | |
| | | | 180 | | | | | 185 | | | | | 190 | | | | |
| Glu | Lys | Thr | Ala | Ala | Tyr | Val | Met | Thr | Lys | Glu | Asp | Ser | Ile | Asp | Val | | |
| | | 195 | | | | | 200 | | | | | 205 | | | | | |
| Asp | Asp | His | Phe | Asp | Phe | Thr | Gly | Val | Ile | Gly | Arg | Ile | Tyr | Phe | Asp | | |
| | 210 | | | | | 215 | | | | | 220 | | | | | | |
| Tyr | Gln | Arg | Arg | Glu | Gln | Gln | Asn | Lys | Pro | Phe | Tyr | Lys | Arg | Glu | Leu | | |
| 225 | | | | | 230 | | | | | 235 | | | | | 240 | | |
| Lys | Arg | Leu | Cys | Glu | Gln | Arg | Val | His | Asp | Ser | Leu | Val | Ile | Gly | Asp | | |
| | | | | 245 | | | | | 250 | | | | | 255 | | | |
| Ser | Arg | Leu | Leu | Ala | Leu | Leu | Leu | Asp | Gly | Phe | Asp | Asn | Ile | Ser | Ile | | |
| | | | 260 | | | | | 265 | | | | | 270 | | | | |
| Gly | Gly | Met | Thr | Ala | Ser | Thr | Ser | Leu | Glu | Asn | Gln | Gly | Leu | Phe | Leu | | |
| | | 275 | | | | | 280 | | | | | 285 | | | | | |
| Ala | Thr | Pro | Ile | Lys | Lys | Val | Leu | Leu | Ser | Leu | Gly | Val | Asn | Asp | Leu | | |
| | 290 | | | | | 295 | | | | | 300 | | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Thr | Asp | Tyr | Pro | Leu | His | Met | Ile | Glu | Asp | Thr | Ile | Arg | Gln | Leu |
| 305 | | | | | 310 | | | | | 315 | | | | | 320 |
| Met | Glu | Ser | Leu | Val | Ser | Lys | Ala | Glu | Gln | Val | Glu | Val | Thr | Thr | Ile |
| | | | | 325 | | | | | 330 | | | | | 335 | |
| Ala | Tyr | Thr | Leu | Phe | Arg | Asp | Ser | Val | Ser | Asn | Glu | Glu | Thr | Val | Gln |
| | | | 340 | | | | | 345 | | | | | 350 | | |
| Leu | Asn | Asp | Val | Ile | Val | Gln | Ser | Ala | Ser | Glu | Leu | Gly | Ile | Ser | Val |
| | | 355 | | | | | 360 | | | | | 365 | | | |
| Ile | Asp | Leu | Asn | Glu | Val | Val | Glu | Lys | Glu | Ala | Met | Leu | Asp | Tyr | Gln |
| | 370 | | | | | 375 | | | | | 380 | | | | |
| Tyr | Thr | Asn | Asp | Gly | Leu | His | Phe | Asn | Gln | Ile | Gly | Gln | Glu | Arg | Val |
| 385 | | | | | 390 | | | | | 395 | | | | | 400 |
| Asn | Gln | Leu | Ile | Leu | Thr | Ser | Leu | Thr | Arg | | | | | | |
| | | | | 405 | | | | | 410 | | | | | | |

<210> 29

<211> 6992

<212> DNA

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS1

<400> 29

| | | | | | | |
|------------|------------|------------|------------|------------|------------|-----|
| atcgccaaac | gaaattggca | ttatttgata | tgatagcagt | tgcaatttct | gcaatcttaa | 60 |
| caagtcatat | accaaagct | gatttaaata | gttctggaat | ttttatcata | atgatgggtc | 120 |
| attatattgc | attttttata | tctcgtatgc | cagttgaatt | tgagtataga | ggtaatctga | 180 |
| tagagtttga | aaaaacattt | aactatagta | taatatttgc | aatttttctt | acggcagtat | 240 |
| catttttggt | ggagaataat | ttcgcacttt | caagacgtgg | tgccgtgtat | ttcacattaa | 300 |
| taaacttcgt | tttggtatac | ctatttaacg | taattattaa | gcagtttaag | gatagctttc | 360 |
| tattttcgac | aatctatcaa | aaaaagacga | ttctaattac | aacggctgaa | cgatgggaaa | 420 |

atatgcaagt tttatattgaa tcacataaac aaattcaaaa aaatcttggt gcattggtag 480
 ttttaggtac agaaatagat aaaattaatt tatcattacc gctctattat tctgtggaag 540
 aagctataga gttttcaaca agggaagtgg tcgaccacgt ctttataaat ctaccaagtg 600
 agtttttaga cgtaaagcaa ttcgtttcag attttgagtt gttaggtatt gatgtaagcg 660
 ttgatattaa ttcattcggt tttactgcgt tgaaaaacaa aaaaatccaa ctgctaggtg 720
 accatagcat tgtaactttt tccacaaatt tttataagcc tagtcatatc atgatgaaac 780
 gacttttggg tatactcgga gcggtagtcg ggttaattat ttgtggtata gtttctattt 840
 tgtagttcc aattattcgt agagatgggt gaccggctat ttttgctcag aaacgagttg 900
 gacagaatgg acgcatattt acattctaca agtttcgatc gatgtatgtt gatgctgagg 960
 agcgcaaaaa agacttgctc agccaaaacc agatgcaagg gtgggtatgt tttaaaatgg 1020
 gaaaaacgat cctagaatta ctccaattgg acatttcata cgcaaaaaca agtttagacg 1080
 agttaccaca gttttataat gttttaattg gcgatatgag tctagttggg acacgtccac 1140
 ctacagttga tgaatttgaa aaatatactc ctgggtcaaaa gagacgattg agttttaaac 1200
 cagggattac aggtctctgg caggttagtg gtcgtagtaa tatcacagac ttcgacgacg 1260
 tagttcgggt ggacttagca tacattgata attggactat ctggtcagat attaaaattt 1320
 tattaaagac agtgaaagtt gtattgttga gagaggggaag taagtaaaag tatatgaaag 1380
 tttgtttggg cggttcttca gggggacatt tgactcactt gtatttggtta aaaccgtttt 1440
 ggaaggaaga agaacgtttt tgggtaacat ttgataaaga ggatgcaaga agtcttttga 1500
 agaatgaaaa aatgtatcca tgttactttc caacaaatcg caatctcatt aatttagtga 1560
 aaaatacttt cttagctttc aaaattttac gtgatgagaa accagatgtt attatttcat 1620
 ctgggtgcggc cgttgctgtc cccttctttt acatcggaag actatttgga gcaaagacga 1680
 tttatattga agtatttgat cgagttaata aatctacatt aactggaaaa ctagtttatc 1740
 ccgtaacaga tattttttatt gttcagtggg aagaaatgaa gaaggatatat cctaaatcta 1800
 ttaacttggg gagtattttt taatgatttt tgtaacagta ggaactcatg aacaacagtt 1860
 taatcgattg ataaaagaga ttgattttatt gaaaaaaaat ggaagtataa ccgacgaaat 1920
 atttattcaa acaggatatt ctgactatat tccagaatat tgcaagtata aaaaatttct 1980

cagttacaaa gaaatggaac aatatattaa caaatcagaa gtagttatth gccacggagg 2040
ccccgctact tttatgaatt cattatccaa agggaaaaaa caattattgt ttcctagaca 2100
aaaaaagtat ggtgaacatg taaatgatca tcaagtagag tttgtaagaa gaattttaca 2160
agataataat attttattta tagaaaatat agatgatttg tttgaaaaaa ttattgaagt 2220
ttctaagcaa actaacttta catcaaataa taattttttt tgtgaaagat taaaacaaat 2280
agttgaaaaa tttaatgagg atcaagaaaa tgaataataa aaaagatgca tatttgataa 2340
tggcttatca taatttttct cagattttac tggagaggga tacagatatt atcatcttct 2400
ctcaggagaa tgcacaccat tagttccttc agaataacctg tataattatt ttaaattattc 2460
tcaggattta tatgttgaat ttacaaaaga tgagcaaaaa tataaagaaa ataggatata 2520
tgaacgagtt aaatgttaca gattatttcc taatatatca gaaaaaacta ttgataatgt 2580
actgtttaga attttattaa gaatgtatcg agcttttgaa tactatttac aaagattgtt 2640
gtttattgat agaataaaaa acatggtcta agaataagat ttggttctaa ttgggtttcg 2700
cttcacatg attttgtggc aattctttta tcaaatagaa acgaaacagc ttatttattt 2760
aagtaatcta aatgtccaga tgaactatth atacagacaa ttatagaaaa atatgaattt 2820
tcaaatagat tatctaaata tggaaattta agatatataa agtggaaaaa atcaacatct 2880
tctcctattg tctttacaga tgattctatt gatgaattgc taaatgcaag aaatttaggt 2940
tttttatttg ctagaaagt aaataagaa aataaatcta aatttaaaga aattattact 3000
aaaaaataaa atagttgatt ttgtgagagt aatgtatgtt taaattattt aaatatgacc 3060
cggaatattt tatttttaag tacttctggt tgattatttt tattccagag caaaagtatg 3120
tatttttatt aatttttatg aatttaattt tatttcatat aaaatttttg aaaactaagc 3180
taatattaaa aaatgaaatt ttattgtttt tattatggtc tatattatgt tttgtttcag 3240
tagtcacaag tatgtttgtt gaaataaatt ttgaaagatt atttgcagat ttactgctc 3300
ccataatttg gattattgca ataatgtatt ataatttgta ttcatttata aatattgatt 3360
ataaaaaatt aaaaaatagt atctttttta gttttttagt tttattaggt atatctgcat 3420
tgtatattat tcaaatggg aaagatattg tatttttaga cagacacctt ataggactag 3480
actatcttat aacaggcgctc aaaacaaggt tgggtggctt tatgaactat cctacgtaa 3540

ataccactac aattatagtt tcaattccgt taatctttgc acttataaaa aataaaatgc 3600
 aacaattttt tttcttgtgt cttgctttta taccgatcta ttttaagtga tcgagaattg 3660
 gtagtttata gctagcaata ttaattatat gcttggtatg gagatatata ggtggaaaat 3720
 ttgcttggat aaaaaagcta atagtaatat ttgtaatact acttattatt ttaaatactg 3780
 aattgcttta ccatgaaatt ttggctgttt ataattctag agaatcaagt aacgaagcta 3840
 gatttattat ttatcaagga agtattgata aagtattaga aaacaatatt ttatttggat 3900
 atggaatatc cgaatattca gttacgggaa cttggctcgg aagtcattca ggctatatat 3960
 cattttttta taaatcagga atagttgggt tgattttact gatgttttct tttttttatg 4020
 ttataaaaaa aagttatgga gttaatgggg aaacagcact attttatttt acatcattag 4080
 ccatattttt catatatgaa acaatagatc cgattattat tatattagta ctattctttt 4140
 cttcaatagg tatttgggaat aatataaatt ttaaaaagga tatggagaca aaaaatgaat 4200
 gatttaattt cagttattgt accaatttat aatgtccaag attatcttga taaatgtatt 4260
 aacagtatta ttaaccaaac atatactaatt ttagaggtta ttctcgtaa tgatggaagt 4320
 actgatgatt ctgagaaaat ttgcttaaac tatatgaaga acgatggaag aattaaatat 4380
 tacaagaaaa ttaatggcgg tctagcagat gctcgaaatt tcggactaga acatgcaaca 4440
 ggtaaatata ttgcttttgt cgattctgat gactatatag aagttgcaat gttcgagaga 4500
 atgcatgata atataactga gtataatgcc gatatagcag agatagattt ttgttttagta 4560
 gacgaaaacg ggtatacaaa gaaaaaaaga aatagtaatt ttcattgtctt aacgagagaa 4620
 gagactgtaa aagaattttt gtcaggatct aatatagaaa ataatgtttg gtgcaagctt 4680
 tattcacgag atattataaa agatataaaa ttccaaatta ataatagaag tattggtgag 4740
 gatttgcttt ttaatttgga ggtcttgaac aatgtaacac gtgtagtagt tgatactaga 4800
 gaatattatt ataattatgt cattcgtaac agttcgctta ttaatcagaa attctctata 4860
 aataatattg atttagtcac aagattggag aattaccctt ttaagttaaa aagagagttt 4920
 agtcattatt ttgatgcaaa agttattaaa gagaaggtta aatgtttaaa caaaatgtat 4980
 tcaacagatt gtttggataa tgagttcttg ccaatattag agtcttatcg aaaagaaata 5040
 cgtagatatc catttattaa agcgaaaaga tatttatcaa gaaagcattt agttacgttg 5100

tatttgatga aattttcgcc taaactatat gtaatgttat ataagaaatt tcaaaagcag 5160
tagaggtaaa aatggataaa attagtgtta ttgttccagt ttataatgta gataaatatt 5220
taagtagttg tatagaaagc attattaatc aaaattataa aaatatagaa atattattga 5280
tagatgatgg ctctgtagat gattctgcta aaatatgcaa ggaatatgca gaaaaagata 5340
aaagagtaaa aatttttttc actaatcata gtggagtatc aaatgctaga aatcatggaa 5400
taaagcggag tacagctgaa tatattatgt ttgttgactc tgatgatggt gttgatagta 5460
gattagtaga aaaattatat tttaatatta taaaaagtag aagtgattta tctggttggt 5520
tgtacgctac tttttcagaa aatataaata attttgaagt gaataatcca aatattgatt 5580
ttgaagcaat taataccgtg caggacatgg gagaaaaaaa ttttatgaat ttgtatataa 5640
ataatatttt ttctactcct gtttgtaaac tatataagaa aagatacata acagatcttt 5700
ttcaagagaa tcaatgggtta ggagaagatt tactttttta tctgcattat ttaaagaata 5760
tagatagagt tagttatttg actgaacatc tttattttta taggagaggt atactaagta 5820
cagtaaattc ttttaaagaa ggtgtgtttt tgcaattgga aaatttgcaa aaacaagtga 5880
tagtattggt taagcaaata tatggtgagg attttgacgt atcaattggt aaagatacta 5940
tacgttggca agtattttat tatagcttac taatgtttta atacggaaaa cagtctattt 6000
ttgacaaatt ttttaattttt agaaatcttt ataaaaaata ttatttttaac ttgttaaaag 6060
tatctaacia aaattctttg tctaaaaatt tttgtataag aattgtttcg aacaaagttt 6120
ttaaaaaaat attatgggtta taataggaag atatcatgga tactattagt aaaatttcta 6180
taattgtacc tatatataat gtagaaaaat atttatctaa atgtatagat agcattgtaa 6240
atcagaccta caaacatata gagattcttc tggatgaatga cggtagtacg gataattcgg 6300
aagaaatttg tttagcatat gcgaagaaag atagtcgcat tcgttatttt aaaaaagaga 6360
acggcgggct atcagatgcc cgtaattatg gcataagtcg cgccaagggt gactacttag 6420
cttttataga ctcatgat tttattcatt cggagttcat ccaacgttta cacgaagcaa 6480
ttgagagaga gaatgccctt gtggcagttg ctggttatga tagggtagat gcttcggggc 6540
atttcttaac agcagagccg cttcctacaa atcaggctgt tctgagcggc aggaatgttt 6600
gtaaaaagct gctagaggcg gatggtcatc gctttgtggt ggctgtaat aaactctata 6660

aaaaagaact atttgaagat tttcgatttg aaaagggtaa gattcatgaa gatgaatact 6720
 tcacttatcg cttgctctat gagtttagaaa aagttgcaat agttaaggag tgcttgtact 6780
 attatgttga ccgagaaaaat agtatcacia cttctagcat gactgaccat cgcttccatt 6840
 gcctactgga atttcaaaaat gaacgaatgg acttctatga aagtagagga gataaagagc 6900
 tcttactaga gtgttatcgt tcatttttag cctttgctgt tttgttttta ggcaaatata 6960
 atcattgggtt gagcaaacag caaaagaagc tt 6992

<210> 30

<211> 454

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS1E

<400> 30

| | | | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|----|
| Arg | Gln | Thr | Lys | Leu | Ala | Leu | Phe | Asp | Met | Ile | Ala | Val | Ala | Ile | Ser | 1 | 5 | 10 | 15 |
| Ala | Ile | Leu | Thr | Ser | His | Ile | Pro | Asn | Ala | Asp | Leu | Asn | Arg | Ser | Gly | 20 | 25 | 30 | |
| Ile | Phe | Ile | Ile | Met | Met | Val | His | Tyr | Phe | Ala | Phe | Phe | Ile | Ser | Arg | 35 | 40 | 45 | |
| Met | Pro | Val | Glu | Phe | Glu | Tyr | Arg | Gly | Asn | Leu | Ile | Glu | Phe | Glu | Lys | 50 | 55 | 60 | |
| Thr | Phe | Asn | Tyr | Ser | Ile | Ile | Phe | Ala | Ile | Phe | Leu | Thr | Ala | Val | Ser | 65 | 70 | 75 | 80 |
| Phe | Leu | Leu | Glu | Asn | Asn | Phe | Ala | Leu | Ser | Arg | Arg | Gly | Ala | Val | Tyr | 85 | 90 | 95 | |
| Phe | Thr | Leu | Ile | Asn | Phe | Val | Leu | Val | Tyr | Leu | Phe | Asn | Val | Ile | Ile | 100 | 105 | 110 | |
| Lys | Gln | Phe | Lys | Asp | Ser | Phe | Leu | Phe | Ser | Thr | Ile | Tyr | Gln | Lys | Lys | 115 | 120 | 125 | |

| | | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|--|--|
| Thr | Ile | Leu | Ile | Thr | Thr | Ala | Glu | Arg | Trp | Glu | Asn | Met | Gln | Val | Leu | | | |
| | 130 | | | | | 135 | | | | | 140 | | | | | | | |
| Phe | Glu | Ser | His | Lys | Gln | Ile | Gln | Lys | Asn | Leu | Val | Ala | Leu | Val | Val | | | |
| 145 | | | | | 150 | | | | | 155 | | | | | 160 | | | |
| Leu | Gly | Thr | Glu | Ile | Asp | Lys | Ile | Asn | Leu | Ser | Leu | Pro | Leu | Tyr | Tyr | | | |
| | | | | 165 | | | | | 170 | | | | | 175 | | | | |
| Ser | Val | Glu | Glu | Ala | Ile | Glu | Phe | Ser | Thr | Arg | Glu | Val | Val | Asp | His | | | |
| | | | 180 | | | | | 185 | | | | | 190 | | | | | |
| Val | Phe | Ile | Asn | Leu | Pro | Ser | Glu | Phe | Leu | Asp | Val | Lys | Gln | Phe | Val | | | |
| | 195 | | | | | | 200 | | | | | 205 | | | | | | |
| Ser | Asp | Phe | Glu | Leu | Leu | Gly | Ile | Asp | Val | Ser | Val | Asp | Ile | Asn | Ser | | | |
| | 210 | | | | | 215 | | | | | 220 | | | | | | | |
| Phe | Gly | Phe | Thr | Ala | Leu | Lys | Asn | Lys | Lys | Ile | Gln | Leu | Leu | Gly | Asp | | | |
| 225 | | | | | 230 | | | | | 235 | | | | | 240 | | | |
| His | Ser | Ile | Val | Thr | Phe | Ser | Thr | Asn | Phe | Tyr | Lys | Pro | Ser | His | Ile | | | |
| | | | | 245 | | | | | 250 | | | | | 255 | | | | |
| Met | Met | Lys | Arg | Leu | Leu | Asp | Ile | Leu | Gly | Ala | Val | Val | Gly | Leu | Ile | | | |
| | | | 260 | | | | | 265 | | | | | 270 | | | | | |
| Ile | Cys | Gly | Ile | Val | Ser | Ile | Leu | Leu | Val | Pro | Ile | Ile | Arg | Arg | Asp | | | |
| | 275 | | | | | | 280 | | | | | 285 | | | | | | |
| Gly | Gly | Pro | Ala | Ile | Phe | Ala | Gln | Lys | Arg | Val | Gly | Gln | Asn | Gly | Arg | | | |
| | 290 | | | | | 295 | | | | | 300 | | | | | | | |
| Ile | Phe | Thr | Phe | Tyr | Lys | Phe | Arg | Ser | Met | Tyr | Val | Asp | Ala | Glu | Glu | | | |
| 305 | | | | | 310 | | | | | 315 | | | | | 320 | | | |
| Arg | Lys | Lys | Asp | Leu | Leu | Ser | Gln | Asn | Gln | Met | Gln | Gly | Trp | Val | Cys | | | |
| | | | | 325 | | | | | 330 | | | | | 335 | | | | |
| Phe | Lys | Met | Gly | Lys | Thr | Ile | Leu | Glu | Leu | Leu | Gln | Leu | Asp | Ile | Ser | | | |
| | | | 340 | | | | | 345 | | | | | 350 | | | | | |
| Tyr | Ala | Lys | Thr | Ser | Leu | Asp | Glu | Leu | Pro | Gln | Phe | Tyr | Asn | Val | Leu | | | |
| | 355 | | | | | | 360 | | | | | 365 | | | | | | |
| Ile | Gly | Asp | Met | Ser | Leu | Val | Gly | Thr | Arg | Pro | Pro | Thr | Val | Asp | Glu | | | |
| | 370 | | | | | 375 | | | | | 380 | | | | | | | |
| Phe | Glu | Lys | Tyr | Thr | Pro | Gly | Gln | Lys | Arg | Arg | Leu | Ser | Phe | Lys | Pro | | | |
| 385 | | | | | 390 | | | | | 395 | | | | | 400 | | | |

Gly Ile Thr Gly Leu Trp Gln Val Ser Gly Arg Ser Asn Ile Thr Asp
 405 410 415
 Phe Asp Asp Val Val Arg Leu Asp Leu Ala Tyr Ile Asp Asn Trp Thr
 420 425 430
 Ile Trp Ser Asp Ile Lys Ile Leu Leu Lys Thr Val Lys Val Val Leu
 435 440 445
 Leu Arg Glu Gly Ser Lys
 450

<210> 31

<211> 149

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS1F

<400> 31

Met Lys Val Cys Leu Val Gly Ser Ser Gly Gly His Leu Thr His Leu
 1 5 10 15
 Tyr Leu Leu Lys Pro Phe Trp Lys Glu Glu Glu Arg Phe Trp Val Thr
 20 25 30
 Phe Asp Lys Glu Asp Ala Arg Ser Leu Leu Lys Asn Glu Lys Met Tyr
 35 40 45
 Pro Cys Tyr Phe Pro Thr Asn Arg Asn Leu Ile Asn Leu Val Lys Asn
 50 55 60
 Thr Phe Leu Ala Phe Lys Ile Leu Arg Asp Glu Lys Pro Asp Val Ile
 65 70 75 80
 Ile Ser Ser Gly Ala Ala Val Ala Val Pro Phe Phe Tyr Ile Gly Lys
 85 90 95
 Leu Phe Gly Ala Lys Thr Ile Tyr Ile Glu Val Phe Asp Arg Val Asn
 100 105 110
 Lys Ser Thr Leu Thr Gly Lys Leu Val Tyr Pro Val Thr Asp Ile Phe
 115 120 125

Ile Val Gln Trp Glu Glu Met Lys Lys Val Tyr Pro Lys Ser Ile Asn
130 135 140

Leu Gly Ser Ile Phe
145

<210> 32

<211> 164

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS1G

<400> 32

Met Ile Phe Val Thr Val Gly Thr His Glu Gln Gln Phe Asn Arg Leu
1 5 10 15

Ile Lys Glu Ile Asp Leu Leu Lys Lys Asn Gly Ser Ile Thr Asp Glu
20 25 30

Ile Phe Ile Gln Thr Gly Tyr Ser Asp Tyr Ile Pro Glu Tyr Cys Lys
35 40 45

Tyr Lys Lys Phe Leu Ser Tyr Lys Glu Met Glu Gln Tyr Ile Asn Lys
50 55 60

Ser Glu Val Val Ile Cys His Gly Gly Pro Ala Thr Phe Met Asn Ser
65 70 75 80

Leu Ser Lys Gly Lys Lys Gln Leu Leu Phe Pro Arg Gln Lys Lys Tyr
85 90 95

Gly Glu His Val Asn Asp His Gln Val Glu Phe Val Arg Arg Ile Leu
100 105 110

Gln Asp Asn Asn Ile Leu Phe Ile Glu Asn Ile Asp Asp Leu Phe Glu
115 120 125

Lys Ile Ile Glu Val Ser Lys Gln Thr Asn Phe Thr Ser Asn Asn Asn
130 135 140

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Phe | Phe | Cys | Glu | Arg | Leu | Lys | Gln | Ile | Val | Glu | Lys | Phe | Asn | Glu | Asp |
| 145 | | | | | 150 | | | | | 155 | | | | | 160 |

Gln Glu Asn Glu

<210> 33

<211> 388

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS1H

<400> 33

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Phe | Lys | Leu | Phe | Lys | Tyr | Asp | Pro | Glu | Tyr | Phe | Ile | Phe | Lys | Tyr |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Phe | Trp | Leu | Ile | Ile | Phe | Ile | Pro | Glu | Gln | Lys | Tyr | Val | Phe | Leu | Leu |
| | | 20 | | | | | 25 | | | | | 30 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Phe | Met | Asn | Leu | Ile | Leu | Phe | His | Ile | Lys | Phe | Leu | Lys | Thr | Lys |
| | 35 | | | | | 40 | | | | | 45 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Ile | Leu | Lys | Asn | Glu | Ile | Leu | Leu | Phe | Leu | Leu | Trp | Ser | Ile | Leu |
| 50 | | | | | 55 | | | | | 60 | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Cys | Phe | Val | Ser | Val | Val | Thr | Ser | Met | Phe | Val | Glu | Ile | Asn | Phe | Glu |
| 65 | | | | 70 | | | | | 75 | | | | | | 80 |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arg | Leu | Phe | Ala | Asp | Phe | Thr | Ala | Pro | Ile | Ile | Trp | Ile | Ile | Ala | Ile |
| | | | 85 | | | | | 90 | | | | | | 95 | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Tyr | Tyr | Asn | Leu | Tyr | Ser | Phe | Ile | Asn | Ile | Asp | Tyr | Lys | Lys | Leu |
| | | | 100 | | | | 105 | | | | | | 110 | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Lys | Asn | Ser | Ile | Phe | Phe | Ser | Phe | Leu | Val | Leu | Leu | Gly | Ile | Ser | Ala |
| | 115 | | | | | 120 | | | | | | 125 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Tyr | Ile | Ile | Gln | Asn | Gly | Lys | Asp | Ile | Val | Phe | Leu | Asp | Arg | His |
| 130 | | | | | 135 | | | | | | 140 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Ile | Gly | Leu | Asp | Tyr | Leu | Ile | Thr | Gly | Val | Lys | Thr | Arg | Leu | Val |
| 145 | | | | 150 | | | | | 155 | | | | | | 160 |

| | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|--|
| Gly | Phe | Met | Asn | Tyr | Pro | Thr | Leu | Asn | Thr | Thr | Thr | Ile | Ile | Val | Ser | | |
| | | | | 165 | | | | | 170 | | | | | 175 | | | |
| Ile | Pro | Leu | Ile | Phe | Ala | Leu | Ile | Lys | Asn | Lys | Met | Gln | Gln | Phe | Phe | | |
| | | | 180 | | | | | 185 | | | | | 190 | | | | |
| Phe | Leu | Cys | Leu | Ala | Phe | Ile | Pro | Ile | Tyr | Leu | Ser | Gly | Ser | Arg | Ile | | |
| | | 195 | | | | | 200 | | | | | 205 | | | | | |
| Gly | Ser | Leu | Ser | Leu | Ala | Ile | Leu | Ile | Ile | Cys | Leu | Leu | Trp | Arg | Tyr | | |
| | 210 | | | | | 215 | | | | | 220 | | | | | | |
| Ile | Gly | Gly | Lys | Phe | Ala | Trp | Ile | Lys | Lys | Leu | Ile | Val | Ile | Phe | Val | | |
| 225 | | | | | 230 | | | | | 235 | | | | | 240 | | |
| Ile | Leu | Leu | Ile | Ile | Leu | Asn | Thr | Glu | Leu | Leu | Tyr | His | Glu | Ile | Leu | | |
| | | | | 245 | | | | | 250 | | | | | 255 | | | |
| Ala | Val | Tyr | Asn | Ser | Arg | Glu | Ser | Ser | Asn | Glu | Ala | Arg | Phe | Ile | Ile | | |
| | | | 260 | | | | | 265 | | | | | 270 | | | | |
| Tyr | Gln | Gly | Ser | Ile | Asp | Lys | Val | Leu | Glu | Asn | Asn | Ile | Leu | Phe | Gly | | |
| | 275 | | | | | | 280 | | | | | 285 | | | | | |
| Tyr | Gly | Ile | Ser | Glu | Tyr | Ser | Val | Thr | Gly | Thr | Trp | Leu | Gly | Ser | His | | |
| | 290 | | | | | 295 | | | | | 300 | | | | | | |
| Ser | Gly | Tyr | Ile | Ser | Phe | Phe | Tyr | Lys | Ser | Gly | Ile | Val | Gly | Leu | Ile | | |
| 305 | | | | | 310 | | | | | 315 | | | | 320 | | | |
| Leu | Leu | Met | Phe | Ser | Phe | Phe | Tyr | Val | Ile | Lys | Lys | Ser | Tyr | Gly | Val | | |
| | | | | 325 | | | | | 330 | | | | | 335 | | | |
| Asn | Gly | Glu | Thr | Ala | Leu | Phe | Tyr | Phe | Thr | Ser | Leu | Ala | Ile | Phe | Phe | | |
| | | | 340 | | | | | 345 | | | | | 350 | | | | |
| Ile | Tyr | Glu | Thr | Ile | Asp | Pro | Ile | Ile | Ile | Ile | Leu | Val | Leu | Phe | Phe | | |
| | 355 | | | | | 360 | | | | | | 365 | | | | | |
| Ser | Ser | Ile | Gly | Ile | Trp | Asn | Asn | Ile | Asn | Phe | Lys | Lys | Asp | Met | Glu | | |
| | 370 | | | | | 375 | | | | | 380 | | | | | | |
| Thr | Lys | Asn | Glu | | | | | | | | | | | | | | |
| 385 | | | | | | | | | | | | | | | | | |

<210> 34

<211> 322

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS1I

<400> 34

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
| Met | Asn | Asp | Leu | Ile | Ser | Val | Ile | Val | Pro | Ile | Tyr | Asn | Val | Gln | Asp | |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | | |
| Tyr | Leu | Asp | Lys | Cys | Ile | Asn | Ser | Ile | Ile | Asn | Gln | Thr | Tyr | Thr | Asn | |
| | | | 20 | | | | | 25 | | | | | 30 | | | |
| Leu | Glu | Val | Ile | Leu | Val | Asn | Asp | Gly | Ser | Thr | Asp | Asp | Ser | Glu | Lys | |
| | | 35 | | | | | 40 | | | | | 45 | | | | |
| Ile | Cys | Leu | Asn | Tyr | Met | Lys | Asn | Asp | Gly | Arg | Ile | Lys | Tyr | Tyr | Lys | |
| | 50 | | | | | 55 | | | | | 60 | | | | | |
| Lys | Ile | Asn | Gly | Gly | Leu | Ala | Asp | Ala | Arg | Asn | Phe | Gly | Leu | Glu | His | |
| 65 | | | | | 70 | | | | | 75 | | | | | 80 | |
| Ala | Thr | Gly | Lys | Tyr | Ile | Ala | Phe | Val | Asp | Ser | Asp | Asp | Tyr | Ile | Glu | |
| | | | 85 | | | | | | 90 | | | | | 95 | | |
| Val | Ala | Met | Phe | Glu | Arg | Met | His | Asp | Asn | Ile | Thr | Glu | Tyr | Asn | Ala | |
| | | 100 | | | | | | 105 | | | | | 110 | | | |
| Asp | Ile | Ala | Glu | Ile | Asp | Phe | Cys | Leu | Val | Asp | Glu | Asn | Gly | Tyr | Thr | |
| | | 115 | | | | | 120 | | | | | 125 | | | | |
| Lys | Lys | Lys | Arg | Asn | Ser | Asn | Phe | His | Val | Leu | Thr | Arg | Glu | Glu | Thr | |
| | 130 | | | | | 135 | | | | | 140 | | | | | |
| Val | Lys | Glu | Phe | Leu | Ser | Gly | Ser | Asn | Ile | Glu | Asn | Asn | Val | Trp | Cys | |
| 145 | | | | | 150 | | | | | 155 | | | | | 160 | |
| Lys | Leu | Tyr | Ser | Arg | Asp | Ile | Ile | Lys | Asp | Ile | Lys | Phe | Gln | Ile | Asn | |
| | | | | 165 | | | | | 170 | | | | | 175 | | |
| Asn | Arg | Ser | Ile | Gly | Glu | Asp | Leu | Leu | Phe | Asn | Leu | Glu | Val | Leu | Asn | |
| | | | 180 | | | | | 185 | | | | | 190 | | | |
| Asn | Val | Thr | Arg | Val | Val | Val | Asp | Thr | Arg | Glu | Tyr | Tyr | Tyr | Asn | Tyr | |
| | | 195 | | | | | 200 | | | | | 205 | | | | |
| Val | Ile | Arg | Asn | Ser | Ser | Leu | Ile | Asn | Gln | Lys | Phe | Ser | Ile | Asn | Asn | |
| | 210 | | | | | 215 | | | | | 220 | | | | | |

Ile Asp Leu Val Thr Arg Leu Glu Asn Tyr Pro Phe Lys Leu Lys Arg
 225 230 235 240
 Glu Phe Ser His Tyr Phe Asp Ala Lys Val Ile Lys Glu Lys Val Lys
 245 250 255
 Cys Leu Asn Lys Met Tyr Ser Thr Asp Cys Leu Asp Asn Glu Phe Leu
 260 265 270
 Pro Ile Leu Glu Ser Tyr Arg Lys Glu Ile Arg Arg Tyr Pro Phe Ile
 275 280 285
 Lys Ala Lys Arg Tyr Leu Ser Arg Lys His Leu Val Thr Leu Tyr Leu
 290 295 300
 Met Lys Phe Ser Pro Lys Leu Tyr Val Met Leu Tyr Lys Lys Phe Gln
 305 310 315 320
 Lys Gln

<210> 35

<211> 322

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS1J

<400> 35

Met Asp Lys Ile Ser Val Ile Val Pro Val Tyr Asn Val Asp Lys Tyr
 1 5 10 15
 Leu Ser Ser Cys Ile Glu Ser Ile Ile Asn Gln Asn Tyr Lys Asn Ile
 20 25 30
 Glu Ile Leu Leu Ile Asp Asp Gly Ser Val Asp Asp Ser Ala Lys Ile
 35 40 45
 Cys Lys Glu Tyr Glu Lys Asp Lys Arg Val Lys Ile Phe Phe Thr Asn
 50 55 60

| | | | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| His | Ser | Gly | Val | Ser | Asn | Ala | Arg | Asn | His | Gly | Ile | Lys | Arg | Ser | Thr | 65 | 70 | 75 | 80 |
| Ala | Glu | Tyr | Ile | Met | Phe | Val | Asp | Ser | Asp | Asp | Val | Val | Asp | Ser | Arg | 85 | 90 | 95 | |
| Leu | Val | Glu | Lys | Leu | Tyr | Phe | Asn | Ile | Ile | Lys | Ser | Arg | Ser | Asp | Leu | 100 | 105 | 110 | |
| Ser | Gly | Cys | Leu | Tyr | Ala | Thr | Phe | Ser | Glu | Asn | Ile | Asn | Asn | Phe | Glu | 115 | 120 | 125 | |
| Val | Asn | Asn | Pro | Asn | Ile | Asp | Phe | Glu | Ala | Ile | Asn | Thr | Val | Gln | Asp | 130 | 135 | 140 | |
| Met | Gly | Glu | Lys | Asn | Phe | Met | Asn | Leu | Tyr | Ile | Asn | Asn | Ile | Phe | Ser | 145 | 150 | 155 | 160 |
| Thr | Pro | Val | Cys | Lys | Leu | Tyr | Lys | Lys | Arg | Tyr | Ile | Thr | Asp | Leu | Phe | 165 | 170 | 175 | |
| Gln | Glu | Asn | Gln | Trp | Leu | Gly | Glu | Asp | Leu | Leu | Phe | Asn | Leu | His | Tyr | 180 | 185 | 190 | |
| Leu | Lys | Asn | Ile | Asp | Arg | Val | Ser | Tyr | Leu | Thr | Glu | His | Leu | Tyr | Phe | 195 | 200 | 205 | |
| Tyr | Arg | Arg | Gly | Ile | Leu | Ser | Thr | Val | Asn | Ser | Phe | Lys | Glu | Gly | Val | 210 | 215 | 220 | |
| Phe | Leu | Gln | Leu | Glu | Asn | Leu | Gln | Lys | Gln | Val | Ile | Val | Leu | Phe | Lys | 225 | 230 | 235 | 240 |
| Gln | Ile | Tyr | Gly | Glu | Asp | Phe | Asp | Val | Ser | Ile | Val | Lys | Asp | Thr | Ile | 245 | 250 | 255 | |
| Arg | Trp | Gln | Val | Phe | Tyr | Tyr | Ser | Leu | Leu | Met | Phe | Lys | Tyr | Gly | Lys | 260 | 265 | 270 | |
| Gln | Ser | Ile | Phe | Asp | Lys | Phe | Leu | Ile | Phe | Arg | Asn | Leu | Tyr | Lys | Lys | 275 | 280 | 285 | |
| Tyr | Tyr | Phe | Asn | Leu | Leu | Lys | Val | Ser | Asn | Lys | Asn | Ser | Leu | Ser | Lys | 290 | 295 | 300 | |
| Asn | Phe | Cys | Ile | Arg | Ile | Val | Ser | Asn | Lys | Val | Phe | Lys | Lys | Ile | Leu | 305 | 310 | 315 | 320 |
| Trp | Leu | | | | | | | | | | | | | | | | | | |

<210> 36

<211> 278

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS1K

<400> 36

Met Asp Thr Ile Ser Lys Ile Ser Ile Ile Val Pro Ile Tyr Asn Val
1 5 10 15

Glu Lys Tyr Leu Ser Lys Cys Ile Asp Ser Ile Val Asn Gln Thr Tyr
20 25 30

Lys His Ile Glu Ile Leu Leu Val Asn Asp Gly Ser Thr Asp Asn Ser
35 40 45

Glu Glu Ile Cys Leu Ala Tyr Ala Lys Lys Asp Ser Arg Ile Arg Tyr
50 55 60

Phe Lys Lys Glu Asn Gly Gly Leu Ser Asp Ala Arg Asn Tyr Gly Ile
65 70 75 80

Ser Arg Ala Lys Gly Asp Tyr Leu Ala Phe Ile Asp Ser Asp Asp Phe
85 90 95

Ile His Ser Glu Phe Ile Gln Arg Leu His Glu Ala Ile Glu Arg Glu
100 105 110

Asn Ala Leu Val Ala Val Ala Gly Tyr Asp Arg Val Asp Ala Ser Gly
115 120 125

His Phe Leu Thr Ala Glu Pro Leu Pro Thr Asn Gln Ala Val Leu Ser
130 135 140

Gly Arg Asn Val Cys Lys Lys Leu Leu Glu Ala Asp Gly His Arg Phe
145 150 155 160

Val Val Ala Cys Asn Lys Leu Tyr Lys Lys Glu Leu Phe Glu Asp Phe
165 170 175

Arg Phe Glu Lys Gly Lys Ile His Glu Asp Glu Tyr Phe Thr Tyr Arg
180 185 190

Leu Leu Tyr Glu Leu Glu Lys Val Ala Ile Val Lys Glu Cys Leu Tyr
 195 200 205
 Tyr Tyr Val Asp Arg Glu Asn Ser Ile Thr Thr Ser Ser Met Thr Asp
 210 215 220
 His Arg Phe His Cys Leu Leu Glu Phe Gln Asn Glu Arg Met Asp Phe
 225 230 235 240
 Tyr Glu Ser Arg Gly Asp Lys Glu Leu Leu Leu Glu Cys Tyr Arg Ser
 245 250 255
 Phe Leu Ala Phe Ala Val Leu Phe Leu Gly Lys Tyr Asn His Trp Leu
 260 265 270
 Ser Lys Gln Gln Lys Lys
 275

<210> 37

<211> 4519

<212> DNA

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS9

<400> 37

aagcttatcg tcaaggtggt cgctatatcg tggcgacatc tcatagacga aaagggatgt 60
 ttgaaacacc agaaaaagtt atcatgacta actttcttca atttaaagac gcagtagcag 120
 aagtttatcc tgaaatacga ttgtgctatg gtgctgaatt gtattatagt aaagatatat 180
 taagcaaact tgaaaaaaag aaagtaccca cacttaatgg ctgcgctat attcttttgg 240
 agttcagtag tgatactcct tggaaagaga ttcaagaagc agtgaacgaa gtgacgctac 300
 ttgggctaac tcccgtactt gcccatatag aacgatatga cgccctagcg tttcatgcag 360
 agagagtaga agagttaatt gacaagggat gctatactca ggtaaatagt aatcatgtgc 420
 tgaagcccac tttaattggg gatcgagcaa aagaatttaa aaaacgtact cggatattttt 480
 tagagcagga tttagtacat tgtgttgcta gcgatatgca taatttatct agtagacctc 540

cgtttatgag ggaggcttat aagttgctaa cagaggaatt tggcaaagat aaagcgaaag 600
 cgttgctaaa aaagaatcct cttatgctat taaaaaacca ggcgatttaa actggttact 660
 ctagattgtg gagagaaaaa tggatttagg aactgttact gataaactgt tagaacgcaa 720
 cagtaaacga ttgatactcg tgtgcatgga tacgtgtctt cttatagttt ccatgatttt 780
 gagcagactg tttttggatg ttattattga cataccagat gaacgcttca ttcttgacgt 840
 tttattcgta tcaattttat atttgattct atcgtttaga ttaaaagtct tttcattaat 900
 tacgcgttac acagggatc agagttatgt aaaaatagga cttagtttaa tatctgcgca 960
 ttcattgttt ttaattatct caatgggtgt gtggcaggct tttagttatc gtttcacctt 1020
 agtatcctta tttttgtcgt atgtaatgct cattactccg aggattgttt ggaaagtctt 1080
 acatgagacg agaaaaaatg ctatccgtaa gaaggatagc ccactaagaa tcttagtagt 1140
 aggtgctgga gatgggtgga atatttttat caatactgtc aaagatcgaa aattgaattt 1200
 tgaaattgtc ggtatcggtg atcgatgatcc aaataaactt ggaacattta tccgtacggc 1260
 taaagtttta ggaaaccgta atgatattcc acgactggta gaggaattag ctgttgacca 1320
 agtgacgatt gccatccctt ctttaaattg taaggagcga gagaagattg ttgaaatctg 1380
 taacactaca ggagtgaccg tcaataatat gccgagtatt gaagacatta tggcggggaa 1440
 catgtctgtc agtgcccttc aggaaattga cgtagcagac cttcttggtc gaccagaggt 1500
 tgttttggat caggatgaat tgaatcagtt tttccaaggg aaaacaatcc ttgtcacagg 1560
 agcaggtggc tctatcggtt cagagctatg tcgtcaaatt gctaagttta cgcctaaacg 1620
 cttgttggtg cttggacatg gagaaaattc aatctatctc attcatcgag agttactgga 1680
 aaagtaccaa ggtaagattg agttggtccc tctcattgca gatattcaag atagagaatt 1740
 gatttttagc ataattggctg aatatcaacc cgatgttggt tatcatgctg cagcacataa 1800
 gcatgttcct ttgatggaat ataatccaca tgaagcagtg aagaataata tttttggaac 1860
 gaagaatgtg gctgaggcgg ctaaaactgc aaagggtgcc aaatttgta tggtttcaac 1920
 agataaagct gttaatccac caaatgtcat gggagcgact aaacgtgttg cagaaatgat 1980
 tgttacaggt ttaaacgagc caggtcagac tcaatttgcg gcagtccggt ttgggaatgt 2040
 tctaggtagt cgtggaagtg ttgttccgct attcaaagag caaattagaa aaggtggacc 2100

tgttacggtt accgacttta ggatgactcg ttatttcatg acgattcctg aggcaagtcg 2160
 tttgggttatc caagctggac atttggtgcaa aggtggagaa atatttgtct tggatatggg 2220
 cgagccagta caaatcctgg aattggcaag aaaagttatc ttgttaagtg gacacacaga 2280
 ggaagaaatc gggattgtag aatctggaat cagaccaggc gagaaactct acgaggaatt 2340
 attatcaaca gaagaacgtg tcagcgaaca gattcatgaa aaaatatttg tgggtcgcgt 2400
 taaaaataag cagtcggaca ttgtcaattc atttatcaat ggattactcc aaaaagatag 2460
 aatgaatta aaaaatatgt tgattgaatt tgcaaaacaa gaataagaaa gtaaaaaata 2520
 tttttacttt cctagagttt aaacgatgtt taagttctag gaaggttaga atacctaatt 2580
 aacaacaata ttactattta ttaagagtca gataatagca actaagtgct acaactatc 2640
 ttataataa gtatatttgg tcaaaaggga gatgtgaaat gtatccaatt tgtaaacgta 2700
 ttttagcaat tattatctca gggattgcta ttgttggtct gagtccaatt ttattattga 2760
 ttgcattggc aattaaatta gattctaaag gtccggtatt atttaaaca aagcgggttg 2820
 gtaaaaaaca gtcatacttt atgatttata aattccgttc tatgtacgtt gacgcaccaa 2880
 gtgatatgcc gactcatcta ttaaaggatc ctaaggcgat gattaccaag gtgggcgcgt 2940
 ttctcagaaa aacaagttta gatgaactgc cacagctttt taatattttt aaaggtgaaa 3000
 tggcgattgt tgggtccacgc ccagccttat ggaatcaata tgacttaatt gaagagcgag 3060
 ataaatatgg tgcaaatgat attcgtcctg gactaaccgg ttgggtcaa attaatggtc 3120
 gtgatgaatt ggaaattgat gaaaagtcaa aattagatgg atattatgtt caaaatatga 3180
 gtctaggttt ggatattaaa tgtttcttag gtacattcct cagtgtagcc agaagcgaag 3240
 gtgttggtga aggtggaaca gggcagaaag gaaaaggatg aaattttcag tattaatgtc 3300
 ggtctatgag aaagaaaaac cagagtttct tagggaatct ttggaaagca tccttgtcaa 3360
 tcaaacaatg attccaacgg aggttgtctt ggtagaggat gggccactca atcagagctt 3420
 atatagtatt ttagaagaat ttaaaagtcg attttcattt tttaaaacga tagccttgga 3480
 aaagaattcg ggtttaggaa ttgcactgaa tgaaggtttg aaacattgta attatgagtg 3540
 ggtttgcacg aatggattc tgatgatgtt gcatatacat acacgttttg aaaagcaagt 3600
 taactttata aaacaaaacc cgactataga tattgagata gatgagttct taaattctac 3660

tagtgaaata gtttctcata aaaatgttcc aaccagcac gatgaaatat taaagatggc 3720
aaggcgggag aaatccatgt gccacatgac tgtaatgttt aaaaagaaaa gtgtcgagag 3780
agcagggggg tatcaaacac ttccgtacgt agaagattat ttcctttggg tgcgcatgat 3840
tgcttcagga tcgaaatttg caaacattga tgaaacacta gttcttgcac gtgttgga 3900
tgggatgttc aataggaggg ggaacagaga acaaattaac agttggacat tactaattga 3960
atztatgtta gctcaaggaa ttgttacacc actagatgta tttattaatc aaatttacat 4020
tagggctctt gtttatatgc caacttggat aaagaaactc atztatggaa aaatcttaag 4080
gaaatagtat gattacagta ttgatggcta catataatgg aagcccatth ataataaac 4140
agttagattc aattcgaaat caaagtgtat cagcagacaa agttattatt tgggatgatt 4200
gctcgacaga tgatacaata aaaataataa aagattatat aaaaaaatat tctttggatt 4260
catgggttgt ctctcaaat aaatctaatc aggggcatta tcaaacattt ataaatttga 4320
caaagttagt tcaggaagga atagtctttt tttcagatca agatgatatt tgggactgtc 4380
ataaaattga gacaatgctt ccaatctttg acagagaaaa tgtatcaatg gtgttttgca 4440
aatccagatt gattgatgaa aacggaaata ttatcagtag ccagatact tcggatagaa 4500
tcaatacgta ctctctaga 4519

<210> 38

<211> 215

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS9D

<400> 38

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Tyr | Arg | Gln | Gly | Val | Arg | Tyr | Ile | Val | Ala | Thr | Ser | His | Arg | Arg |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |

| | | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|--|--|
| Lys | Gly | Met | Phe | Glu | Thr | Pro | Glu | Lys | Val | Ile | Met | Thr | Asn | Phe | Leu | | | |
| | | | 20 | | | | | 25 | | | | | 30 | | | | | |
| Gln | Phe | Lys | Asp | Ala | Val | Ala | Glu | Val | Tyr | Pro | Glu | Ile | Arg | Leu | Cys | | | |
| | | 35 | | | | | 40 | | | | | 45 | | | | | | |
| Tyr | Gly | Ala | Glu | Leu | Tyr | Tyr | Ser | Lys | Asp | Ile | Leu | Ser | Lys | Leu | Glu | | | |
| | 50 | | | | | 55 | | | | | 60 | | | | | | | |
| Lys | Lys | Lys | Val | Pro | Thr | Leu | Asn | Gly | Ser | Arg | Tyr | Ile | Leu | Leu | Glu | | | |
| 65 | | | | | 70 | | | | | 75 | | | | | 80 | | | |
| Phe | Ser | Ser | Asp | Thr | Pro | Trp | Lys | Glu | Ile | Gln | Glu | Ala | Val | Asn | Glu | | | |
| | | | | 85 | | | | | 90 | | | | | 95 | | | | |
| Val | Thr | Leu | Leu | Gly | Leu | Thr | Pro | Val | Leu | Ala | His | Ile | Glu | Arg | Tyr | | | |
| | | | 100 | | | | | 105 | | | | | 110 | | | | | |
| Asp | Ala | Leu | Ala | Phe | His | Ala | Glu | Arg | Val | Glu | Glu | Leu | Ile | Asp | Lys | | | |
| | | 115 | | | | | 120 | | | | | 125 | | | | | | |
| Gly | Cys | Tyr | Thr | Gln | Val | Asn | Ser | Asn | His | Val | Leu | Lys | Pro | Thr | Leu | | | |
| | 130 | | | | | 135 | | | | | 140 | | | | | | | |
| Ile | Gly | Asp | Arg | Ala | Lys | Glu | Phe | Lys | Lys | Arg | Thr | Arg | Tyr | Phe | Leu | | | |
| 145 | | | | | 150 | | | | | 155 | | | | | 160 | | | |
| Glu | Gln | Asp | Leu | Val | His | Cys | Val | Ala | Ser | Asp | Met | His | Asn | Leu | Ser | | | |
| | | | | 165 | | | | | 170 | | | | | 175 | | | | |
| Ser | Arg | Pro | Pro | Phe | Met | Arg | Glu | Ala | Tyr | Lys | Leu | Leu | Thr | Glu | Glu | | | |
| | | | 180 | | | | | 185 | | | | | | 190 | | | | |
| Phe | Gly | Lys | Asp | Lys | Ala | Lys | Ala | Leu | Leu | Lys | Lys | Asn | Pro | Leu | Met | | | |
| | | 195 | | | | | 200 | | | | | 205 | | | | | | |
| Leu | Leu | Lys | Asn | Gln | Ala | Ile | | | | | | | | | | | | |
| | 210 | | | | | 215 | | | | | | | | | | | | |

<210> 39

<211> 608

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS9E

<400> 39

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Asp | Leu | Gly | Thr | Val | Thr | Asp | Lys | Leu | Leu | Glu | Arg | Asn | Ser | Lys |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |
| Arg | Leu | Ile | Leu | Val | Cys | Met | Asp | Thr | Cys | Leu | Leu | Ile | Val | Ser | Met |
| | | | 20 | | | | | 25 | | | | | 30 | | |
| Ile | Leu | Ser | Arg | Leu | Phe | Leu | Asp | Val | Ile | Ile | Asp | Ile | Pro | Asp | Glu |
| | | 35 | | | | | 40 | | | | | 45 | | | |
| Arg | Phe | Ile | Leu | Ala | Val | Leu | Phe | Val | Ser | Ile | Leu | Tyr | Leu | Ile | Leu |
| | 50 | | | | | 55 | | | | | 60 | | | | |
| Ser | Phe | Arg | Leu | Lys | Val | Phe | Ser | Leu | Ile | Thr | Arg | Tyr | Thr | Gly | Tyr |
| 65 | | | | | 70 | | | | | 75 | | | | | 80 |
| Gln | Ser | Tyr | Val | Lys | Ile | Gly | Leu | Ser | Leu | Ile | Ser | Ala | His | Ser | Leu |
| | | | | 85 | | | | | 90 | | | | | 95 | |
| Phe | Leu | Ile | Ile | Ser | Met | Val | Leu | Trp | Gln | Ala | Phe | Ser | Tyr | Arg | Phe |
| | | | 100 | | | | | 105 | | | | | 110 | | |
| Ile | Leu | Val | Ser | Leu | Phe | Leu | Ser | Tyr | Val | Met | Leu | Ile | Thr | Pro | Arg |
| | | 115 | | | | | 120 | | | | | 125 | | | |
| Ile | Val | Trp | Lys | Val | Leu | His | Glu | Thr | Arg | Lys | Asn | Ala | Ile | Arg | Lys |
| | 130 | | | | | 135 | | | | | 140 | | | | |
| Lys | Asp | Ser | Pro | Leu | Arg | Ile | Leu | Val | Val | Gly | Ala | Gly | Asp | Gly | Gly |
| 145 | | | | | 150 | | | | | 155 | | | | | 160 |
| Asn | Ile | Phe | Ile | Asn | Thr | Val | Lys | Asp | Arg | Lys | Leu | Asn | Phe | Glu | Ile |
| | | | | 165 | | | | | 170 | | | | | 175 | |
| Val | Gly | Ile | Val | Asp | Arg | Asp | Pro | Asn | Lys | Leu | Gly | Thr | Phe | Ile | Arg |
| | | | 180 | | | | | 185 | | | | | 190 | | |
| Thr | Ala | Lys | Val | Leu | Gly | Asn | Arg | Asn | Asp | Ile | Pro | Arg | Leu | Val | Glu |
| | | 195 | | | | | 200 | | | | | 205 | | | |
| Glu | Leu | Ala | Val | Asp | Gln | Val | Thr | Ile | Ala | Ile | Pro | Ser | Leu | Asn | Gly |
| | 210 | | | | | 215 | | | | | 220 | | | | |
| Lys | Glu | Arg | Glu | Lys | Ile | Val | Glu | Ile | Cys | Asn | Thr | Thr | Gly | Val | Thr |
| 225 | | | | | 230 | | | | | 235 | | | | | 240 |
| Val | Asn | Asn | Met | Pro | Ser | Ile | Glu | Asp | Ile | Met | Ala | Gly | Asn | Met | Ser |
| | | | | 245 | | | | | 250 | | | | | 255 | |

| | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|--|
| Val | Ser | Ala | Phe | Gln | Glu | Ile | Asp | Val | Ala | Asp | Leu | Leu | Gly | Arg | Pro | | |
| | | | 260 | | | | | 265 | | | | | 270 | | | | |
| Glu | Val | Val | Leu | Asp | Gln | Asp | Glu | Leu | Asn | Gln | Phe | Phe | Gln | Gly | Lys | | |
| | | 275 | | | | | 280 | | | | | 285 | | | | | |
| Thr | Ile | Leu | Val | Thr | Gly | Ala | Gly | Gly | Ser | Ile | Gly | Ser | Glu | Leu | Cys | | |
| | 290 | | | | | 295 | | | | | 300 | | | | | | |
| Arg | Gln | Ile | Ala | Lys | Phe | Thr | Pro | Lys | Arg | Leu | Leu | Leu | Leu | Gly | His | | |
| 305 | | | | | 310 | | | | | 315 | | | | | 320 | | |
| Gly | Glu | Asn | Ser | Ile | Tyr | Leu | Ile | His | Arg | Glu | Leu | Leu | Glu | Lys | Tyr | | |
| | | | | 325 | | | | | 330 | | | | | 335 | | | |
| Gln | Gly | Lys | Ile | Glu | Leu | Val | Pro | Leu | Ile | Ala | Asp | Ile | Gln | Asp | Arg | | |
| | | | 340 | | | | | 345 | | | | | 350 | | | | |
| Glu | Leu | Ile | Phe | Ser | Ile | Met | Ala | Glu | Tyr | Gln | Pro | Asp | Val | Val | Tyr | | |
| | | 355 | | | | | 360 | | | | | 365 | | | | | |
| His | Ala | Ala | Ala | His | Lys | His | Val | Pro | Leu | Met | Glu | Tyr | Asn | Pro | His | | |
| | 370 | | | | | 375 | | | | | 380 | | | | | | |
| Glu | Ala | Val | Lys | Asn | Asn | Ile | Phe | Gly | Thr | Lys | Asn | Val | Ala | Glu | Ala | | |
| 385 | | | | | 390 | | | | | 395 | | | | | 400 | | |
| Ala | Lys | Thr | Ala | Lys | Val | Ala | Lys | Phe | Val | Met | Val | Ser | Thr | Asp | Lys | | |
| | | | | 405 | | | | | 410 | | | | | 415 | | | |
| Ala | Val | Asn | Pro | Pro | Asn | Val | Met | Gly | Ala | Thr | Lys | Arg | Val | Ala | Glu | | |
| | | | 420 | | | | | 425 | | | | | 430 | | | | |
| Met | Ile | Val | Thr | Gly | Leu | Asn | Glu | Pro | Gly | Gln | Thr | Gln | Phe | Ala | Ala | | |
| | 435 | | | | | | 440 | | | | | 445 | | | | | |
| Val | Arg | Phe | Gly | Asn | Val | Leu | Gly | Ser | Arg | Gly | Ser | Val | Val | Pro | Leu | | |
| | 450 | | | | | 455 | | | | | 460 | | | | | | |
| Phe | Lys | Glu | Gln | Ile | Arg | Lys | Gly | Gly | Pro | Val | Thr | Val | Thr | Asp | Phe | | |
| 465 | | | | | 470 | | | | | 475 | | | | | 480 | | |
| Arg | Met | Thr | Arg | Tyr | Phe | Met | Thr | Ile | Pro | Glu | Ala | Ser | Arg | Leu | Val | | |
| | | | | 485 | | | | | 490 | | | | | 495 | | | |
| Ile | Gln | Ala | Gly | His | Leu | Ala | Lys | Gly | Gly | Glu | Ile | Phe | Val | Leu | Asp | | |
| | | | 500 | | | | | 505 | | | | | 510 | | | | |
| Met | Gly | Glu | Pro | Val | Gln | Ile | Leu | Glu | Leu | Ala | Arg | Lys | Val | Ile | Leu | | |
| | | 515 | | | | | 520 | | | | | 525 | | | | | |

Leu Ser Gly His Thr Glu Glu Glu Ile Gly Ile Val Glu Ser Gly Ile
530 535 540

Arg Pro Gly Glu Lys Leu Tyr Glu Glu Leu Leu Ser Thr Glu Glu Arg
545 550 555 560

Val Ser Glu Gln Ile His Glu Lys Ile Phe Val Gly Arg Val Thr Asn
565 570 575

Lys Gln Ser Asp Ile Val Asn Ser Phe Ile Asn Gly Leu Leu Gln Lys
580 585 590

Asp Arg Asn Glu Leu Lys Asn Met Leu Ile Glu Phe Ala Lys Gln Glu
595 600 605

<210> 40

<211> 200

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS9F

<400> 40

Met Tyr Pro Ile Cys Lys Arg Ile Leu Ala Ile Ile Ile Ser Gly Ile
1 5 10 15

Ala Ile Val Val Leu Ser Pro Ile Leu Leu Leu Ile Ala Leu Ala Ile
20 25 30

Lys Leu Asp Ser Lys Gly Pro Val Leu Phe Lys Gln Lys Arg Val Gly
35 40 45

Lys Asn Lys Ser Tyr Phe Met Ile Tyr Lys Phe Arg Ser Met Tyr Val
50 55 60

Asp Ala Pro Ser Asp Met Pro Thr His Leu Leu Lys Asp Pro Lys Ala
65 70 75 80

Met Ile Thr Lys Val Gly Ala Phe Leu Arg Lys Thr Ser Leu Asp Glu
85 90 95

Leu Pro Gln Leu Phe Asn Ile Phe Lys Gly Glu Met Ala Ile Val Gly
100 105 110

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Pro | Arg | Pro | Ala | Leu | Trp | Asn | Gln | Tyr | Asp | Leu | Ile | Glu | Glu | Arg | Asp |
| | | 115 | | | | | 120 | | | | | 125 | | | |
| Lys | Tyr | Gly | Ala | Asn | Asp | Ile | Arg | Pro | Gly | Leu | Thr | Gly | Trp | Ala | Gln |
| | 130 | | | | | 135 | | | | | 140 | | | | |
| Ile | Asn | Gly | Arg | Asp | Glu | Leu | Glu | Ile | Asp | Glu | Lys | Ser | Lys | Leu | Asp |
| 145 | | | | | 150 | | | | | 155 | | | | | 160 |
| Gly | Tyr | Tyr | Val | Gln | Asn | Met | Ser | Leu | Gly | Leu | Asp | Ile | Lys | Cys | Phe |
| | | | | 165 | | | | | 170 | | | | | 175 | |
| Leu | Gly | Thr | Phe | Leu | Ser | Val | Ala | Arg | Ser | Glu | Gly | Val | Val | Glu | Gly |
| | | | 180 | | | | | 185 | | | | | 190 | | |
| Gly | Thr | Gly | Gln | Lys | Gly | Lys | Gly | | | | | | | | |
| | 195 | | | | | | 200 | | | | | | | | |

<210> 41

<211> 269

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS2G

<400> 41

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Lys | Phe | Ser | Val | Leu | Met | Ser | Val | Tyr | Glu | Lys | Glu | Lys | Pro | Glu |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |
| Phe | Leu | Arg | Glu | Ser | Leu | Glu | Ser | Ile | Leu | Val | Asn | Gln | Thr | Met | Ile |
| | | | 20 | | | | | 25 | | | | | 30 | | |
| Pro | Thr | Glu | Val | Val | Leu | Val | Glu | Asp | Gly | Pro | Leu | Asn | Gln | Ser | Leu |
| | | 35 | | | | | 40 | | | | | 45 | | | |
| Tyr | Ser | Ile | Leu | Glu | Glu | Phe | Lys | Ser | Arg | Phe | Ser | Phe | Phe | Lys | Thr |
| | 50 | | | | | 55 | | | | | 60 | | | | |
| Ile | Ala | Leu | Glu | Lys | Asn | Ser | Gly | Leu | Gly | Ile | Ala | Leu | Asn | Glu | Gly |
| 65 | | | | | 70 | | | | | 75 | | | | | 80 |

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
| Leu | Lys | His | Cys | Asn | Tyr | Glu | Trp | Val | Cys | Thr | Lys | Trp | Ile | Leu | Met | |
| | | | | 85 | | | | | 90 | | | | | 95 | | |
| Met | Leu | His | Ile | His | Thr | Arg | Phe | Glu | Lys | Gln | Val | Asn | Phe | Ile | Lys | |
| | | | 100 | | | | | 105 | | | | | 110 | | | |
| Gln | Asn | Pro | Thr | Ile | Asp | Ile | Glu | Ile | Asp | Glu | Phe | Leu | Asn | Ser | Thr | |
| | | 115 | | | | | 120 | | | | | 125 | | | | |
| Ser | Glu | Ile | Val | Ser | His | Lys | Asn | Val | Pro | Thr | Gln | His | Asp | Glu | Ile | |
| | 130 | | | | | 135 | | | | | 140 | | | | | |
| Leu | Lys | Met | Ala | Arg | Arg | Glu | Lys | Ser | Met | Cys | His | Met | Thr | Val | Met | |
| 145 | | | | | 150 | | | | | 155 | | | | | 160 | |
| Phe | Lys | Lys | Lys | Ser | Val | Glu | Arg | Ala | Gly | Gly | Tyr | Gln | Thr | Leu | Pro | |
| | | | | 165 | | | | | 170 | | | | | 175 | | |
| Tyr | Val | Glu | Asp | Tyr | Phe | Leu | Trp | Val | Arg | Met | Ile | Ala | Ser | Gly | Ser | |
| | | | 180 | | | | | 185 | | | | | 190 | | | |
| Lys | Phe | Ala | Asn | Ile | Asp | Glu | Thr | Leu | Val | Leu | Ala | Arg | Val | Gly | Asn | |
| | | 195 | | | | | 200 | | | | | 205 | | | | |
| Gly | Met | Phe | Asn | Arg | Arg | Gly | Asn | Arg | Glu | Gln | Ile | Asn | Ser | Trp | Thr | |
| | 210 | | | | | 215 | | | | | 220 | | | | | |
| Leu | Leu | Ile | Glu | Phe | Met | Leu | Ala | Gln | Gly | Ile | Val | Thr | Pro | Leu | Asp | |
| 225 | | | | | 230 | | | | | 235 | | | | | 240 | |
| Val | Phe | Ile | Asn | Gln | Ile | Tyr | Ile | Arg | Val | Phe | Val | Tyr | Met | Pro | Thr | |
| | | | | 245 | | | | | 250 | | | | | 255 | | |
| Trp | Ile | Lys | Lys | Leu | Ile | Tyr | Gly | Lys | Ile | Leu | Arg | Lys | | | | |
| | | | 260 | | | | | 265 | | | | | | | | |

<210> 42

<211> 143

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS9H

<400> 42

Met Ile Thr Val Leu Met Ala Thr Tyr Asn Gly Ser Pro Phe Ile Ile
1 5 10 15
Lys Gln Leu Asp Ser Ile Arg Asn Gln Ser Val Ser Ala Asp Lys Val
20 25 30
Ile Ile Trp Asp Asp Cys Ser Thr Asp Asp Thr Ile Lys Ile Ile Lys
35 40 45
Asp Tyr Ile Lys Lys Tyr Ser Leu Asp Ser Trp Val Val Ser Gln Asn
50 55 60
Lys Ser Asn Gln Gly His Tyr Gln Thr Phe Ile Asn Leu Thr Lys Leu
65 70 75 80
Val Gln Glu Gly Ile Val Phe Phe Ser Asp Gln Asp Asp Ile Trp Asp
85 90 95
Cys His Lys Ile Glu Thr Met Leu Pro Ile Phe Asp Arg Glu Asn Val
100 105 110
Ser Met Val Phe Cys Lys Ser Arg Leu Ile Asp Glu Asn Gly Asn Ile
115 120 125
Ile Ser Ser Pro Asp Thr Ser Asp Arg Ile Asn Thr Tyr Ser Leu
130 135 140

<210> 43

<211> 3738

<212> DNA

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS7

<400> 43

ctgcagcaca taagcatggt ccattgatgg aatataatcc acatgaagca gtgaagaata 60
atatttttgg aacgaagaat gtggctgagg cggctaaaac tgcaaagggt gccaaatttg 120
ttatgggtttc aacagataaa gctgttaatc cgccaaatgt catgggagcg actaaacgtg 180

ttgcagaaat gattgtaaca ggtttaaacg agccagggtca gactcaattt gcggcagttcc 240
 gttttgggaa tgttctaggt agtcgtggaa gtgttggtcc gctattcaaa gagcaaatta 300
 gaaaagggtg acctgttacg gttaccgact ttaggatgac tcgttatttc atgacgattc 360
 ctgaggcaag tcgtttgggt atccaagctg gacatttggc aaaagggtgga gaaatctttg 420
 tcttgatat gggtgagcca gtacaaatcc tggaattggc aagaaaagtt atcttggtta 480
 gcggacatac agaggaagaa atcgggattg tagaatctgg aatcagacca ggcgagaaac 540
 tctacgagga attgttatca acagaagaac gtgtcagcga acagattcat gaaaaaatat 600
 ttgtgggtcg cgttacaaat aagcagtcgg acattgtcaa ttcatttatt aatggattac 660
 tccaaaaaga tagaaatgaa ttaaaagata tgttgattga atttgcaaaa caagaataag 720
 aaagtaaaaa atattttttac tttcctagag tttaaacgat gtttaagttc taggaagggt 780
 ggaattgctt tcgtggaggt gatagataga aacctatata tttgtagaag aaaggatatt 840
 aaactaaagg tgaatcggaa cataaagttt agatagagtt ggtatttaat gccaaacagg 900
 tgaatgcaac ctctcgctcg ttactaagca ggagatagta aagttgcttg aaagagagtt 960
 tgtaaatcag tataagtagg cttaaagtga aatatatatc tattattatc ggtaatgata 1020
 ctattattga gaattattgt agtggggata aaaataattt ttggtgattt tatcgtccga 1080
 cttaaagggtg gggttaaaaa gtacttatat tcttttagaa ttgatgaaaa atatggggga 1140
 atataatatt tataggagat acgatgacta gagtagagtt gattactaga gaatttttta 1200
 agaagaatga agcaaccagt aaatatcttc agaagataga atcaagaaga ggtgaattat 1260
 ttattaaatt ctttatggat aagttacttg cgcttatcct attattgcta ttatccccag 1320
 taatcattat attagctatt tggataaaat tagatagtaa ggggccaatt ttttatcgcc 1380
 aagaacgtgt tacgagatat ggtcgaattt ttagaatatt taagtttaga acaatgattt 1440
 ctgatgcgga taaagtcgga agtcctgtca cagtcggtca agataatcgt attacgaaag 1500
 tcggtcacat tatcagaaaa tatcggctgg acgaagtgcc ccaacttttt aatgttttaa 1560
 tgggggatat gagctttgta ggtgtaagac cagaagtaca aaaatatgta aatcagtata 1620
 ctgatgaaat gtttgcgacg ttacttttac ctgcaggaat tacttcacca gcgagtattg 1680
 catataagga tgaagatatt gttttagaag aatattgttc tcaaggctat agtcctgatg 1740

aagcatatgt tcaaaaagta ttaccagaaa aaatgaagta caatttggaa tatatcagaa 1800
actttggaat tatttctgat tttaaagtaa tgattgatac agtaattaaa gtaataaaat 1860
aggagattaa aatgacaaaa agacaaaata ttccattttc accaccagat attacccaag 1920
ctgaaattga tgaagttatt gacacactaa aatctgggtg gattacaaca ggaccaaaga 1980
caaaagagct agaacgtcgg ctatcagtat ttacaggaac caataaaaact gtgtgtttaa 2040
attctgctac tgcaggattg gaactagtct tacgaattct tgggtgttga cccggagatg 2100
aagttattgt tcttgctatg acctatactg cctcatgtag tgtcattact catgtaggag 2160
caactcctgt gatggttgat attcaaaaaa acagctttga gatggaatat gatgctttgg 2220
aaaaagcgat tactccgaaa acaaaagtta tcattcctgt tgatctagct ggtattcctt 2280
gtgattatga taagatttat accatcgtag aaaacaaacg ctctttgtat gttgcttctg 2340
ataataaatg gcagaaactt tttgggcgag ttattatcct atctgatagt gcacactcac 2400
taggtgctag ttataaggga aaaccagcgg gttccctagc agattttacc tcattttctt 2460
tccatgcagt taagaatttt acaactgctg aaggaggtag tgtgacatgg agatcacatc 2520
ctgatttggg tgacgaagag atgtataaag agtttcagat ttactctctt catggtcaga 2580
caaaggatgc attagctaag acacaattag ggtcatggga atatgacatt gttattcctg 2640
gttacaagtg taatatgaca gatattatgg caggtatcgg tcttgtgcaa ttagaacggt 2700
acccatcttt gttgaatcgt cgcagagaaa tcattgagaa atacaatgct ggctttgagg 2760
ggacttcgat taagccgttg gtacacctga cggaagataa acaatcgtct atgcacttgt 2820
atatcacgca tctacaaggc tatactttag aacaacgaaa tgaagtcatt caaaaaatgg 2880
ctgaagcagg tattgcgtgc aatgttcact acaaaccatt acctcttctc acagcctaca 2940
agaatcttgg ttttgaaatg aaagattttc cgaatgccta tcagtatttt gaaaatgaag 3000
ttacactgcc tcttcatacc aacttgagtg atgaagatgt ggagtatgtg atagaaatgt 3060
ttttaaaaat tgtagtaga gattagttat tttggaagga gatatggtgg aaagagatat 3120
ggtggaaaga gacacgttgg tatctataat aatgccctcg tggaatacag ctaagtatat 3180
atctgaatca atccagtcag tgttggaaca aacacaccaa aattgggaac ttataatcgt 3240
tgatgattgt tctaatacgc aaactgaaaa agttgtttcg catttcaaag attcaagaat 3300

```

aaagtttttt aaaaattcga ataatttagg ggcagctcta acacgaaata aggcactaag 3360
aaaagctaga ggtaggtgga ttgcgttctt ggattcagat gatttatggc acccgagtaa 3420
gctagaaaaa cagcttgaat ttatgaaaaa taatggatat tcatttactt atcacaattt 3480
tgaaaagatt gatgaatcta gtcagtcttt acgtgtcctg gtgtcaggac cagcaattgt 3540
gactagaaaa atgatgtaca attacggcta tccagggtgt ttgactttca tgtatgatgc 3600
agacaaaatg ggtttaattc agataaaaaga tataaagaaa aataacgatt atgcgatatt 3660
acttcaattg tgtaagaagt atgactgtta tcttttaaata gaaagtttag cttcgtatcg 3720
aattagaaaa aaatcgat 3738

```

<210> 44

<211> 238

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS7E

<400> 44

```

Ala Ala His Lys His Val Pro Leu Met Glu Tyr Asn Pro His Glu Ala
1          5          10          15
Val Lys Asn Asn Ile Phe Gly Thr Lys Asn Val Ala Glu Ala Ala Lys
20          25          30
Thr Ala Lys Val Ala Lys Phe Val Met Val Ser Thr Asp Lys Ala Val
35          40          45
Asn Pro Pro Asn Val Met Gly Ala Thr Lys Arg Val Ala Glu Met Ile
50          55          60
Val Thr Gly Leu Asn Glu Pro Gly Gln Thr Gln Phe Ala Ala Val Arg
65          70          75          80
Phe Gly Asn Val Leu Gly Ser Arg Gly Ser Val Val Pro Leu Phe Lys
85          90          95

```

| | | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|--|--|
| Glu | Gln | Ile | Arg | Lys | Gly | Gly | Pro | Val | Thr | Val | Thr | Asp | Phe | Arg | Met | | | |
| | | | 100 | | | | | 105 | | | | | 110 | | | | | |
| Thr | Arg | Tyr | Phe | Met | Thr | Ile | Pro | Glu | Ala | Ser | Arg | Leu | Val | Ile | Gln | | | |
| | | 115 | | | | | 120 | | | | | 125 | | | | | | |
| Ala | Gly | His | Leu | Ala | Lys | Gly | Gly | Glu | Ile | Phe | Val | Leu | Asp | Met | Gly | | | |
| | 130 | | | | | 135 | | | | | 140 | | | | | | | |
| Glu | Pro | Val | Gln | Ile | Leu | Glu | Leu | Ala | Arg | Lys | Val | Ile | Leu | Leu | Ser | | | |
| 145 | | | | | 150 | | | | | 155 | | | | | 160 | | | |
| Gly | His | Thr | Glu | Glu | Glu | Ile | Gly | Ile | Val | Glu | Ser | Gly | Ile | Arg | Pro | | | |
| | | | | 165 | | | | | 170 | | | | | 175 | | | | |
| Gly | Glu | Lys | Leu | Tyr | Glu | Glu | Leu | Leu | Ser | Thr | Glu | Glu | Arg | Val | Ser | | | |
| | | | 180 | | | | | 185 | | | | | 190 | | | | | |
| Glu | Gln | Ile | His | Glu | Lys | Ile | Phe | Val | Gly | Arg | Val | Thr | Asn | Lys | Gln | | | |
| | | 195 | | | | | 200 | | | | | 205 | | | | | | |
| Ser | Asp | Ile | Val | Asn | Ser | Phe | Ile | Asn | Gly | Leu | Leu | Gln | Lys | Asp | Arg | | | |
| | 210 | | | | | 215 | | | | | 220 | | | | | | | |
| Asn | Glu | Leu | Lys | Asp | Met | Leu | Ile | Glu | Phe | Ala | Lys | Gln | Glu | | | | | |
| 225 | | | | | 230 | | | | | 235 | | | | | | | | |

<210> 45

<211> 232

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS7F

<400> 45

| | | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|--|--|
| Met | Thr | Arg | Val | Glu | Leu | Ile | Thr | Arg | Glu | Phe | Phe | Lys | Lys | Asn | Glu | | | |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | | | | |
| Ala | Thr | Ser | Lys | Tyr | Phe | Gln | Lys | Ile | Glu | Ser | Arg | Arg | Gly | Glu | Leu | | | |
| | | | 20 | | | | | 25 | | | | | 30 | | | | | |
| Phe | Ile | Lys | Phe | Phe | Met | Asp | Lys | Leu | Leu | Ala | Leu | Ile | Leu | Leu | Leu | | | |
| | | 35 | | | | | 40 | | | | | 45 | | | | | | |

Leu Leu Ser Pro Val Ile Ile Ile Leu Ala Ile Trp Ile Lys Leu Asp
 50 55 60
 Ser Lys Gly Pro Ile Phe Tyr Arg Gln Glu Arg Val Thr Arg Tyr Gly
 65 70 75 80
 Arg Ile Phe Arg Ile Phe Lys Phe Arg Thr Met Ile Ser Asp Ala Asp
 85 90 95
 Lys Val Gly Ser Leu Val Thr Val Gly Gln Asp Asn Arg Ile Thr Lys
 100 105 110
 Val Gly His Ile Ile Arg Lys Tyr Arg Leu Asp Glu Val Pro Gln Leu
 115 120 125
 Phe Asn Val Leu Met Gly Asp Met Ser Phe Val Gly Val Arg Pro Glu
 130 135 140
 Val Gln Lys Tyr Val Asn Gln Tyr Thr Asp Glu Met Phe Ala Thr Leu
 145 150 155 160
 Leu Leu Pro Ala Gly Ile Thr Ser Pro Ala Ser Ile Ala Tyr Lys Asp
 165 170 175
 Glu Asp Ile Val Leu Glu Glu Tyr Cys Ser Gln Gly Tyr Ser Pro Asp
 180 185 190
 Glu Ala Tyr Val Gln Lys Val Leu Pro Glu Lys Met Lys Tyr Asn Leu
 195 200 205
 Glu Tyr Ile Arg Asn Phe Gly Ile Ile Ser Asp Phe Lys Val Met Ile
 210 215 220
 Asp Thr Val Ile Lys Val Ile Lys
 225 230

<210> 46

<211> 404

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS7G

<400> 46

| | | | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|----|
| Met | Thr | Lys | Arg | Gln | Asn | Ile | Pro | Phe | Ser | Pro | Pro | Asp | Ile | Thr | Gln | 1 | 5 | 10 | 15 |
| Ala | Glu | Ile | Asp | Glu | Val | Ile | Asp | Thr | Leu | Lys | Ser | Gly | Trp | Ile | Thr | 20 | 25 | 30 | |
| Thr | Gly | Pro | Lys | Thr | Lys | Glu | Leu | Glu | Arg | Arg | Leu | Ser | Val | Phe | Thr | 35 | 40 | 45 | |
| Gly | Thr | Asn | Lys | Thr | Val | Cys | Leu | Asn | Ser | Ala | Thr | Ala | Gly | Leu | Glu | 50 | 55 | 60 | |
| Leu | Val | Leu | Arg | Ile | Leu | Gly | Val | Gly | Pro | Gly | Asp | Glu | Val | Ile | Val | 65 | 70 | 75 | |
| Pro | Ala | Met | Thr | Tyr | Thr | Ala | Ser | Cys | Ser | Val | Ile | Thr | His | Val | Gly | 85 | 90 | 95 | |
| Ala | Thr | Pro | Val | Met | Val | Asp | Ile | Gln | Lys | Asn | Ser | Phe | Glu | Met | Glu | 100 | 105 | 110 | |
| Tyr | Asp | Ala | Leu | Glu | Lys | Ala | Ile | Thr | Pro | Lys | Thr | Lys | Val | Ile | Ile | 115 | 120 | 125 | |
| Pro | Val | Asp | Leu | Ala | Gly | Ile | Pro | Cys | Asp | Tyr | Asp | Lys | Ile | Tyr | Thr | 130 | 135 | 140 | |
| Ile | Val | Glu | Asn | Lys | Arg | Ser | Leu | Tyr | Val | Ala | Ser | Asp | Asn | Lys | Trp | 145 | 150 | 155 | |
| Gln | Lys | Leu | Phe | Gly | Arg | Val | Ile | Ile | Leu | Ser | Asp | Ser | Ala | His | Ser | 165 | 170 | 175 | |
| Leu | Gly | Ala | Ser | Tyr | Lys | Gly | Lys | Pro | Ala | Gly | Ser | Leu | Ala | Asp | Phe | 180 | 185 | 190 | |
| Thr | Ser | Phe | Ser | Phe | His | Ala | Val | Lys | Asn | Phe | Thr | Thr | Ala | Glu | Gly | 195 | 200 | 205 | |
| Gly | Ser | Val | Thr | Trp | Arg | Ser | His | Pro | Asp | Leu | Asp | Asp | Glu | Glu | Met | 210 | 215 | 220 | |
| Tyr | Lys | Glu | Phe | Gln | Ile | Tyr | Ser | Leu | His | Gly | Gln | Thr | Lys | Asp | Ala | 225 | 230 | 235 | |
| Leu | Ala | Lys | Thr | Gln | Leu | Gly | Ser | Trp | Glu | Tyr | Asp | Ile | Val | Ile | Pro | 245 | 250 | 255 | |
| Gly | Tyr | Lys | Cys | Asn | Met | Thr | Asp | Ile | Met | Ala | Gly | Ile | Gly | Leu | Val | 260 | 265 | 270 | |

Gln Leu Glu Arg Tyr Pro Ser Leu Leu Asn Arg Arg Arg Glu Ile Ile
 275 280 285
 Glu Lys Tyr Asn Ala Gly Phe Glu Gly Thr Ser Ile Lys Pro Leu Val
 290 295 300
 His Leu Thr Glu Asp Lys Gln Ser Ser Met His Leu Tyr Ile Thr His
 305 310 315 320
 Leu Gln Gly Tyr Thr Leu Glu Gln Arg Asn Glu Val Ile Gln Lys Met
 325 330 335
 Ala Glu Ala Gly Ile Ala Cys Asn Val His Tyr Lys Pro Leu Pro Leu
 340 345 350
 Leu Thr Ala Tyr Lys Asn Leu Gly Phe Glu Met Lys Asp Phe Pro Asn
 355 360 365
 Ala Tyr Gln Tyr Phe Glu Asn Glu Val Thr Leu Pro Leu His Thr Asn
 370 375 380
 Leu Ser Asp Glu Asp Val Glu Tyr Val Ile Glu Met Phe Leu Lys Ile
 385 390 395 400
 Val Ser Arg Asp

<210> 47

<211> 210

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS7H

<400> 47

Met Val Glu Arg Asp Met Val Glu Arg Asp Thr Leu Val Ser Ile Ile
 1 5 10 15
 Met Pro Ser Trp Asn Thr Ala Lys Tyr Ile Ser Glu Ser Ile Gln Ser
 20 25 30
 Val Leu Asp Gln Thr His Gln Asn Trp Glu Leu Ile Ile Val Asp Asp
 35 40 45

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Cys | Ser | Asn | Asp | Glu | Thr | Glu | Lys | Val | Val | Ser | His | Phe | Lys | Asp | Ser |
| 50 | | | | | | 55 | | | | | 60 | | | | |
| Arg | Ile | Lys | Phe | Phe | Lys | Asn | Ser | Asn | Asn | Leu | Gly | Ala | Ala | Leu | Thr |
| 65 | | | | | 70 | | | | | 75 | | | | | 80 |
| Arg | Asn | Lys | Ala | Leu | Arg | Lys | Ala | Arg | Gly | Arg | Trp | Ile | Ala | Phe | Leu |
| | | | | 85 | | | | | 90 | | | | | 95 | |
| Asp | Ser | Asp | Asp | Leu | Trp | His | Pro | Ser | Lys | Leu | Glu | Lys | Gln | Leu | Glu |
| | | | 100 | | | | | 105 | | | | | 110 | | |
| Phe | Met | Lys | Asn | Asn | Gly | Tyr | Ser | Phe | Thr | Tyr | His | Asn | Phe | Glu | Lys |
| | | 115 | | | | | 120 | | | | | 125 | | | |
| Ile | Asp | Glu | Ser | Ser | Gln | Ser | Leu | Arg | Val | Leu | Val | Ser | Gly | Pro | Ala |
| | 130 | | | | | 135 | | | | | 140 | | | | |
| Ile | Val | Thr | Arg | Lys | Met | Met | Tyr | Asn | Tyr | Gly | Tyr | Pro | Gly | Cys | Leu |
| 145 | | | | | 150 | | | | | 155 | | | | | 160 |
| Thr | Phe | Met | Tyr | Asp | Ala | Asp | Lys | Met | Gly | Leu | Ile | Gln | Ile | Lys | Asp |
| | | | | 165 | | | | | 170 | | | | | 175 | |
| Ile | Lys | Lys | Asn | Asn | Asp | Tyr | Ala | Ile | Leu | Leu | Gln | Leu | Cys | Lys | Lys |
| | | | 180 | | | | | 185 | | | | | 190 | | |
| Tyr | Asp | Cys | Tyr | Leu | Leu | Asn | Glu | Ser | Leu | Ala | Ser | Tyr | Arg | Ile | Arg |
| | | 195 | | | | | 200 | | | | | 205 | | | |
| Lys | Lys | | | | | | | | | | | | | | |
| | 210 | | | | | | | | | | | | | | |

<210> 48

<211> 101

<212> DNA

<213> Streptococcus suis

<220>

<221> misc_feature

<222> (1)..(101)

<223> N may be any nucleotide

<220>

```

<221> misc_feature
<223> 100 base pair repeat between CPS2G and CPS2H
<400> 48
aagggcacct ctataaactc ccaaaattgc gaatttggag ttacgaaagc cttgttaaata 60
caancatttt aaattttaga aaattagttt ttagagctcc c 101

<210> 49
<211> 101
<212> DNA
<213> Streptococcus suis
<220>
<221> misc_feature
<222> (1)..(101)
<223> N may be any nucleotide
<220>
<221> misc_feature
<223> 100 base pair repeat within CPS2M
<400> 49
ggcgccacct ctataaattc ccaaaattgc gaatttcgag ttacgaaagc cttgttaaata 60
caancatctt aaattttaga aaattagttt ttagaggctcc c 101

<210> 50
<211> 101
<212> DNA
<213> Streptococcus suis
<220>
<221> misc_feature

```

<223> 100 base pair repeat between CPS2O and CPS2P

<400> 50

aagggcacct ctataaactc ccaaaattgc gaatttcgag ttacgaaagc cttgttaaatt 60

caaacatttt aaattttaga aaattagttt ttagaggtcc c 101

<210> 51

<211> 120

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> N-terminal part of CPS2J

<400> 51

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Ala | Lys | Val | Ser | Ile | Ile | Val | Pro | Ile | Phe | Asn | Thr | Glu | Lys | Tyr |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Arg | Glu | Cys | Leu | Asp | Ser | Ile | Ile | Ser | Gln | Ser | Tyr | Thr | Asn | Leu |
| | | | 20 | | | | | 25 | | | | | 30 | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Glu | Ile | Leu | Leu | Ile | Asp | Asp | Gly | Ser | Ser | Asp | Ser | Ser | Thr | Asp | Ile |
| | | 35 | | | | | 40 | | | | | 45 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Cys | Leu | Glu | Tyr | Ala | Glu | Gln | Asp | Gly | Arg | Ile | Lys | Leu | Phe | Arg | Leu |
| | 50 | | | | | 55 | | | | | 60 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Pro | Asn | Gly | Gly | Val | Ser | Asn | Ala | Arg | Asn | Tyr | Gly | Ile | Lys | Asn | Ser |
| 65 | | | | | 70 | | | | | 75 | | | | | 80 |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Thr | Ala | Asn | Tyr | Ile | Met | Phe | Val | Asp | Ser | Asp | Asp | Ile | Val | Asp | Gly |
| | | | | 85 | | | | | 90 | | | | | 95 | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Ile | Val | Glu | Ser | Leu | Tyr | Thr | Cys | Leu | Lys | Glu | Asn | Asp | Ser | Asp |
| | | | 100 | | | | | 105 | | | | | 110 | | |

| | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Ser | Gly | Gly | Leu | Leu | Ala | Thr |
| | | 115 | | | | | 120 |

<210> 52

<211> 120

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> N-terminal part of CPS2K

<220>

<221> misc_feature

<222> (1)..(120)

<223> Xaa may be any amino acid

<400> 52

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Ile | Asn | Ile | Ser | Ile | Ile | Val | Pro | Ile | Tyr | Asn | Val | Glu | Gln | Tyr |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Ser | Lys | Cys | Ile | Asn | Ser | Ile | Val | Asn | Gln | Thr | Tyr | Lys | His | Ile |
| | | | 20 | | | | | 25 | | | | | 30 | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Glu | Leu | Leu | Val | Asn | Asp | Gly | Ser | Ser | Thr | Asp | Asn | Ser | Glu | Glu | Ile |
| | | | 35 | | | | 40 | | | | | 45 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Cys | Leu | Ala | Tyr | Ala | Lys | Lys | Asp | Ser | Arg | Ile | Arg | Tyr | Phe | Lys | Lys |
| | 50 | | | | | 55 | | | | | 60 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Glu | Asn | Gly | Gly | Leu | Ser | Asp | Ala | Arg | Asn | Tyr | Gly | Ile | Ser | Arg | Ala |
| 65 | | | | | 70 | | | | | 75 | | | | | 80 |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Lys | Gly | Asp | Tyr | Leu | Ala | Phe | Ile | Asp | Ser | Asp | Asp | Phe | Ile | His | Ser |
| | | | | 85 | | | | | 90 | | | | | 95 | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Glu | Phe | Ile | Gln | Arg | Leu | Xaa | His | Glu | Ala | Ile | Glu | Arg | Glu | Asn | Ala |
| | | | 100 | | | | | 105 | | | | | 110 | | |

| | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Xaa | Xaa | Val | Ala | Val | Ala | Gly |
| | | | 115 | | | | 120 |

<210> 53

<211> 419

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> ORF2Y

<400> 53

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
| Met | Lys | Lys | Tyr | Gln | Val | Ile | Ile | Gln | Asp | Ile | Leu | Thr | Gly | Ile | Glu | |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | | |
| Glu | His | Arg | Phe | Lys | Arg | Gly | Glu | Lys | Leu | Pro | Ser | Ile | Arg | Gln | Leu | |
| | | | 20 | | | | | 25 | | | | | 30 | | | |
| Arg | Glu | Gln | Tyr | His | Cys | Ser | Lys | Asp | Thr | Val | Gln | Lys | Ala | Met | Leu | |
| | | 35 | | | | | 40 | | | | | 45 | | | | |
| Glu | Leu | Lys | Tyr | Gln | Asn | Lys | Ile | Tyr | Ala | Val | Glu | Lys | Ser | Gly | Tyr | |
| | 50 | | | | | 55 | | | | | 60 | | | | | |
| Tyr | Ile | Leu | Glu | Asp | Arg | Asp | Phe | Gln | Asp | His | Thr | Cys | Arg | Ala | Gln | |
| 65 | | | | | 70 | | | | | 75 | | | | | 80 | |
| Ser | Tyr | Arg | Leu | Ser | Arg | Ile | Thr | Tyr | Glu | Asp | Phe | Arg | Ile | Cys | Leu | |
| | | | | 85 | | | | | 90 | | | | | 95 | | |
| Lys | Glu | Ser | Leu | Ile | Gly | Arg | Glu | Asn | Tyr | Leu | Phe | Asn | Tyr | Tyr | His | |
| | | | 100 | | | | | 105 | | | | | 110 | | | |
| Gln | Gln | Glu | Gly | Leu | Ala | Glu | Leu | Ile | Ser | Ser | Val | Gln | Ser | Leu | Leu | |
| | | 115 | | | | | 120 | | | | | 125 | | | | |
| Met | Asp | Tyr | His | Val | Tyr | Thr | Lys | Lys | Asp | Gln | Leu | Val | Ile | Thr | Ala | |
| | 130 | | | | | 135 | | | | | 140 | | | | | |
| Gly | Ser | Gln | Gln | Ala | Leu | Tyr | Ile | Leu | Thr | Gln | Met | Glu | Thr | Leu | Ala | |
| 145 | | | | | 150 | | | | | 155 | | | | | 160 | |
| Gly | Lys | Thr | Glu | Ile | Leu | Ile | Glu | Asn | Pro | Thr | Tyr | Ser | Arg | Met | Ile | |
| | | | | 165 | | | | | 170 | | | | | 175 | | |
| Glu | Leu | Ile | Arg | His | Gln | Gly | Ile | Pro | Tyr | Gln | Thr | Ile | Glu | Arg | Asn | |
| | | | 180 | | | | | 185 | | | | | 190 | | | |
| Leu | Asp | Gly | Ile | Asp | Leu | Glu | Glu | Leu | Glu | Ser | Ile | Phe | Gln | Thr | Gly | |
| | | 195 | | | | | 200 | | | | | | 205 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Lys | Ile | Lys | Phe | Phe | Tyr | Thr | Ile | Pro | Arg | Leu | His | Asn | Pro | Leu | Gly |
| 210 | | | | | | 215 | | | | | 220 | | | | |
| Ser | Thr | Tyr | Asp | Ile | Ala | Thr | Lys | Thr | Ala | Ile | Val | Lys | Leu | Ala | Lys |
| 225 | | | | | 230 | | | | | 235 | | | | | 240 |
| Gln | Tyr | Asp | Val | Tyr | Ile | Ile | Glu | Asp | Asp | Tyr | Leu | Ala | Asp | Phe | Asp |
| | | | | 245 | | | | | 250 | | | | | 255 | |
| Ser | Ser | His | Ser | Leu | Pro | Leu | His | Tyr | Leu | Asp | Thr | Asp | Asn | Arg | Val |
| | | | 260 | | | | | 265 | | | | | 270 | | |
| Ile | Tyr | Ile | Lys | Ser | Phe | Thr | Pro | Thr | Leu | Phe | Pro | Ala | Leu | Arg | Ile |
| | | 275 | | | | | 280 | | | | | 285 | | | |
| Gly | Ala | Ile | Ser | Leu | Pro | Asn | Gln | Leu | Arg | Asp | Ile | Phe | Ile | Lys | His |
| | 290 | | | | | 295 | | | | | 300 | | | | |
| Lys | Ser | Leu | Ile | Asp | Tyr | Asp | Thr | Asn | Leu | Ile | Met | Gln | Lys | Ala | Leu |
| 305 | | | | | 310 | | | | | 315 | | | | | 320 |
| Ser | Leu | Tyr | Ile | Asp | Asn | Gly | Met | Phe | Ala | Arg | Asn | Thr | Gln | His | Leu |
| | | | | 325 | | | | | 330 | | | | | 335 | |
| His | His | Ile | Tyr | His | Ala | Gln | Trp | Asn | Lys | Ile | Lys | Asp | Cys | Leu | Glu |
| | | | 340 | | | | | 345 | | | | | 350 | | |
| Lys | Tyr | Ala | Leu | Asn | Ile | Pro | Tyr | Arg | Ile | Pro | Lys | Gly | Ser | Val | Thr |
| | | 355 | | | | | 360 | | | | | 365 | | | |
| Phe | Gln | Leu | Ser | Lys | Gly | Ile | Leu | Ser | Pro | Ser | Ile | Gln | His | Met | Phe |
| | 370 | | | | | 375 | | | | | 380 | | | | |
| Gly | Lys | Cys | Tyr | Tyr | Phe | Ser | Gly | Gln | Lys | Ala | Asp | Phe | Leu | Gln | Ile |
| 385 | | | | | 390 | | | | | 395 | | | | | 400 |
| Phe | Phe | Glu | Gln | Asp | Phe | Ala | Asp | Lys | Leu | Glu | Gln | Phe | Val | Arg | Tyr |
| | | | | 405 | | | | | 410 | | | | | 415 | |
| Leu | Asn | Glu | | | | | | | | | | | | | |

TABLE 1. Bacterial strains and plasmids

| strain/plasmid | relevant characteristics | source/reference |
|----------------|--------------------------------|------------------|
| Strain | | |
| <i>E. coli</i> | | |
| CC118 | PhoA ⁻ | (28) |
| XL2 blue | Stratagene | |
| <i>E. coli</i> | | |
| XL2 blue | Stratagene | |
| <i>S. suis</i> | | |
| 10 | virulent serotype 2 strain | (49) |
| 3 | serotype 2 | (63) |
| 17 | serotype 2 | (63) |
| 735 | reference strain serotype 2 | (63) |
| T15 | serotype 2 | (63) |
| 6555 | reference strain serotype 1 | (63) |
| 6388 | serotype 1 | (63) |
| 6290 | serotype 1 | (63) |
| 5637 | serotype 1 | (63) |
| 5673 | serotype 1/2 | (63) |
| 5679 | serotype 1/2 | (63) |
| 5928 | serotype 1/2 | (63) |
| 5934 | serotype 1/2 | (63) |
| 5209 | reference strains serotype 1/2 | (63) |
| 5218 | reference strain serotype 9 | (63) |

| strain/plasmid | relevant characteristics | source/reference |
|-------------------|---|--------------------|
| 5973 | serotype 9 | (63) |
| 6437 | serotype 9 | (63) |
| 6207 | serotype 9 | (63) |
| reference strains | serotypes 1-34 | (9, 56, 14) |
| <i>S. suis</i> | | |
| 10 | virulent serotype 2 strain | (51) |
| 10cpsB | isogenic cpsB mutant of strain 10 | this work |
| 10cpsEF | isogenic cpsEF mutant of strain 10 | this work |
| Plasmid | | |
| pKUN19 | replication functions pUC, Amp ^R | (23) |
| pGEM7Zf (+) | replication functions pUC, Amp ^R | Promega Corp. |
| pIC19R | replication functions pUC, Amp ^R | (29) |
| pIC20R | replication functions pUC, Amp ^R | (29) |
| pIC-spc | pIC19R containing spc ^R gene of pDL282 | labcollection |
| pDL282 | replication functions of pBR 322 and pVT736-1, Amp ^R , Spc ^R | (43) |
| pPHOS2 | pIC-spc containing the truncated <i>phoA</i> gene of pPHO7 as a <i>Pst</i> I- <i>Bam</i> HI fragment | this work |
| pPHO7 | contains truncated <i>phoA</i> gene | (15) |
| pPHOS7 | pPHOS2 containing chromosomal <i>S. suis</i> DNA | this work |
| pCPS6 | pKUN19 containing 6 kb <i>Hind</i> III fragment of <i>cps</i> operon | this work (Fig. 1) |
| pCPS7 | pKUN19 containing 3,5 kb <i>Eco</i> RI- <i>Hind</i> III fragment of <i>cps</i> operon | this work (Fig. 1) |
| pCPS11 | pCPS7 in which 0.4 kb <i>Pst</i> I- <i>Bam</i> HI fragment of <i>cpsB</i> gene is replaced by Spc ^R gene of pIC-spec | this work (Fig. 1) |

| strain/plasmid | relevant characteristics | source/reference |
|----------------|--|--------------------|
| pCPS17 | pKUN19 containing 3.1 kb <i>Kpn</i> I fragment of <i>cps</i> operon | this work (Fig. 1) |
| pCPS18 | pKUN19 containing 1.8 kb <i>Sna</i> BI fragment of <i>cps</i> operon | this work (Fig. 1) |
| pCPS20 | pKUN19 containing 3.3 kb <i>Xba</i> I- <i>Hind</i> III fragment of <i>cps</i> operon | this work (Fig. 1) |
| pCPS23 | pGEM7Zf (+) containing 1.5 kb <i>Mlu</i> I fragment of <i>cps</i> operon | this work (Fig. 1) |
| pCPS25 | pIC20R containing 2.5 kb <i>Kpn</i> I- <i>Sal</i> I fragment of pCPS17 | this work (Fig. 1) |
| pCPS26 | pKUN19 containing 3.0 kb <i>Hind</i> III fragment of <i>cps</i> operon | this work (Fig. 1) |
| pCPS27 | pCPS25 containing 2.3 kb <i>Xba</i> I (blunt) - <i>Cl</i> aI fragment of pCPS20 | this work (Fig. 1) |
| pCPS28 | pCPS27 containing the 1.2 kb <i>Pst</i> I- <i>Xho</i> I <i>Spc</i> ^R gene of pIC-spc | this work (Fig. 1) |
| pCPS29 | pKUN19 containing 2.2 kb <i>Sac</i> I- <i>Pst</i> I fragment of <i>cps</i> operon | this work (Fig. 1) |
| pCPS1-1 | pKUN19 containing 5 kb <i>Eco</i> RV fragment of <i>cps</i> operon of type 1 | this work (Fig. 1) |
| pCPS1-2 | pKUN19 containing 2.2 kb <i>Hind</i> III fragment of <i>cps</i> operon of type 1 | this work (Fig. 1) |
| pCPS9-1 | pKUN19 containing 1 kb <i>Hind</i> III- <i>Xba</i> I fragment of <i>cps</i> operon of serotype 9 | this work (Fig. 1) |
| pCPS9-2 | pKUN19 containing 4.0 kb <i>Xba</i> I- <i>Xba</i> I fragment of <i>cps</i> operon of serotype 9 | this work (Fig. 1) |

Amp^R: ampicillin resistant
 Spc^R: spectinomycin resistant
 cps: capsular polysaccharide

Table 2. Properties of Orfs in the cps locus of *S. suis* serotype 2 and similarities to gene products of other bacteria

| ORF | nucleotide position in sequence | number of amino acids | GC% | proposed function of gene product ¹ | similar gene product (% identity) |
|---------|---------------------------------|-----------------------|-----|--|---|
| Orf2Z | 1- 719 | 240 | 44 | Unknown | <i>B. subtilis</i> YitS (26%) |
| Orf2Y | 2079- 822 | 419 | 38 | Transcription regulation | <i>B. subtilis</i> YcxD (39%) |
| Orf2X | 2202- 2934 | 244 | 39 | Unknown | <i>H. influenzae</i> YAAA (24%) |
| Cps2A | 3041- 4484 | 481 | 39 | Regulation | <i>S. pneumoniae</i> Cps19fA (58%) |
| Cps2B | 4504- 5191 | 229 | 40 | Chain length determination | <i>S. pneumoniae</i> type 3 Orf1 (58%) |
| Cps2C | 5203- 5878 | 225 | 40 | Chain length determination/ Export | <i>S. pneumoniae</i> Cps23fD (63%) |
| Cps2D | 5919- 6648 | 243 | 38 | Unknown | <i>S. pneumoniae</i> CpsB (62%) |
| Cps2E | 6675- 8052 | 459 | 33 | Glycosyltransferase | <i>S. pneumoniae</i> Cps14E (56%) |
| Cps2F | 8089- 9256 | 389 | 32 | Glycosyltransferase | <i>S. pneumoniae</i> Cps23fT |
| Cps2G | 9262-10417 | 385 | 36 | Glycosyltransferase | <i>S. thermophilus</i> EpsF (25%) |
| Cps2H | 10808-12176 | 457 | 31 | Glycosyltransferase | <i>S. mutans</i> RGPEC, ^N (29%) |
| Cps2I | 12213-13443 | 410 | 29 | CP polymerase | <i>S. pneumoniae</i> Cps23fI (48%) |
| Cps2J | 13583-14579 | 332 | 29 | Glycosyltransferase | <i>S. pneumoniae</i> Cps14J (31%) |
| Cps2K | 14574-15576 | 334 | 37 | Glycosyltransferase | <i>S. pneumoniae</i> Cps14J (40%) |
| “Cps2L” | 15618-16635 | 103 | 37 | Unknown | - |
| “Cps2M” | 16811-17322 | - | 38 | - | <i>S. agalactiae</i> CpsF ^N (77%) <i>E. coli</i> NeuA, ^N (47%) |

| ORF | nucleotide position in sequence | number of amino acids | GC% | proposed function of gene product ¹ | similar gene product (% identity) |
|---------|---------------------------------|-----------------------|-----|--|--|
| “Cps2N” | 17559-18342 | - | 39 | - | <i>S. agalactiae</i> CpsJ (43%) |
| Cps2O | 18401-19802 | 476 | 40 | Repeat unit transporter | <i>S. agalactiae</i> CpsK (41%) |
| Cps2P | 20327-21341 | 338 | 39 | Sialic acid synthesis | <i>S. agalactiae</i> NeuB (80%) <i>E. coli</i> NeuB (59%) |
| Cps2Q | 21355-21865 | 170 | 42 | Sialic acid synthesis | <i>S. agalactiae</i> NeuC ^N (61%) <i>E. coli</i> NeuC ^N (54%) |
| Cps2R | 21933-22483 | 184 | 40 | Sialic acid synthesis | <i>S. agalactiae</i> NeuC ^C (55%) <i>E. coli</i> NeuC ^C (40%) |
| Cps2S | 22501-23125 | 208 | 42 | Sialic acid synthesis | <i>E. coli</i> NeuD (32%) |
| Cps2T | 23136-24366 | 395 | 40 | CMP-NeuNAc synthetase | <i>S. agalactiae</i> CpsF (49%) <i>E. coli</i> NeuA (34%) |
| “Orf2U” | 24566-25488 | 168 | 42 | Transposase | <i>S. thermophilus</i> IS1194 (51%) |
| “Orf2V” | 25691-26281 | 116 | 37 | Transposase | <i>S. pneumoniae</i> orf1 (85%) |

¹ Predicted by sequence similarity

^N Similarity refers to the amino-terminal part of the gene product

^C Similarity refers to the carboxy-terminal part of the gene product

ORFS between “ ” are truncated or non-functional as the result of frame-shift or point mutations

TABLE 3. Properties of ORFs in the cps gene of *S. suis* serotypes 1 and 9 and similarities to gene products of other bacteria

| ORF | nucleotide position in sequence | G + C% | number of amino acids | predicted mol. mass (kDa) | predicted pI | proposed function of gene product ¹ | similar gene product (%) identity) | reference/ accession nr. |
|--------------------|---------------------------------|--------|-----------------------|---------------------------|--------------|--|--|--------------------------|
| Cps1E ² | 1-1363 | 34% | 454 | 52.2 | 8.0 | Glucosyltransferase | <i>Streptococcus suis</i> Cps2E (86%) | (26) |
| Cps1F | 1374-1821 | 33% | 149 | 17.3 | 8.2 | Unknown | <i>Streptococcus pneumoniae</i> Cps14E (48%) | (12) |
| Cps1G | 1823-2315 | 25% | 164 | 19.5 | 7.5 | Glycosyltransferase | <i>Streptococcus pneumoniae</i> Cps14F (83%) | (14) |
| Cps1H | 3035-4202 | 24% | 389 | 45.5 | 8.4 | CP polymerase | <i>Streptococcus pneumoniae</i> Cps14G (50%) | (14) |
| Cps1I | 4917- | | | | | Glycosyltransferase | <i>Streptococcus pneumoniae</i> Cps14H (30%) | (14) |
| | | | | | | | <i>Streptococcus pneumoniae</i> Cps14J (38%) | (13) |
| | | | | | | | <i>Lactococcus lactis</i> EpsG (31%) | (29) |
| | | | | | | | <i>Streptococcus thermophilus</i> EpsI (33%) | (28) |
| Cps1J | | | | | | Glycosyltransferase | <i>Streptococcus pneumoniae</i> Cps14J (%) | (13) |

| ORF | nucleotide position in sequence | G + C% | number of amino acids | predicted mol. mass (kDa) | predicted pI | proposed function of gene product ¹ | similar gene product (% identity) | reference/ accession nr. |
|--------------------|---------------------------------|--------|-----------------------|---------------------------|--------------|--|---|--------------------------|
| Cps1K ³ | | 37% | 278 | 32.5 | 7.8 | Glycosyltransferase | <i>Streptococcus pneumoniae</i> Cps14J (44%) | (13) |
| Cps9D ² | 1-646 | 37% | 215 | 24.9 | 8.1 | Unknown | <i>Streptococcus suis</i> Cps2D (89%) | (26) |
| Cps9E | 680- | | | | | Glycosyltransferase | <i>Staphylococcus aureus</i> Cap1D (27%) | (18) |
| Cps9F | | 36% | 200 | 22.3 | 8.2 | Glycosyltransferase | <i>Staphylococcus aureus</i> Cap5M (52%) | (17) |
| Cps9G | | 35% | 269 | 31.5 | 8.0 | Unknown | <i>Actinobacillus actinomycetemcomitans</i> (43%) | (AB002668_4) |
| Cps9H ³ | | 30% | 143 | 16.5 | 7.2 | Unknown | <i>Haemophilus influenzae</i> Lsg (43%) | (O05081) |
| | | | | | | | <i>Yersinia enterocolitica</i> RfbB (28%) | (33) |

¹ Predicted by sequence similarity

² N-terminal part of protein is lacking

³ C-terminal part of protein is lacking

Table 4. Hybridization of serotype 2 cps genes and neighboring sequences with chromosomal DNA of serotypes

| serotypes | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 1/2 | | |
|------------------|---|---|---|---|---|---|---|---|---|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|-----|--|--|
| DNA probes | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <i>orf2Z</i> | + | + | + | + | + | + | + | + | + | + | + | + | ± | + | + | + | + | + | + | + | - | + | + | + | + | + | + | + | + | + | + | + | - | - | + | | |
| <i>orf2Y</i> | + | + | + | + | + | + | + | + | + | + | + | ± | ± | + | + | + | + | + | + | ± | + | - | + | + | + | + | + | + | + | + | + | + | - | - | + | | |
| <i>orf2X</i> | + | + | + | + | + | + | + | + | + | + | + | ± | ± | + | + | + | + | + | + | - | + | - | + | + | + | + | + | + | + | + | + | + | - | - | + | | |
| <i>cps2A</i> | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | - | + | - | + | + | + | + | + | + | + | + | + | + | - | - | + | | |
| <i>cps2B</i> | + | + | + | + | + | + | + | + | + | + | - | - | ± | + | - | ± | ± | ± | ± | ± | - | - | + | + | + | + | - | - | + | + | ± | + | - | ± | + | | |
| <i>cps2C</i> | + | + | + | + | + | + | + | + | + | + | + | - | ± | + | - | ± | - | - | - | - | - | - | + | + | + | + | + | ± | ± | + | + | - | - | ± | + | | |
| <i>cps2D</i> | + | + | + | + | + | + | + | + | + | + | + | ± | ± | + | - | ± | + | + | + | ± | - | - | + | + | + | + | - | + | + | ± | + | - | - | + | + | | |
| <i>cps2E</i> | + | + | - | - | - | - | - | - | - | - | - | - | - | + | - | - | - | - | - | - | - | - | - | - | - | - | + | - | - | - | - | - | - | + | | | |
| <i>cps2F</i> | - | + | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | + | | | |
| <i>cps2G</i> | - | + | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ± | + | | | |
| <i>cps2H</i> | - | + | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | + | | | |
| <i>cps2I</i> | - | + | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | + | | | |
| <i>cps2J</i> | - | + | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | + | | | |
| <i>cps2K</i> | + | + | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | + | | | |
| “ <i>cps2L</i> ” | + | + | - | - | - | - | - | - | - | - | - | - | - | + | + | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | + | | | |
| “ <i>cps2M</i> ” | + | + | - | - | - | - | - | - | - | - | - | - | - | + | + | - | - | - | - | - | - | - | - | - | - | - | + | - | - | - | - | - | - | + | | | |
| <i>cps2N</i> ” | + | + | - | - | - | - | - | - | - | - | - | - | - | + | + | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | + | | | |
| <i>cps2O</i> | + | + | - | - | - | - | - | - | - | - | - | - | - | + | + | - | - | - | - | - | - | - | - | - | - | - | + | - | - | - | - | - | - | + | | | |
| <i>cps2P</i> | + | + | - | - | - | - | - | - | - | - | - | - | - | + | + | - | - | - | - | - | - | - | - | - | - | - | + | + | - | - | - | - | - | + | | | |
| <i>cps2Q</i> | + | + | - | - | - | - | - | - | - | - | - | - | - | + | + | - | - | - | - | - | - | - | - | - | - | - | + | + | - | - | - | - | - | + | | | |
| <i>cps2R</i> | + | + | - | - | - | - | - | - | - | - | - | - | - | + | + | - | - | - | - | - | - | - | - | - | - | - | + | + | - | - | - | - | - | + | | | |
| <i>cps2S</i> | + | + | - | - | - | - | - | - | - | - | - | - | - | + | + | - | - | - | - | - | - | - | - | - | - | - | + | + | - | - | - | - | - | + | | | |

| serotypes | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 1/2 | |
|----------------------|---|---|---|---|---|---|---|---|---|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|-----|---|
| <i>cps2T</i> | + | + | - | - | - | - | - | - | - | - | - | - | - | + | - | - | - | - | - | - | - | - | - | - | - | - | + | - | - | - | - | - | - | - | - | + |
| “ <i>orf2U</i> ” | + | + | - | - | - | - | + | - | - | - | - | - | - | + | - | - | - | - | - | - | - | - | - | + | - | - | + | - | - | - | - | + | - | + | + | + |
| “ <i>orf2V</i> ” | + | + | ± | ± | ± | - | ± | - | - | - | - | - | - | + | + | - | + | ± | - | - | - | ± | + | - | - | + | - | - | - | - | + | + | ± | ± | + | + |
| <i>100-bp repeat</i> | + | + | - | - | - | - | - | - | - | - | - | - | + | + | - | - | - | - | - | - | - | + | - | + | - | - | + | - | - | - | - | + | + | + | + | + |
| <i>16SrRNA</i> | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |

Table 5. Hybridization of serotypes 1 and 9 *cps* genes with chromosomal DNA of other *S. suis* serotypes

| Serotype | DNA probes | | | | | | | | | |
|----------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------|
| | <i>cps1E</i> | <i>cps1F</i> | <i>cps1G</i> | <i>cps1H</i> | <i>cps1I</i> | <i>cps9E</i> | <i>cps9F</i> | <i>cps9G</i> | <i>cps9H</i> | 16rRNA |
| 1 | + | + | + | + | + | - | - | - | - | - |
| 2 | + | - | - | - | - | - | - | - | - | + |
| 3 | - | - | - | + | - | + | - | - | - | + |
| 4 | - | - | - | + | - | + | - | - | - | + |
| 5 | - | - | - | + | - | + | - | - | - | + |
| 6 | - | - | - | - | - | - | - | - | - | + |
| 7 | - | - | - | + | - | + | - | - | - | + |
| 8 | - | - | - | - | - | - | - | - | - | + |
| 9 | - | - | - | + | - | + | + | + | + | + |
| 10 | - | - | - | + | - | + | + | - | - | + |
| 11 | - | - | - | + | - | + | ± | - | - | + |
| 12 | - | - | - | ± | - | + | ± | - | - | + |
| 13 | - | - | - | + | - | + | - | - | - | + |
| 14 | + | + | + | + | + | - | - | - | - | + |
| 15 | - | - | - | - | - | - | - | - | - | + |

| Serotype | <i>cps1E</i> | <i>cps1F</i> | <i>cps1G</i> | <i>cps1H</i> | <i>cps1I</i> | <i>cps9E</i> | <i>cps9F</i> | <i>cps9G</i> | <i>cps9H</i> | 16rRNA |
|----------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------|
| 16 | - | - | - | - | - | - | - | - | - | + |
| 17 | - | - | - | + | - | + | - | - | - | + |
| 18 | - | - | - | + | - | + | - | - | - | + |
| 19 | - | - | - | + | - | + | - | - | - | + |
| 20 | - | - | - | - | - | - | - | - | - | + |
| 21 | - | - | - | + | - | + | ± | - | - | + |
| 22 | - | - | - | - | - | - | - | - | - | + |
| 23 | - | - | - | + | - | + | - | - | - | + |
| 24 | - | - | - | + | - | + | + | - | - | + |
| 25 | - | - | - | - | - | - | - | - | - | + |
| 26 | - | - | - | - | - | - | ± | - | - | + |
| 27 | + | - | - | - | - | - | - | - | - | + |
| 28 | - | - | - | + | - | + | ± | - | - | + |
| 29 | - | - | - | + | - | + | - | - | - | + |
| 30 | - | - | - | + | - | + | ± | - | - | + |
| 31 | - | - | - | + | - | + | - | - | - | + |
| 32 | - | - | - | - | - | - | - | - | - | + |
| 33 | - | - | - | - | - | - | ± | - | - | + |
| 34 | - | - | - | - | - | - | - | - | - | + |
| ½ | + | - | - | - | - | - | - | - | - | + |

TABLE 6. Virulence of wild-type and capsular mutant *S. suis* strains in germfree pigs

| <i>S. suis</i> strains ¹ | pigs/ group (n) | mortality ² (%) | morbidity ³ (%) | clinical index of the group | spec symptoms ⁵ | non-spec. symptoms ⁶ | fever index ⁷ | leucocyte index ⁸ | isolation of <i>S. suis</i> in pigs (n) per group in | CNS | serosae | joints |
|--|--------------------|-------------------------------|-------------------------------|--------------------------------|-------------------------------|------------------------------------|-----------------------------|---------------------------------|---|-----|---------|--------|
| 10 | 4 | 100 | 100 | 11 | 88 | | 43 | 44 | 2 | 3 | | 4 |
| 10cpsB | 4 | 0 | 0 | 0 | 10 | | 1 | 3 | 1 | 3 | | 2 |
| 10cpsEF | 4 | 0 | 0 | 0 | 0 | | 1 | 0 | 1 | 3 | | 2 |

¹ strain10 in the wild-type strain, strains 10cpsB and 10cpsEF are isogenic capsular mutant strains

² piglets which died spontaneously or had to be killed for animal welfare reasons

³ only considering pigs with specific symptoms

⁴ clinical index: % of observations which matched the described criteria

⁵ specific symptoms: ataxia, lameness on at lest one joint, stiffness

⁶ non-specific symptoms: inappetance, depression

⁷ % of observations in the experimental group with a body temperature > 40°C

⁸ % of blood samples in the group in which number of granulocytes > 10¹⁰/l

Table 7. Bacterial strains and plasmids

| strain/plasmid | relevant characteristics |
|-------------------|--|
| Strain | |
| <i>E. coli</i> | |
| XL2 blue | |
| <i>S. suis</i> | |
| reference strains | |
| 5667 | serotypes 1-34 |
| 7037 | serotype 7, tonsil (1993) |
| 7044 | serotype 7, organs (1994) |
| 7068 | serotype 7, brains (1994) |
| 7646 | serotype 7 (1994) |
| 7744 | serotype 7, lungs (1996) |
| 7759 | serotype 7, joints (1996) |
| 8169 | serotype 7 (1997) |
| 15913 | serotype 7, meninges (1998) |
| Plasmid | |
| pKUN19 | replication functions pUC, Amp ^R |
| pGEM7Zf (+) | replication functions pUC, Amp ^R |
| pCPS9-1 | pKUN19 containing 1 kb <i>HindIII-XbaI</i> fragment of <i>cps</i> operon of serotype 9 |
| pCPS9-2 | pKUN19 containing 4.09 kb <i>XbaI-XbaI</i> fragment of <i>cps</i> operon of serotype 9 |
| pCPS7-1 | pKUN19 containing 1.6-kb <i>PstI</i> fragment of <i>cps</i> operon of type 7 |
| pCPS7-2 | pGEM7 containing 2.7-kb <i>ScaI-ClaI</i> fragment of <i>cps</i> operon of type 7 |

Amp^R: ampicillin resistant
cps: capsular polysaccharide

Table 8. Properties of Orfs in the *cps* genes of *S. suis* serotype 7 and similarities to gene products of other bacteria

| Orf | nucleotide position in sequence | proposed function of gene product | similar gene product (% identity) |
|------------|--|--|---|
| Cps7E | 1-719 | Glycosyltransferase | <i>Streptococcus suis</i> Cps9E (99%) |
| Cps7F | 1164-1863 | Glycosyltransferase | <i>Bordetella pertussis</i> BpIG ¹ (43%) <i>Streptococcus suis</i> Cps2E ¹ (33%) |
| Cps7G | 1872-3086 | Biosynthesis amino sugar | <i>Bordetella pertussis</i> BpIF (48%) |
| Cps7H | 3104-3737 | Glycosyltransferase | <i>Escherichia coli</i> WbdN (35%) <i>Streptococcus suis</i> Cps2K ² (31%) |

¹ similarity refers to the C-terminal part of the gene product

² similarity refers to the N-terminal part of the gene product

Table 9. Hybridization of serotype 7 *cps* probes with chromosomal DNA of *S. suis* serotypes

| serotypes | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 1/2 | | | |
|----------------|---|---|---|---|---|---|---|---|---|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|-----|--|--|--|
| DNA probes | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <i>cps7E</i> | - | - | + | + | + | - | + | - | + | + | + | + | + | + | - | + | + | + | + | - | + | - | + | + | + | - | - | - | + | + | - | - | - | - | - | | | |
| <i>cps7F</i> | - | - | + | + | - | + | - | - | - | - | - | - | - | - | - | - | + | - | - | - | - | - | + | - | - | - | - | - | - | - | - | - | - | - | - | | | |
| <i>cps7G</i> | - | - | + | + | - | + | - | - | - | - | - | - | - | - | - | - | + | - | - | - | - | - | + | - | - | - | - | - | - | - | - | - | - | - | - | | | |
| <i>cps7H</i> | - | - | - | - | - | + | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | | |
| <i>16SrRNA</i> | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | |

REFERENCES

1. Arends, J. P., and H. C. Zanen. 1988. Meningitis caused by *Streptococcus suis* in humans. Rev. Infect. Dis. 10:131-137.
2. Arrecubieta, C., E. Garcia, and R. Lopez. 1995. Sequence and transcriptional analysis of a DNA region involved in the production of capsular polysaccharide in *Streptococcus pneumoniae* type 3. Gene 167:1-7
3. Arrecubieta, C., R. Lopez, and E. Garcia. 1994. Molecular characterization of *cap3A*, a gene from the operon required for the synthesis of the capsule of *Streptococcus pneumoniae* type 3: sequencing of mutations responsible for the unencapsulated phenotype and localization of the capsular cluster on the pneumococcal chromosome. J. Bacteriol. 176:6375-6383.
4. Clifton-Hadley, F.A. 1983. *Streptococcus suis* type 2 infections. Br. Vet. J. 139:1-5.
5. Charland, N., J. Harel, M. Kobisch, S. Lacasse, and M. Gottschalk. 1998. *Streptococcus suis* serotype 2 mutants deficient in capsular expression. Microbiol. 144:325-332.
6. Cross, A. S. 1990. The biological significance of bacterial encapsulation. Curr. Top. Microbiol. Immunol. 150:87-95.
7. Elliott, S. D. and J. Y. Tai. 1978. The type-specific polysaccharide of *Streptococcus suis*. J. Exp. Med. 148:1699-1704.
8. Feder, I., M. M. Chengappa, B. Fenwick, M. Rider and J. Staats. 1994. Partial characterization of *Streptococcus suis* type 2 hemolysin. J. Clin. Microbiol. 32:1256-1260.
9. Gottschalk, M., R. Higgins, M. Jacques, M. Beaudoin, and J. Henrichsen. 1991. Characterization of six new capsular types (23 through 28) of *Streptococcus suis*. J. Clin. Microbiol. 29:2590-2594.
10. Gottschalk, M., S. Lacouture, and J. D. Dubreuil. 1995. Characterization of *Streptococcus suis* type 2 haemolysin. Microbiology 141:189-195.
11. Gottschalk, M., A. Lebrun, M. Jacques, and R. Higgins. 1990. Haemagglutination properties of *Streptococcus suis*. J. Clin. Microbiol. 28:2156-2158.
12. Guidolin, A., J. M. Morona, R. Morona, D. Hansman, and J. C. Paton. 1994. Nucleotide sequence analysis of genes essential for capsular polysaccharide biosynthesis in *Streptococcus pneumoniae* type 19F. 1994. Infect. Immun. 62:5384-5396.
13. Guitierrez, C., and J. C. Devedjian. 1989. Plasmid facilitating *in vitro* construction of PhoA fusions in *Escherichia coli*. Nucl. Acid. Res. 17:3999.
14. Higgins, R., M. Gottschalk, M. Boudreau, A. Lebrun, and J. Henrichsen. 1995. Description of six new capsular types (28 through 34) of *Streptococcus suis*. J. Vet. Diagn. Invest. 7:405-406

15. Jacobs, A. A., P. L. W. Loeffen, A. J. G. van den Berg, and P. K. Storm. 1994. Identification, purification and characterization of a thiol-activated hemolysin (suilysin) of *Streptococcus suis*. *Infect. Immun.* 62:1742-1748.
16. Jacques, M., M. Gottschalk, B. Foiry B. and R. Higgins. 1990. Ultrastructural study of surface components of *Streptococcus suis*. *J. Bacteriol.* 172:2833-2838.
17. Klein P., M. Kanehisa and C. DeLisi. 1985. The detection and classification of membrane spanning proteins. *Biochim. Biophys. Acta.* 851:468-476.
18. Kolkman, M. A. B., D. A. Morrison, B. A. M. van der Zeijst, and P. J. M. Nuijten. 1996. The capsule polysaccharide synthesis locus of *Streptococcus pneumoniae* serotype 14: identification of the glycosyl transferase gene *cps14E*. *J. Bacteriol.* 178: 3736-3541.
19. Kolkman, M. A. B., W. Wakarchuk, P. J. M. Nuijten, and B. A. M. van der Zeijst. 1997. Capsular polysaccharide synthesis in *Streptococcus pneumoniae* serotype 14: molecular analysis of the complete *cps* locus and identification of genes encoding glycosyltransferases required for the biosynthesis of the tetrasaccharide subunit. *Mol. Microbiol.* 26:197-208.
20. Kolkman, M. A. B., B. A. M. van der Zeijst and P. J. M. Nuijten. 1997. Functional analysis of glycosyltransferases encoded by the capsular polysaccharide biosynthesis locus of *Streptococcus pneumoniae* serotype 14. *J. Biol. Chem.* 272:19502-19508.
21. Konings, R. N. H., E. J. M. Verhoeven, and B. P. H. Peeters. 1987. pKUN vectors for the separate production of both DNA strands of recombinant plasmids. *Methods Enzymol.* 153:12-34.
22. Korolik, V., B. N. Fry, M. R. Alderton, B. A. M. van der Zeijst, and P. J. Coloe. 1997. Expression of *Campylobacter hyoilei* lipo-oligosaccharide (LOS) antigens in *Escherichia coli*. *Microbiol.* 143:3481-3489.
23. Leij, P. C. J., R. van Furth, and T. L. van Zwet. 1986. In vitro determination of phagocytosis and intracellular killing of polymorphonuclear and mononuclear phagocytes. In *Handbook of Experimental Immunology*, vol. 2. Cellular Immunology, pp. 46.1-46.21. Edited by D. M. Weir, L. A. Herzenberg, C. Blackwell and L. A. Herzenberg. Blackwell Scientific Publications, Oxford.
24. Lin, W. S., T. Cunneen, and C. Y. Lee. 1994. Sequence analysis and molecular characterization of genes required for the biosynthesis of type 1 capsular polysaccharide in *Staphylococcus aureus*. *J. Bacteriol.* 176:7005-7016.

25. Liu, D., A. M. Haase, L. Lindqvist, A. A. Lindberg, and P. R. Reeves. 1993. Glycosyl transferases of O-antigen biosynthesis in *Salmonella enteritica*: Identification and characterization of transferase genes of group B, C2, and E1. *J. Bacteriol.* 175:3408-3413.
26. Manoil, C., and J. Beckwith. 1985. A transposon probe for protein export signals. *Proc. Natl. Acad. Sci. USA* 82:8129-8133.
27. Marsh, J. L., N. Erfle, and E. J. Wykes. 1984. The pIC plasmid and phage vectors with versatile cloning sites for recombinant selection by insertional inactivation. *Gene* 32:481-485.
28. Miller, J. 1972. *Experiments in Molecular Genetics*. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory.
29. Morona, J. K., K. Morona, and J. C. Paton. 1997. Characterization of the locus encoding the *Streptococcus pneumoniae* type 19F capsular polysaccharide biosynthesis pathway. *Mol. Microbiol.* 23:761-763.
30. Muñoz, R., M. Mollerach, K. Lopez and E. Garcia. 1997. Molecular organization of the genes required for the synthesis of type 1 capsular polysaccharide of *Streptococcus pneumoniae*; formation of binary encapsulated pneumococci and identification of cryptic dTDP-rhamnose biosynthesis genes. *Mol. Microbiol.* 25:79-92.
31. Pearce B. J., Y. B. Yin, and H. R. Masure. 1993. Genetic identification of exported proteins in *Streptococcus pneumoniae*. *Mol. Microbiol.* 9:1037-1050.
32. Roberts, I. S. 1996. The biochemistry and genetics of capsular polysaccharide production in bacteria. *Ann. Rev. Microbiol.* 50:285-315.
33. Rossbach, S., D. A. Kulpa, U. Rossbach, and F. J. de Bruin. 1994. Molecular and genetic characterization of the rhizopine catabolism (mocABRC) genes of *Rhizobium meliloti* L5-30. *Mol. Gen. Genet.* 245:11-24.
34. Rubens, C. E., L. M. Heggen, R. F. Haft, and R. M. Wessels. 1993. Identification of *cpsD*, a gene essential for type III capsule expression in group B streptococci. *Mol. Microbiol.* 8:843-855.
35. Rubens, C. E., L. M. R. Wessels, L. M. Heggen, and D. L. Kasper. 1987. Transposon mutagenesis of type III group B Streptococcus: correlation of capsule expression with virulence. *Proc. Natl. Acad. Sci. USA* 84:7208-7212.
36. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. *Molecular cloning. A laboratory manual*. Second edition. Cold Spring Harbor Laboratory Press. Cold Spring Harbor, New York.

37. Smith, H. E., U. Vecht, H. J. Wisselink, N. Stockhofe-Zurwieden, Y. Biermann, and M. A. Smits. 1996. Mutants of *Streptococcus suis* types 1 and 2 impaired in expression of muramidase-released protein and extracellular protein induce disease in newborn germfree pigs. *Infect Immun.* 64:4409-4412.
38. Smith, H. E., H. J. Wisselink, U. Vecht, A. L. J. Gielkens and M. A. Smits. 1995. High-efficiency transformation and gene inactivation in *Streptococcus suis* type 2. *Microbiol.* 141:181-188.
39. Sreenivasan, P. K., D. L. LeBlanc, L. N. Lee, and P. Fives-Taylor. 1991. Transformation of *Actinobacillus actinomycetemcomitans* by electroporation, utilizing constructed shuttle plasmids. *Infect. Immun.* 59:4621-4627.
40. Stringele F., J. R. Neeser, and B. Mollet. 1996. Identification and characterization of the *eps* (exopolysaccharide) gene cluster from *Streptococcus thermophilus* Sfi6. *J. Bacteriol.* 178:1680-1690.
41. Stockhofe-Zurwieden, N., U. Vecht, H. J. Wisselink, H. van Lieshout, and H. E. Smith. 1996. Comparative studies on the pathogenicity of different *Streptococcus suis* serotype 1 strains. In *Proceedings of the 14th IPVS Congress.* pp. 299.
42. van Kranenburg, R., J. D. Marugg, I. I. van Swam, N. J. Willem and W. M. de Vos. 1997. Molecular characterization of the plasmid-encoded *eps* gene cluster essential for exopolysaccharide biosynthesis in *Lactococcus lactis*. *Mol. Microbiol.* 24:387-397.
43. van Leengoed, L. A., E. M. Kamp, and J. M. A. Pol. 1989. Toxicity of *Haemophilus pleuropneumoniae* to porcine lung macrophages. *Vet. Microbiol.* 19:337-349.
44. van Leengoed, L. A. M. G., U. Vecht, and E. R. M. Verheyen. 1987. *Streptococcus suis* type 2 infections in pigs in The Netherlands (part two). *Vet Quart.* 9, 111-117.
45. Vecht, U., J. P. Arends, E. J. van der Molen, and L. A. M. G. van Leengoed. 1989. Differences in virulence between two strains of *Streptococcus suis* type 2 after experimentally induced infection of newborn germfree pigs. *Am. J. Vet. Res.* 50:1037-1043.
46. Vecht, U., L. A. M. G. van Leengoed, and E. R. M. Verheyen. 1985. *Streptococcus suis* infections in pigs in The Netherlands (part one). *Vet. Quart.* 7:315-321
47. Vecht, U., H. J. Wisselink, M. L. Jellema, and H. E. Smith. 1991. Identification of two proteins associated with virulence of *Streptococcus suis* type 2. *Infect. Immun.* 59:3156-3162.

48. Vecht, U., H. J. Wisselink, N. Stockhofe-Zurwieden, and H. E. Smith. 1996. Characterization of virulence of the *Streptococcus suis* serotype 2 reference strain Henrichsen S. 735 in newborn gnotobiotic pigs. *Vet. Microbiol.* 51:125-136.
49. Vecht, U., H. J. Wisselink, J. E. van Dijk, and H. E. Smith. 1992. Virulence of *Streptococcus suis* type 2 strains in newborn germfree pigs depends on phenotype. *Infect. Immun.* 60:550-556.
50. Wagenaar, F., G. L. Kok, J. M. Broekhuijsen-Davies, and J. M. A. Pol. 1993. Rapid cold fixation of tissue samples by microwave irradiation for use in electron microscopy. *Histochemical J.* 25:719-725.
51. Wessels, M. R. and M. S. Bronze. 1994. Critical role of the group A streptococcal capsule in pharyngeal colonization and infection in mice. *Proc. Natl. Acad. Sci. USA* 91:12238-12242.
52. Wessels, M. R., A. E. Moses, J. B. Goldberg, and T. J. DiCesare. 1991. Hyaluronic acid capsule is a virulence factor for mucoid group A streptococci. *Proc. Natl. Acad. Sci. USA.* 88:8317-8321.
53. Yamane, K., M. Kumamano, and K. Kurita. 1996. The 25°-36° region of the *Bacillus subtilis* chromosome: determination of the sequence of a 146 kb segment and identification of 113 genes. *Microbiol.* 142:3047-3056.
54. Butler, J. C., R. F. Breiman, H. B. Lipman, J. Hofmann, and R. R. Facklam. 1995. Serotype distribution of *Streptococcus pneumoniae* infections among preschool children in the United States, 1978-1994: implications for development of a conjugate vaccine. *J. Infect. Dis.* 171:885-889.
55. Charland, N., M. Jacques, S. Lacoutre and N. Gottschalk. 1997. Characterization and protective activity of a monoclonal antibody against a capsular epitope shared by *Streptococcus suis* serotypes 1, 2 and 1/2. *Microbiol.* 143:3607-3614.
56. Gottschalk, M., R. Higgins, M. Jacques, K. R. Mittal, and J. Henrichsen. Description of 14 new capsular types of *Streptococcus suis*. *J. Clin. Microbiol.* 27:2633-2636.
57. Heath, P. J., B. W. Hunt, and J. P. Duff. 1996. *Streptococcus suis* serotype 14 as a cause of pig disease in the UK. *Vet. Rec.* 2:450-451.
58. Hommez, J., L. A. Devrieze, J. Henrichsen, and F. Castryck. 1986. Identification and characterization of *Streptococcus suis*. *Vet. Microbiol.* 16:349-355.
59. Killper-Balz, R., and K. H. Schleifer. 1987. *Streptococcus suis* sp. nov. nom. rev. *Int. J. Syst. Bacteriol.* 37:160-162.

60. Kolkman, M. A. B., B. A. M. van der Zeijst, and P. J. M. Nuijten. 1998. Diversity of capsular polysaccharide synthesis gene clusters in *Streptococcus pneumoniae*. Submitted for publication.
61. Lee, J. C., S. Xu, A. Albus, and P. J. Livolsi. 1994. Genetic analysis of type 5 capsular polysaccharide expression by *Staphylococcus aureus*. J. Bacteriol. 176:4883-4889.
62. Reek, F. H., M. A. Smits, E. M. Kamp, and H. E. Smith. 1995. Use of multiscreen plates for the preparation of bacterial DNA suitable for PCR. BioTechniques 19:282-285.
63. Sau, S., N. Bhasin, E. R. Wann, J. C. Lee, T. J. Foster, and C. Y. Lee. 1997. The *Staphylococcus aureus* allelic genetic loci for serotype 5 and 8 capsule expression contain the type-specific genes flanked by common genes. Microbiol. 143: 2395-2405.
64. Sau, S., and C. Y. Lee. 1996. Cloning of type 8 capsule genes and analysis of gene clusters for the production of different capsular polysaccharides in *Staphylococcus aureus*. J. Bacteriol. 178:2118-2126.
65. Sau, S., and C. Y. Lee. 1997. Molecular characterization and transcriptional analysis of type 8 capsule genes in *Staphylococcus aureus*. J. Bacteriol. 179:1614-1621.
66. Smith, H. E., M. Rijnsburger, N. Stockhofe-Zurwieden, H. J. Wisselink, U. Vecht, and M. A. Smits. 1997. Virulent strains of *Streptococcus suis* serotype 2 and highly virulent strains of *Streptococcus suis* serotype 1 can be recognized by a unique ribotype profile. J. Clin. Microbiol. 35:1049-1053.
67. Yamazaki, M., L. Thorne, M. Mikolajczak, R. W. Armentrout, and T. J. Pollock. 1996. Linkage of genes essential for synthesis of a polysaccharide capsule in *Sphingomonas* strain S88. J. Bacteriol. 178:2676-2687.
68. Zhang, L., A. Al-Hendy, P. Toivanen, and M. Skurnik. 1993. Genetic organization and sequence of the *rfb* gene cluster of *Yersinia enterocolitica* serotype 0:3: similarities to the dTDP-L-rhamnose biosynthesis pathway of *Salmonella* and to the bacterial polysaccharide transport systems. Mol. Microbiol. 9:309-321.
69. Clifton-Hadley, F.A. (1983). *Streptococcus suis* type 2 infections. Br. Vet. J. 139, 1-5.
70. Vecht, U., van Leengoed, L. A. M. G. and Verheyen, E. R. M. (1985). *Streptococcus suis* infections in pigs in The Netherlands (part one). Vet. Quart. 7, 315-321.
71. Arends, J. P. and Zanen, H. C. (1988). Meningitis caused by *Streptococcus suis* in humans. Rev. Infect. Dis. 10, 131-137.
72. Hommez, J., Devrieze, L.A., Henrichsen, J. and Castryck, F. (1986). Identification and characterization of *Streptococcus suis*. Vet. Microbiol. 16, 349-355.

73. Killper-Balz, R. and Schleifer, K. H. (1987). *Streptococcus suis* sp. nov. nom.rev. Int. J. Syst. Bacteriol. 37, 160-162.
74. Gottschalk, M., Higgins, R. and Jacques, M. (1993). Production of capsular material by *Streptococcus suis* serotype 2 under different conditions. Can. J. Vet. Res. 57, 49-52.
75. Higgins, R. and Gottschalk, M. (1990). Update on *Streptococcus suis* identification. J. Vet. Diagn. Invest. 2, 249-252.
76. Gottschalk, M., Higgins, R., Jacques, M., Beaudoin, M. and Henrichsen, J. (1991). Characterization of six new capsular types (23 through 28) of *Streptococcus suis*. J. Clin. Microbiol. 29, 2590-2594.
77. Gottschalk, M., Higgins, R., Jacques, M., Mittal, K. R. and Henrichsen, J. (1989). Description of 14 new capsular types of *Streptococcus suis*. J. Clin. Microbiol. 27, 2633-2636.
78. Higgins, R., Gottschalk, M., Boudreau, M., Lebrun, A. and Henrichsen, J. (1995). Description of six new capsular types (28 through 34) of *Streptococcus suis*. J. Vet. Diagn. Invest. 7, 405-406.
79. Aarestrup, F. M., Jorsal, S. E. and Jensen, N. E. (1998). Serological characterization and antimicrobial susceptibility of *Streptococcus suis* isolates from diagnostic samples in Denmark during 1995 and 1996. Vet. Microbiol. 15, 59-66.
80. MacLennan, M., Foster, G., Dick, K., Smith, W. J. and Nielsen, B. (1996). *Streptococcus suis* serotypes 7, 8 and 14 from diseased pigs in Scotland. Vet Rec. 139, 423-424.
81. Sihvonen, L., Kurl, D. N. and Henrichsen, J. (1988). *Streptococcus suis* isolates from pigs in Finland. Acta Vet. Scand. 29, 9-13.
82. Boetner, A. G., Binder, M. and Bille-Hansen, V. (1987). *Streptococcus suis* infections in Danish pigs and experimental infection with *Streptococcus suis* serotype 7. Acta Path. Microbiol. Immunol. Scand. Sect. B, 95, 233-239.
83. Smith, H. E., Veenbergen, V., van der Velde, J., Damman, M., Wisselink, H. J. and Smits, M. A. (1999). The cps genes of *Streptococcus suis* serotypes 1, 2 and 9: development of rapid serotype-specific PCR assays. J. Clin. Microbiol. submitted
84. Smith, H. E., Damman, M., van der Velde, J., Wagenaar, F., Wisselink, H. J., Stockhofe-Zurwieden, N. and Smits, M. A. (1999). Identification and characterization of the cps locus of *Streptococcus suis* serotype 2: the capsule protects against phagocytosis and is an important virulence factor. Infect. Immun. 67, 1750-1756.

85. Miller, J. (1972). Experiments in Molecular Genetics. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
86. Sambrook, J., E. F. Fritsch, and T. Maniatis. (1989). Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
87. Allen, A. and Maskell, D. (1996). The identification, cloning and mutagenesis of a genetic locus required for lipopolysaccharide biosynthesis in *Bordetella pertussis*. Mol. Microbiol. 19, 37-52.
88. Wang, L. and Reeves, P. R. (1998). Organization of *Escherichia coli* O157 O antigen gene cluster and identification of its specific genes. Infect. Immun. 66, 3545-3551.
89. Wisselink, H. J., Reek, F. H., Vecht, U., Stockhofe-Zurwieden, N., Smits, M. A. and Smith, H. E. (1999). Detection of virulent strains of *Streptococcus suis* type 2 and highly virulent strains of *Streptococcus suis* type 1 in tonsillar specimens of pigs by PCR. Vet. Microbiol. 67, 143-157.
90. Konings, R. N. H., Verhoeven, E. J. M. and Peeters, B. P. H. (1987). pKUN vectors for the separate production of both DNA strands of recombinant plasmids. Methods Enzymol. 153, 12-34.

ABSTRACT OF THE DISCLOSURE

The invention relates to *Streptococcus suis* infection in pigs, vaccines directed against those infections and tests for diagnosing *Streptococcus suis* infections. The invention provides an isolated or recombinant nucleic acid encoding a capsular gene cluster of *Streptococcus suis* or a gene or gene fragment derived thereof. The invention further provides a nucleic acid probe or primer allowing species or serotype-specific detection of *Streptococcus suis*. The invention also provides a *Streptococcus suis* antigen and vaccine derived thereof.

N:\2183\4726\pat.app.clean all.doc